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Summary 
Prions are unconventional infectious agents that cause always fatal neurodegenerative 
diseases termed prion disease or transmissible spongiform encephalopathies in 
mammals. Prion diseases are caused by an accumulation of the misfolded, aggregated 
host encoded prion protein (PrP).  The normal, cellular, α-helix rich isoform (PrPC) is 
converted into the disease-associated β-sheet rich pathogenic isoform (PrPSc). PrPSc can 
adopt multiple conformations that likely encipher prion strain characteristics. Currently, 
prion therapeutic clinical trials lack success and there is an urgent need for novel 
therapeutics. The aim of this study was to develop a cell-based assay for high content 
screening of large compound libraries with an automated microscope to identify 
compounds that might impair prion replication. Furthermore, identified compounds 
should be tested on prion infected organotypic slice cultures to test whether in vitro 
detected anti-prion compounds are also effective in a more complex neuronal 
environment. Additionally, two promising compounds, FeTMPyP and PIM-B31, identified 
by our collaboration partner Emiliano Biasini (University of Trento), were tested ex vivo. 
Beside this a comparative study of host response between ex vivo and in vivo should 
evaluate the transferability between the two systems, as this has not been was not 
shown until now. In the established screen 152 compounds were tested, 84 had an 
inhibitory effect on PrPSc accumulation in persistently infected N2a22L cells and the seven 
strongest inhibitors were further validated by western blot analysis. The most promising 
candidate, PHA665752, was tested ex vivo and showed a reduction of PrPSc
accumulation that was however not significant. FeTMPyP showed strong toxicity and 
PIM-B31 showed inconsistent results that depended on different concentration and 
strain-specificity. Beside this, pathway analysis of ex vivo and in vivo infected mouse 
cerebella with different strains at various time points was performed with DAVID 6.8, an 
online bioinformatics resource. Analysis of the 250 most significant differentially 
expressed genes revealed that several comparable pathways were changed due to 
prion infection in brain slices and brains. The calcium signaling pathways and 
neuroactive ligand-receptor pathways were deregulated the most by prion infection ex 
vivo as well as in vivo.  
Introduction 
2 
1 Introduction 
1.1 The origin of prions 
At the latest since the BSE crisis in Europe during the 1980s and 1990s a major part of 
the western population has heard of prions (1). But: what are prions? How do they 
propagate and how do prions cause prion diseases? Prions are unconventional 
infectious agents that cause slowly developing, always fatal neurodegenerative 
diseases, called prion diseases or TSEs (transmissible spongiform encephalopathies) 
that affect many mammalian species. Prion diseases were first documented as early as 
1750 by Leopold (2), who recognized sheep suffering from this disease and already 
noted its infectious nature. In the following centuries different transmission routes were 
described and some authors suggested the coexistence of infected and non-infected 
animals or a spontaneous origin of the disease (2, 3). Others proposed a hereditary 
predisposition, transmission by asymptomatic animals and the existence of hereditary 
and non-hereditary forms was assumed (2, 3). In 1954, prion diseases were described 
as a slow-virus disease due to the remarkably long incubation time (4), though no virus 
could be isolated from prion diseased individuals. Additionally, the causative agent could 
not be inactivated by methods that were used for nucleic acid destruction like heat, 
nuclease treatment and UV-radiation. The unusually small size of the agent and the fact 
that methods that can be used to destroy proteins, namely hydrolysis and protein 
denaturation, were capable of destroying prions led to the suggestion that the agent 
might be a protein (5-7). This hypothesis was supported as Prusiner purified a protein 
from a prion-infected hamster brain that was not found in an uninfected hamster brain. It 
was described as a 27 - 30 kDa, proteinase K resistant protein. The amount of protein 
correlated with the titer of the agent (8). Prusiner postulated that this protein is the 
predominant if not sole component of the infectious particles, which he named “prion” 
(small proteinaceous infectious particle). According to the protein-only hypothesis, 
which states that the cellular prion protein (PrPC) can undergo conformational changes 
to a misfolded isoform that then in turn serves as template for continuous conversion of 
prion proteins to their misfolded isoforms in the absence of any coding nucleic acid (8). 
For this novel finding he was awarded the Nobel Prize of medicine in 1997. Further 
investigation showed a more detailed description of the prion protein.  
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1.2 The prion protein 
1.2.1 The PRNP gene and biosynthesis of PrP 
The prion protein (PrP) is expressed in skeletal muscle, kidney, heart, secondary 
lymphoid organs and the central nervous system (CNS). In the CNS PrPC is highly 
expressed in synaptic membranes of neurons and in astrocytes. In the periphery PrPC is 
particularly expressed in lymphocytes and in follicular dendritic cells (9).  
PrP is encoded by the PRNP gene located on chromosome 20 in humans and on 
chromosome 2 in mice (10). It is a highly conserved gene that shows homology of 
approximately 80 % from amphibians to mammals. In humans PRNP consists of 2 
exons, whereas PRNP in mice is composed of 3 exons. The last exon encodes the open 
reading frame (ORF) and the 3´untranslated region (UTR). The ORF codes for 253 
amino acid residues (aa) in humans and 254 aa in mice (11, 12) (Figure 1 A). The 
amino-terminus of the ORF encodes for a signal peptide (aa 1 – 22) responsible for 
translocation of the primary translation product to the endoplasmatic reticulum (ER) 
(Figure 1 B). Aa 51 – 90 contain the octapeptide repeat region, which is supposed to be 
important for copper binding (9) and could be involved in prion pathogenesis (13). The 
hydrophilic charged cluster is followed by the hydrophobic core (aa 111 – 134) that is 
important during conversion processes (14). The carboxy-terminus contains the 
membrane anchor region at aa 231 – 254. 
The amino-terminus of the matured cellular prion protein (Figure 1 C) is cleaved after the 
signal peptide region by a signal peptidase in the ER. The amino-terminus is flexible and 
unstructured (aa 22-121) (15, 16). Complex carbohydrates can be linked to two 
asparagine residues (in humans aa 181 and 197, in mice aa 180 and 196) resulting in 
un-, mono- and diglycosylated PrPC (17). Furthermore, an intramolecular disulfide bond 
is formed between two cysteine residues (in humans aa 179 and 214, in mice aa 178 
and 213) (18). The folded domain contains three α-helixes and a short two stranded β-
sheet and is linked to the membrane with a glycosylphosphatidylinositol (GPI) anchor 
(19, 20). 
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Figure 1. Structure of murine PRNP gene, the primary translation product and matured 
PrPC. (A) The murine PRNP gene consists of 3 exons. Exon 1 and 2 are non-coding, exon 3 
encodes for the open reading frame (ORF) and contains a 3´untranslated region (UTR). (B) The 
primary translation product contains a signal peptide (SP), the octapeptide repeat region (OR), 
the charged cluster (CC) and the hydrophobic core (HC), followed by a signal peptide region for 
attachment of the glycosylphosphatidylinositol anchor (GPI). aa = amnio acid. (C) In the matured 
PrPC both signal peptides are cleaved (SP and GPI) and the carboxy-terminus is covalently linked 
to a phospholipid bilayer via a GPI anchor. Two complex carbohydrates can be linked to two 
asparagine residues and an intramolecular disulfide bond is formed between two cysteine 
residues. 
 
PrPC is translated on the surface of the rough ER and passes through the Golgi 
apparatus to the cell surface (21). Within the ER and the Golgi, the protein undergoes 
post-translational modification like glycosylation of two asparagine residues, formation of 
a disulfide bond and attachment of the GPI anchor (Figure 1 C). At the plasma 
membrane PrPC is incorporated into lipid rafts and caveolae. Lipid rafts and caveolae are 
cholesterol and sphingolipid enriched membranes (22). Early incorporation of PrPC into 
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lipid rafts appears to be crucial for correct folding of PrPC (23). PrPC exists as a 
membrane-bound, but also as an extracellular and an intracellular form. A small fraction 
of membrane-bound PrPC can undergo proteolytic processing by metalloproteases, 
resulting in membrane-attached caboxyterminal fragments and extracellularly released 
aminoterminal fragments (24). Furthermore, small portions of full-length PrPC can be 
released to the extracellular space either within exosomes (25) or as naked protein (26). 
However, PrPC can also be found intracellularly in vesicles of the endolysosomal 
pathway and in multivesicular bodies (27). Beside this, a small portion of PrPC is located 
in the cytosol (28) and in the nucleus, associated with chromatin (29).  
1.2.2 Intracellular trafficking and physiological function of PrPC 
Membrane bound PrPC can be readily and constitutively internalized by endocytosis 
induced by different external stimuli like binding of copper or stress-inducible protein 1 
(STI1) (21). The internalization of PrPC is a dynamin-dependent but GPI-anchor 
independent event mediated by interaction with other proteins (30). Potential interactors 
include laminin-receptor precursor LRP/LR, the low-density lipoprotein receptor-related 
protein 1 (LPR1) and glycosaminoglycans (GAGs) (31, 32). PrPC is either directly 
endocytosed from lipid rafts (Figure 2 3a) (33) or it is first translocated out of the raft 
(Figure 2 3b) (34). Endocytosis can occur clathrin-dependently and independently. 
Internalized PrPC is either transported by early endosomes (EE), before it is degraded 
(Figure 2 6) via the endolysosomal pathway or it is transferred rapidly and directly to 
recycling endosomes (RE) and transported back to the cell surface (Figure 2 5) (35).  
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Figure 2. Endocytosis of PrPC and intracellular trafficking. PrPC is translated on the surface 
of the endoplasmatic reticulum (1) and passes through the Golgi apparatus (2) to the plasma 
membrane where it is incorporated into lipid rafts. Membrane-bound PrPC is either internalized 
from lipid rafts (3a) or translocated out of the rafts and endocytosed (3b). Internalized PrPC is 
transported to the early endosome (4) and either transferred to recycling endosomes and 
transported back to the cell surface (5) or degraded by the lysosome (6). Based on Grassmann et 
al (21). 
Many physiological functions of PrPC have been suggested, but its exact function is still 
elusive. PrP knockout mice do not show phenotypical deficits but are resistant to prion 
disease (36). However, some knockout mice show changes in circadian rhythm (37) and 
a mild cognitive deficit could be observed (38). PrP knockout studies also point to a 
possible role of PrPC in neurotransmission (37) and showed that PrPC is sensitive to 
oxidative stress (39). As PrPC has a high affinity to metal ions the capacity of copper 
binding has been attributed to PrPC (40). Furthermore, involvement in immnuoregulation, 
signal transduction, synaptic transmission, cell adhesion, cell cycle regulation and 
differentiation, microRNA metabolism and neuroprotection have been suggested (41). 
Neuronal apoptosis was detected in the hippocampus and cerebellum when anti-PrP 
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antibodies were intracranially delivered, which suggests a possible role of PrPC in the 
control of neuronal survival (42). In conclusion, PrPC might exert several functions and 
could be involved in diverse cellular processes. However, regardless of its physiological 
function, conversion of PrPC into its pathogenic form results in neurodegeneration.  
1.3 Pathogenic isoform of PrP 
The key event in prion disease is the conversion of the α-helix rich cellular prion protein 
(PrPC) into the β-sheet rich pathogenic isoform PrPSc. The conversion can occur 
sporadically, upon infectious transmission and can be due to mutations in the PRNP 
gene (43). 
1.3.1 Characterization of PrPC and PrPSc 
PrPC and PrPSc differ only in their secondary and tertiary structure, but these structural 
changes give PrPSc certain biochemical properties resulting finally in prion disease 
(Table 1) (44).  
Table 1. Biochemical and structural characteristic of PrPC and PrPSc 
PrPC PrPSc 
α-helical rich structure β-sheet rich structure 
proteinase K sensitive proteinase K resistent 
detergent soluble detergent insoluble 
no fibril formation aggregated, fibril formation 
non-infectious infectious 
PrPC consists mainly of an α-helical structure (43 %) and only a small fraction of β-
sheets (3 %), whereas PrPSc contains predominantly β-sheets and is capable of forming 
aggregates in contrast to PrPC (44, 45). These structural differences are based on their 
biochemical differences. 
PrPC and PrPSc differ with regards to their solubility, their tendency to form fibrils and 
their proteinase K (PK) resistance (16). PrPC is characterized by its solubility in 
detergents and it is highly susceptible to proteolysis (9). In contrast PrPSc is an insoluble 
protein with a partial resistance to proteolytic digestion (16, 44). PK completely degrades 
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PrPC, while it is only able to cleave off the aminoterminal region of PrPSc (46). The 
carboxyterminal PK resistant region consists of aa 90-231. PK digestion is broadly used 
to discriminate between PrPC and PrPSc by western blot analysis. 
1.3.2 Replication of PrPSc and different prion strains 
Several models have been proposed on how replication of PrPSc occurs, but there is 
growing evidence that prions replicate according to the so-called seeded-polymerization 
model (Figure 3) (47-50).  
In the seeded-polymerization model, an equilibrium between PrPC and an intermediate 
exists, with PrPC being the dominant conformation. The intermediates are metastable 
and unfolded PrP molecules that can be converted into PrPSc seeds, due to mutations 
that destabilize PrPC or infectious transmission (50). These seeds recruit more PrPC 
monomers that turn into PrPSc. Thereby these formerly small seeds elongate and form 
long fibrils, a process which finally results in PrPSc aggregate formation (51). These fibrils 
are usually 6-12 nm in diameter, rigid and non-branching and consist of two to six 
protofilaments that contain β-sheets (52). The protofilaments are twisted around each 
other and form a supercoiled structure (53).  
Figure 3. Replication of PrPSc according to the seeded-polymerization model. PrPC 
monomers are converted to PrPSc via a PrP intermediate. By the conversion of further PrPC 
monomers PrPSc seeds elongate and form aggregates. Fragmentation of aggregates produces 
new infectious seeds.  
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Formed and growing aggregates can be fragmented into smaller entities that function as 
new seeds for conversion of PrPC monomers to PrPSc (50, 51). The underlying 
mechanisms of fragmentation are not fully understood to date. However, heat shock 
proteins and autophagy may play a role in fragmentation (54). It is hypothesized that the 
size of the seeds determines toxicity and infectivity. Particles comprising 14-28 PrP 
molecules appear to be the most infectious (55).  
In the brain conversion of PrPC into PrPSc induces characteristic changes consisting of 
neuronal vacuolation and degeneration, which gives the cerebral grey matter 
‘spongiform’ appearance, and a reactive proliferation of astrocytes and microglia (56). 
Though the spongiform degeneration is frequently detected, it is not obligatory. 
Astrogliosis and microgliosis are more constantly observed, but they are not specific to 
the prion diseases. The lack of a lymphocytic inflammatory response is also an important 
characteristic (56-58). 
Furthermore, the conversion of PrPC into PrPSc can result in conformationally diverse 
types of PrPSc, so-called prion strains (59). Prion strains were first discovered in 1961 
when goats were infected with brain homogenate of sheep suffering from prion disease. 
Those goats developed prion diseases with different phenotypes (60). The same 
phenomenon was observed later, as hamsters were infected with mink-adapted prions. 
The hamsters developed prion disease with different incubation times and lesion profiles 
(61). To study the different strains, infectious isolates from given species were 
transmitted to mice and passaged several times from generation to generation. The 
prion phenotypes remained stable, demonstrating that different strains are characterized 
by differences in the length of the incubation time, the neuropathological lesion profiles, 
the pattern of PrPSc deposition and physicochemical properties of PrPSc (61-65). The 
physicochemical characteristics include PK resistance, glycosylation profile, 
electrophoretic mobility in western blot analysis, temperature stability, difference in 
conformations detected by specific anti-PrP antibodies and the resistance to guanidine 
hydrochloride (GdnHCl) (66-69).  
How different prion strains originate from the same PrPC protein in the absence of 
nucleic acid is not understood. The strain stability in the absence of nucleic acid was 
demonstrated as two different mink prion strains were able to propagate in a cell-free 
system without any co-factors, while maintaining their specific physicochemical 
properties (70). This self-conformation-templating hypothesis was supported by studies 
on protein level with a method called protein misfolding cyclic amplification (PMCA) (71). 
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In this method, recombinant PrP is incubated with small amounts of isolated PrPSc from 
brain of infected animals. This PrPSc functions as a seed and converts the recombinant 
PrP into PrPSc during several repeated cycles of sonication and incubation (72). The 
amplified PrPSc exhibits the same distinct physicochemical properties as the starting 
material (71). This also proofs the protein-only hypothesis, which states that the 
infectious agent (PrP) solely consists of proteins which self-propagate without any 
nucleic acids encoded by a genetic background (8). As the genetic information is not 
responsible for the different prion strains, the prion strain information is likely enciphered 
by heritable alternative conformations of PrPSc (73). One PrPC monomer can adopt 
multiple PrPSc conformations resulting in structurally distinct aggregate forms (PrPSc 
fibrils). PrPSc with distinct conformations serves as templats for conversion of adjoined 
PrPC and thereby preserves strain-specific information (41, 74). Transmission of prions 
isolated from prion diseased sheep to mice led to the establishment of at least 20 
different mouse-adapted strains. Two of the most established and studied mouse-
adapted strains are 22L and RML. The strains display characteristic lesion profiles in 
different brain regions of infected C57BL/6 mice (Figure 4). 
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Figure 4.  Strain specific pathology in 22L or RML infected C57BL/6 mouse brains. Infection 
of mice with prion strains 22L or RML results in distinct pathologies and lesion profiles. PrPSc 
deposition is shown in green, circles indicate spongiosis and stars gliosis. Severity is displayed by 
color and/or size of the different symbols. Figure adapted from Karapetyan et al (75). 
 
Inoculation with 22L results in a very severe PrPSc deposition in the cortex, the 
hippocampus, and the cerebellum, as well as a severe deposition in the brainstem, the 
thalamus, and the striatum. The cerebellum is affected the strongest with a very severe 
spongiosis and gliosis. Also the brainstem and the hippocampus display a very severe 
spongiosis but only a severe to moderate gliosis. The thalamus also exhibits a moderate 
spongiosis but a severe gliosis. PrPSc deposition in the striatum shows the mildest lesion 
profile with a slight spongiosis and gliosis. In contrast, infection with prion strain RML 
leads to very severe PrPSc deposition in the cortex, the hippocampus, the cerebellum, 
the brainstem, the thalamus, and the striatum. However, less spongiosis and gliosis are 
found in the cerebellum and brainstem (severe). Hippocampus and thalamus show a 
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comparable profile to 22L concerning spongiosis and gliosis. The cortex and the striatum 
display a very severe gliosis, but only a moderate to slight spongiosis (75). 
This example shows that different strains favor different brain regions. This might be due 
to different cell compositions or intracellular compartments. It is also possible that the 
cell specific co-factors are favored by certain PrP conformations and thereby promoting 
preferential propagation of one particular strain (76, 77).  
 
1.4 The species barrier and prion disease  
Different prion strains from different species are normally only transmitted within species 
due to the so-called species barrier. Inter-species transmission between related species 
is sometimes possible, but is only a rare event (78). Transmission of prions from one 
species to another leads to a prolonged incubation time and low attack rates in the new 
species (78, 79). The species barrier is mainly determined by differences in the PrP 
amino acid sequence between species, which results in variability in PrP structure (80). 
The second β-strand and the second α-helix can vary between species. This given loop 
mobility affects the resistance to prion disease (79). Additionally, single amino acid 
polymorphism within species in PrP correlate with prion susceptibility and affect the 
propensity of recombinant PrP to self-association into β-sheet enriched, oligomeric, and 
amyloid fibrils in vitro (79). It has been hypothesized, that also the type of prion strain 
influences the species barrier, as host PrPC is more compatible with certain PrPSc 
conformations (74). On rare occasions the species barrier can be overcome and prions 
of one species can infect another resulting in prion disease.  
Prion diseases affect many different species (Table 2). In humans they include 
Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker syndrome (GSS), 
fatal familial insomnia (FFI), kuru and variant CJD (vCJD) (81). Clinical symptoms in 
human prion diseases can vary from progressive dementia, cerebellar ataxia, pyramidal 
signs, chorea, myoclonus, extrapyramidal features, pseudobulbar signs, seizures to 
amyotrophic features and can be seen in variable combinations (57). Bovine spongiform 
encephalopathy (BSE), chronic wasting disease (CWD) in deer, elk and moose and 
scrapie in sheep and goats are important prion diseases of mammals (82). 
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Table 2. Overview of prion diseases in human and mammals  
Disease Host Etiology Mechanism/cause 
Familiar CJD Humans Genetic Mutation: PRNP gene (germinal) 
Iatrogenic CJD Humans Acquired 
Infection: contaminated surgical equipment, 
blood transfusion, transplants 
Variant CJD Humans Acquired 
Infection: ingestion of BSE contaminated 
products 
Sporadic CJD Humans Sporadic 
Mutation: PRNP gene (somatic)?  
Spontaneous: conversion PrPC into PrPSc?  
Fatal familial 
insomnia 
Humans Genetic Mutation: PRNP gene (germinal) 
Gerstmann-
Sträussler-
Scheinker syndrome 
Humans Genetic Mutation: PRNP gene (germinal) 
Kuru Humans Acquired Infection: cannibalism 
Bovine spongiform 
encephalopathy 
Cattle 
Acquired, 
sporadic 
Infection: ingestion of PrPSc contaminated bone 
meal; Spontaneous (rare) 
Chronic wasting 
disease 
Deer, elk 
and 
moose 
Acquired Infection: vertical and horizontal transmission 
Scrapie 
Sheep 
and 
goats 
Acquired, 
sporadic 
Infection: vertical and horizontal transmission; 
Spontaneous 
Exotic ungulate 
encephalopathy 
Exotic 
hoofed 
animals 
Acquired Infection: ingestion of BSE contaminated food 
Feline spongiform 
encephalopathy 
Cats and 
big cats 
Acquired Infection: ingestion of BSE contaminated food 
Transmissible mink 
encephalopathy 
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Prion diseases can be divided etiologically into three forms: inherited, sporadic and 
acquired (83). Most human prion diseases occur sporadically (~ 85 %), with an incidence 
of 1 – 2 cases per million per year, equally distributed between men and women (84, 
85). Over 30 autosomal dominant pathogenic mutations within the PRNP gene are 
known and cause 15 % of human prion diseases (83, 84, 86, 87). Under rare 
circumstances prion disease can be acquired. Iatrogenic CJD resulted from transmission 
of CJD prions trough treatment with pituitary hormones derived from human cadavers, 
implantation of dura mater grafts, corneal transplantation, blood transfusion and the use 
of contaminated electroencephalographic electrodes (57). The best-known acquired 
prion disease is kuru, resulting from ritual cannibalism among the Fore linguistic group of 
the Eastern Highlands in Papua New Guinea (88). More recently variant CJD was found 
in the United Kingdom, which distributed epidemically to Europe and later worldwide 
caused by the consumption of BSE contaminated products (83, 89). BSE occurred in 
cattle in 1986 in the United Kingdom and it was suspected to either originate from dietary 
intake of scrapie-infected sheep products (90, 91) or from a sporadic case (1, 92). 
Scrapie is the first described prion disease and can be vertically and horizontally 
transmitted (93). Recently, research focuses more and more on the study of chronic 
wasting disease (CWD), affecting deer, elk moose and reindeer. CWD occurred first in 
North America and Canada, later in the Republic of Korea and recently in Europe in 
Norway (94-97). CWD transmits naturally horizontally by uptake of prion-contaminated 
excretions contaminating the environment (98). Orally taken up prions are intestinally 
absorbed and transported via the blood and lymphoid fluids. Prions can peripherally 
replicate in the spleen, the appendix, tonsils or the lymphoid tissue. Afterwards they are 
transported primarily by peripheral nerves to the brain (99).  
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1.5 Models to study prion disease 
A complete understanding of prion disease and the underlying pathological mechanisms 
are crucial to identify potential prion therapeutics. In vitro and ex vivo models provide 
fundamental tools to study prion biology (Table 3) (21). 
 
Table 3. Overview of cell lines and organotypic cerebellar slices susceptible to prions. 
Based on Grassmann et al (21). 
Agent Adapted to  Cell lines 
Human prion disease Mouse N2a, GT1, RK13 mouse PrP 
 Human SH-SY5Y 
BSE Mouse MG20 
 Bank vole RK13 bank vole PrP 
CWD Mule deer elk MDB, RK13 elk PrP 
 
 
 
Scrapie 
Mouse 
N2a, GT1, RK13 mouse PrP 
SN56, HpL3-4 mouse PrP, 
CF10 mouse PrP, SMB, CAD, 
MG20, C2C12, L929, 
NIH/3T3, MSC-80, PC12 
 Hamster HaB 
 
Sheep/transgenic mice 
overexpressing ovine PrP 
MovS, RK13 ovine PrP 
Agent Adapted to COCS 
BSE Mouse C57BL/6 
Scrapie Mouse C57BL/6, transgenic mice 
 
1.5.1 Prion cell culture models 
The first cell culture system was already used in 1970, when cells of a mesodermal 
origin were isolated from a brain of a scrapie-infected mouse with clinically symptoms at 
the terminal stage (100). In 1980, another cell line for prion research was established, 
the mouse neuroblastoma cell line N2a, which is nowadays the most commonly used 
cell line in prion research. N2a cells are susceptible to several different mouse-adapted 
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scrapie strains and are able to propagate prions over many passages without cytopathic 
effects (101). Beside N2a cells, several other cell lines are susceptible to prions, 
including fibroblasts, myoblasts, epithelial and microglial cells (102-109). Exposing these 
cells to different prion strains of diverse origins led to persistent prion infection over 
several passages (107, 110). Successful infection of cells was especially achieved with 
prion strain 22L, RML/Chandler, ME7 and 139A (21). Primary cell culture systems 
including bone marrow-derived mesenchymal and neural stem cells, cerebellar neurons 
and astrocytes exist, but often show cytopathic effects (111-116).  
However, in vitro research has disadvantages such as restricted susceptibility of most 
cell lines to prion infection, usually poor infection rates and low prion titers (117). 
Susceptibility of cells to chronic prions infection is influenced by genetic heterogeneity 
and chromosomal instability within a cell population (118, 119) and does not correlate 
with PrPC expression levels (109, 118, 120), although PrPC expression is absolutely 
necessary for infection (121, 122). Cloning of infected and pre-cloning of uninfected cells 
is a useful tool to increase the infection rate and prion titers (118, 123, 124). Additionally, 
persistent prion infection in cells is also highly sensitive to culture conditions and 
changes in growth medium conditions (117, 125). 
 
1.5.2 Transcriptomics in prion disease  
To get a more detailed understanding of the development of prion disease it is useful to 
utilize an approach focusing on whole pathways. Until now a detailed knowledge of the 
molecular processes that lead to prion disease is still missing. In this context, genomic 
approaches are powerful to investigate the molecular basis of prion disease. Large-scale 
gene expression profiling of diseased vs. healthy groups helps to identify differentially 
expressed genes (DEGs). These DEGs can be used to identify novel genes and 
pathways that are deregulated at different time points during the pathogenesis (126). 
Different technologies have been used to detected genes variations including cDNA 
libraries, genome-wide association studies, microarrays, and more recently next-
generation sequencing (NGS). These studies may identify pathways, which help to gain 
insight within the pathogenesis of prion diseases, but also possibly may help to find 
biomarkers for the early detection of preclinical stages or for the identification of potential 
targets (126). 
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Several in vivo studies were performed and different pathways were identified. 
Numerous studies of prion infected brain tissues showed altered expression of genes 
involved in glia activation like glial fibrillary acidic protein (GFAP), lysozyme, MHC class I 
and II, and the chemokines CXCL10 and CXCL13 (127-129).  
Analysis of mRNA levels of cortex, medulla and pons of C57Bl/6 mice infected with prion 
strain 139A (100, 125, 150 and 189 days post infection) revealed 114 genes with altered 
mRNA expression, that were mostly unknown to be involved in prion diseases. Several 
of these genes are involved in the inflammatory reaction and stress response, a known 
result of prion infection that can finally result in neuronal loss. The authors state that a 
limitation of the secondary inflammatory reaction may prolong survival time (130).  
Comparison of gene expression between 22L and RML prion infected C57Bl/6 mouse 
brains at different time points showed similar inflammatory responses. Fifteen previously 
unreported differentially expressed genes related to inflammation or activation of the 
STAT signal transduction pathway were identified. The endogenous interleukin-1 
receptor antagonist (IL-1Ra), an inflammatory marker, was newly identified as increasing 
preclinically and could possibly be used for early detection of the disease (131).   
As described, a lot of transcriptomic studies analyze different kinds of inflammatory 
responses, due to the prominent microgliosis and astrogliosis in prion disease. To 
examine molecular changes unique to neurons, RNA isolation of the CA1 hippocampus 
region is useful as this region is particularly dense of neurons. Analysis of RNA 
expression in this distinct brain region of RML prion infected mice at different time points 
showed a bi-phasic response. During early prion disease neuronal protective 
mechanisms were up-regulated, while this protection was subsequently diminished at 
late stages of infection, in line with the clinical manifestation. The authors claim that 
these findings demonstrate the ability of neurons to mount an initial neuroprotective 
response to prions that could be exploited for therapy development (132).  
Hood et al performed a large comprehensive transcriptome analysis in brains of mice 
infected with eight different strains at 8 – 10 different time points. They identified 333 
core genes that appeared to play a central role to prion disease. Of these, 178 had not 
previously been reported to change in prion-infected mice. They generate a complex 
hypothetical dynamic protein network that could be associated with known pathological 
events in disease progression, including pathways like GAG metabolism, androgen 
metabolism, cholesterol homeostasis and sphingolipid metabolism (133).  
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These examples of studies of the transcriptomic changes in prion diseases show the 
broad range of possible field of applications. These genomic approaches could help to 
find biomarkers, to understand complex processes during symptom and disease 
development and may identify possible sites of actions for therapeutics. 
 
1.5.3 Ex vivo prion model 
To investigate prion infection in a complex neuronal environment, organotypic slice 
culture represents an important tool. This ex vivo model largely recapitulates the in vivo 
cellular environment (134). Organotypic cultures were used to study a variety of different 
brain areas including the hippocampus and the cerebellum (134). In 2008 cultured 
organotypic cerebella slices (COCS) of neonatal mice were used for the first time in 
prion research (135). COCS are incubated with prion-containing inoculum as free-
floating sections (135) and are subsequently grown on membrane inserts (136). COCS 
are susceptible to a mouse-adapted BSE strain and different mouse-adapted scrapie 
strains like 22L, RML and ME7 (137). In COCS PrPSc amplifies five times faster than in 
vivo. Prion infection of COCS recapitulates important hallmarks of prion pathology like 
deposition of PrPSc, vacuolation, neuronal loss, astro- and microgliosis (137, 138) and a 
decrease in Purkinje cell dendritic spine density (139). With all these features, COCS 
provide a powerful tool to study prion diseases. Beside western blot analysis and 
immunofluorescent staining of COCS, recent analysis of the transcriptome in COCS is a 
tool to study prion infection in slices (140) . However, the in vivo transferability 
concerning differential expressed genes and deregulated pathways was not tested until 
now. 
 
1.5.4 Role of in vitro and ex vivo models in prion disease 
In vivo and ex vivo models can be used to identify avenues of therapeutic intervention of 
prion diseases. Compounds that increase survival times in scrapie-infected mice are 
usually also inhibitors of PrPSc levels in cell culture (117). Pentosan polysulfate, one of 
the most active anti-scrapie compounds in vivo (141) strongly inhibits PrPSc formations in 
cells (142). Amphotericin B (143) and some other porphyrins (144, 145) with known anti-
scrapie activity reduce PrPSc formation also in vitro. This clearly demonstrates that 
screening of compounds that effectively inhibit PrPSc formation in cell culture is a good 
alternative for the expensive and time-consuming process of testing drugs against 
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scrapie in vivo. Identification of anti-prion compounds in vitro is currently accomplished 
by low-throughput assays that detect PrPSc levels by immunofluorescence staining or 
western blot analysis. Additionally, a high-throughput screening method exists that 
allows the identification of PrPSc inhibitory compounds on TSE-infected cells by a dot-
blot apparatus (117). In this assay, chronically infected cells are treated with compounds 
on a 96-well plate for distinct time periods. Before cells are lysed, toxic effects are 
determined by light microscopy. Proteinase K treated lysates are transferred to a PVDF 
membrane by a dot-blot apparatus. Subsequently, PrPSc can be detected by antibodies 
(117, 146). However, this assay has several limitations. It is not possible to relate the 
effect of a drug to the cell number analyzed, it delivers no information on PrPSc levels on 
single cell basis and it cannot be used to identify cellular mechanisms that might be 
inhibiting PrPSc formation (117). 
Ex vivo models also provide a good tool to study compound effects on prion disease as 
COCS provide a complex environment with interaction between highly diverse cell types 
including neurons, astrocytes and microglia (147). COCS can also be used to test the 
compound effects on the establishment of infection as well as on persistently infected 
slices. As this method is relative time consuming it is reasonable to examine only in vitro 
pretested compounds. To date, COCS were already successfully used to study the 
pharmacological inhibition of a persistent prion infection with known anti-prion 
compounds (137).  
 
1.6 Objectives 
Currently, prion therapeutic clinical trials have lacked success and there is an urgent 
need for novel therapeutics that can prevent, slow down, and ultimately stop prion 
disease progression (148). Several compounds have been identified that interfere with 
the prion conversion process, alter prion protein trafficking, or enhance prion 
degradation (148-152). However, only pentosan polysulfate and quinacrine were tested 
clinically and failed to reduce the clinical signs of prion disease (153, 154). Therefore, 
the aim of this study was to develop a cell-based assay for high content screening of 
compound libraries to identify compounds that might impair prion replication. Persistently 
prion strain 22L infected, compound treated N2a cells should be analyzed by automated 
high-throughput confocal microscopy. In contrast to already existing methods, this allows 
automated analysis and evaluation of thousands of cells on a single cell basis. Such an 
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assay would provide a powerful tool to identify compounds that reduce levels of PrPSc in 
single cells and can be further analyzed ex vivo or in vivo. Furthermore, identified 
compounds should be tested on prion infected organotypic slice culture to test whether 
in vitro detected anti-prion compounds are also effective in a more complex neuronal 
environment. Such a compound would present a perfect candidate for in vivo analysis 
and may finally result in a new therapeutically approach. 
Beside this, a comparative study of host response between ex vivo and in vivo should 
evaluate the transferability between the two systems, as this was not shown until now. 
To address this, organotypic slice culture from C57BL/6 pups (ex vivo) and C57BL/6 
mice (in vivo) should be infected with 22L- and RML-prions and after different incubation 
times a comparative RNA sequencing analysis should be performed. This analysis 
should show if prion infection results in comparable deregulated pathways ex vivo and in 
vivo and should help to assess the value of organotypic slice culture in prion research.  
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2 Materials and methods 
2.1 Biological safety 
Prion work was accomplished under biosafety level 2 according to the lab operating 
instructions and to the German Gentechnikgesetz (August 31st, 2015). Solid and liquid 
waste were autoclaved for 60 min at 134 °C. Prion contaminated liquids were inactivated 
with 1 M NaOH (final concentration) for at least 24 h.  
 
2.2 Cell biological methods 
All cell culture work was performed under a laminar flow cabinet (Scanlaf, Mars Safety 
Class 2, Labogene, Lynge, Denmark) and hands, bench and all instruments were 
disinfected or sterilized. To prevent contamination with prions, two pairs of gloves and 
protective sleeves were worn.  
 
2.2.1 Cell Lines 
DMEM + GlutaMAX-I    Dulbecco’s Modified Eagle Medium (1x) 
      + 4.5 g/L Glucose, - Pyruvat 
      Invitrogen, Darmstadt, Germany 
F – 12 Nutrient Mixture Kaighn’s Modification of Hams F – 12 
Nutrient Mixture (1x) 
 + L-Glutamine 
 Invitrogen, Darmstadt, Germany 
Fetal calf serum  PAA Laboratories, Pasching, Austria 
Penicillin/streptomycin solution (PenStrep) 10,000 units/mL Penicillin 
 10,000 µg/mL Streptomycin 
 Invitrogen, Darmstadt, Germany 
      
Cell lines were stored in liquid nitrogen. Cell culture media were stored at 4 °C and pre-
warmed to 37 °C in a water bath (GFL, Burgwedel, Germany) before use. 
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 Table 4. Cell lines 
Cell line Description Cultivation 
L929 15.9 
Murine fibroblast cell line L929 (ECACC, L929 
(NCTC), Cat. No. 85103115) subclone highly 
susceptible to mouse-adapted prion strains 22L 
and RML. Produced by Romina Bester by two 
rounds of limiting dilution cloning 
DMEM 
10 % FCS 
1 % PenStrep 
 
L929 22L 
L929 15.9 cell line persistently infected with 
mouse-adapted scrapie strain 22L 
DMEM 
10 % FCS 
1 % PenStrep 
N2a 
Murine neuroblastoma cell line (ATCC CCL 131) DMEM 
10 % FCS 
1 % PenStrep 
N2a 22L 
N2a cell line persistently infected with mouse-
adapted scrapie strain 22L 
DMEM 
10 % FCS 
1 % PenStrep 
 
2.2.2 Thawing of cells 
Cells were stored at -170 °C in liquid nitrogen and thawed at 37 °C in a water bath. 5 mL 
of appropriate pre-warmed cell culture medium was added to the cells and they were 
pelleted at 1,200 g (HeraeusTM MultifugeTM X3R, Thermo Scientific, Rockford, USA) for 5 
min at room temperature (RT). The cell pellet was resuspended in 3 mL medium and 
transferred to a cell culture flask containing medium.  
 
2.2.3 Cultivation of cells 
Phosphate buffered saline (PBS)  Invitrogen, Darmstadt, Germany 
0.25 % Trypsin-EDTA    Invitrogen, Darmstadt, Germany 
 
Cells were grown in either T25 or T75 flasks at 37 °C with 90 % air humidity and 5 % 
CO2 (Incubator: HERAcell 240i, Thermo Scientific, Rockford, USA). At a confluency of 
80 – 90 %, cells were rinsed with pre-warmed PBS and detached by incubating them 
with 500 µL – 1 mL of Trypsin-EDTA for 2 – 3 min at RT. Cells were resuspended by 
pipetting them up and down in 4 – 6 mL of fresh cell culture medium. An appropriate 
 Materials and methods  
 23 
volume of cell suspension was diluted into a new flask containing cell culture medium. 
Cells were split every 3 - 4 days at a ratio of 1:8 to 1:10.  
 
2.2.4 Cryoconservation of cells 
Dimethyl sulfoxide (DMSO)   Sigma-Aldrich, Steinheim, Germany 
 
Nearly confluent monolayers were harvested as described in 2.2.3. Cells were counted 
and pelleted at 1,200 g for 5 min at 4 °C. The supernatant was discarded and the pellet 
was resuspended in an appropriate volume of cell culture medium containing 10 % 
DSMO. Cells were either diluted to 3.5 x 105 cells in 500 µL or 1 x 106 in 1 mL and 
frozen in cryotubes at -80 °C in a box containing 100 % isopropanol for gentle reduction 
of the temperature. After 24 - 48 h, cryotubes were transferred to liquid nitrogen. 
 
2.2.5 Determination of the cell number 
0.4 % Trypan Blue Solution    Sigma-Aldrich, Steinheim, Germany 
 
The number of cells in a cell suspension was determined using an automated cell 
counter (TC20, BioRAD, Hercules, USA). To distinguish between vital and dead cells, 
the cell suspension was diluted 1:2 with trypan blue and transferred to a cell counting 
chamber. The cell counter determined the amount of vital and dead cells and the total 
amount of cells per mL cell suspension.  
 
2.2.6 Preparation of brain homogenates 
Opti-MEM-I (1 X) + GlutaMAX-I  Reduced serum medium 
      Invitrogen, Darmstadt, Germany 
 
Homogenates were prepared from brains of C57BL/6 mice infected with scrapie strains 
22L and RML. Scrapie-infected mouse brains were kindly provided by Prof. Dr. M. 
Groschup, Friedrich-Löffler-Institut, Bundesforschungsinstitut für Tiergesundheit, Isle of 
Riems, Germany and by Dr. Deborah McKenzie, Department of Biological Science, 
University of Alberta, Canada. A 10 % brain homogenate was prepared by 
homogenizing infected mouse brains with a glass dounce homogenizer (Homogenisator 
potter S, Sartorius, Göttingen, Germany) in Opti-MEM. As negative control, Mock brain 
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homogenates were prepared from prion uninfected C57BL/6 mice. Brain homogenate 
was centrifuged at 872 g (HeraeusTM MultifugeTM X3R, Thermo Scientific, Rockford, 
USA) for 5 min at 4 °C to remove the cell debris. Aliquots of the supernatant were stored 
at -80 °C. 
2.2.7 Infections of cells with scrapie strains 22L or RML 
Persistently infected cells were generated by incubating cells with brain homogenates. 
Therefore, 2 x 104 cells were seeded in a 24-well plate (Sigma-Aldrich, Steinheim, 
Germany) and 24 h after seeding, the medium was replaced by growth medium with 
supplements containing 1 % (v/v) brain homogenate. After five hours, the brain 
homogenate was diluted 1:3 with cell culture medium. The medium was replaced by cell 
culture medium approximately 24 h after infection  
 
2.2.8 Treatment of cells with different compounds 
DMSO     Sigma-Aldrich, Steinheim, Germany 
 
Cells were seeded and grown for two hours. Compounds were diluted in DMSO or 
H2Obidest according to manufacturer`s protocol. For treatment of the cells, compounds 
were added to cell culture medium at different concentrations. As control DMSO or 
H2Obidest without any compound were added to the cells. Cells were treated for 44 h.  
 
2.3 Primary slice culture methods 
All primary slice culture methods were based on a modified protocol for the prion 
organotypic slice culture assay (POSCA) from Falsig and Aguzzi (135).  
 
2.3.1 Mouse husbandry 
Female C57BL/6JRj mice with pups were ordered from Janvier (St. Berthevin Cedex, 
France) and housed in cages at a 12:12 light:dark cycle. Food and water were available 
ad libidum. All animal experiments were approved by the Landesamt für Natur, Umwelt 
und Verbraucherschutz NRW and conducted according to the institutional animal care 
committee guidelines and German animal protection laws.  
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2.3.2 Preparation of organotypic cerebellar brain slices 
100 mM Kynurenic acid stock solution  in H2Obidest, pH 7.2 – 7.4 
      Sigma-Aldrich, Steinheim, Germany 
Grey’s balanced salt solution (GBSS) Sigma-Aldrich, Steinheim, Germany 
D-(+)-glucose solution ( 45 %)  Sigma-Aldrich, Steinheim, Germany 
GBSSK     6.662 mL D-(+)-glucose solution (45 %) 
5 mL 100 mM Kynurenic acid stock solution 
      in 500 mL GBSS 
2 % LMP agarose solution   UltraPure Low-melting-point agarose 
      Invitrogen, Darmstadt, Germany 
      in GBSSK 
Glue Glue Roti coll1, Carl Roth, Karlsruhe, 
Germany 
 
Cerebellar brain slices were prepared by decapitation of 9 - 13 days old pups of 
C57BL/6JRj mice. Heads were kept on ice and the skin was removed. The skull was 
opened and the brain was dissected. Brains were kept on ice cold GBSSK and the 
cerebella were dissected from the brains under a stereoscopic microscope. Cerebella 
were imbedded into 2 % low melting agarose in an upright position in a plastic container 
(Ø 22 mm, 7 mL, Carl Roth, Karlsruhe, Germany). Blocks containing the cerebellum 
were cut and glued on the disc of the vibratome (VT1200S, Leica, Biosystems, Wetzlar, 
Germany). The disc was fixed in the inner chamber of the vibratome, filled with ice cold 
GBSSK and the inner chamber was placed into the ice filled outer chamber. A blade 
(VALET AutoStrop, England, UK) was fixed to the slicing arm and 350 µm thick 
cerebellar brain slices were prepared with a speed of 0.24 mm/s and an amplitude of 
1.00 mm. Slices were transferred into an ice cold GBSSK filled 6 cm dish and remaining 
agarose was removed from the slices under a stereoscopic microscope. Cerebellar brain 
slices were either directly transferred to a membrane insert for cultivation (2.3.4) or 
infected with prions as described in 2.3.3. 
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2.3.3 Infection of cerebellar brain slices with scrapie strain 22L or RML 
Cerebellar slices were exposed to prion-infected brain homogenate (2.2.6) under a 
laminar flow cabinet (Scanlaf, Mars Safety Class 2, Labogene, Lynge, Denmark) 
according to the safety instructions. Up to 10 brain slices were transferred to a 24-well 
plate (BD Biosciences, Heidelberg, Germany) containing GBSSK. Cerebellar brain slices 
were exposed to 20 mg/mL prion-infected brain homogenate or, as negative control, to 
uninfected Mock brain homogenates for 1 h at 4 °C under permanent shaking. To 
remove brain homogenate, slices were washed three times with ice cold GBSSK in a 6-
well plate. Cerebellar brain slices were transferred to a membrane insert for cultivation. 
 
2.3.4 Cultivation of cerebellar brain slices 
Minimal essential medium (MEM)  Invitrogen, Darmstadt, Germany 
Basal medium Eagle (BME)    Invitrogen, Darmstadt, Germany 
Horse serum     Heat inactivated 
      Invitrogen, Darmstadt, Germany 
GlutaMAX-I     100X  
      Invitrogen, Darmstadt, Germany 
Penicillin/streptomycin solution 10,000 units/mL Penicillin 
 10,000 µg/mL Streptomycin 
 Invitrogen, Darmstadt, Germany 
D-(+)-glucose solution (45 %)  Sigma-Aldrich, Steinheim, Germany 
2x MEM 1.922 g MEM 
 0.44 g NaHCO3 
 Sigma-Aldrich, Steinheim, Germany 
 In 100 mL in H2Obidest 
Slice culture medium 100 mL 2x MEM 
 100 mL BME 
 100 mL Horse serum 
 4 mL GlutaMAX-I  
 4 mL Penicillin/streptomycin 
 5.5 mL D-(+)-glucose solution (45 %) 
 86.5 mL in H2Obidest 
pH 7.2 – 7.4 
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Up to five infected or uninfected cerebellar brain slices were transferred to membrane 
inserts. Membrane inserts were placed in a 6-well plate containing slice culture medium. 
Cerebellar brain slices were cultured up to 12 weeks at 37 °C with 90 % air humidity and 
5 % CO2 (Incubator: HERAcell 240i, Thermo Scientific, Rockford, USA). Every 2 - 3 days 
medium was replaced by fresh medium.  
 
2.3.5 Treatment of cerebellar slices with different compounds 
DMSO     Sigma-Aldrich, Steinheim, Germany 
 
Cerebellar slices were infected with 22L or RML prion brain homogenate (2.3.3) and 
grown for two weeks. Compounds were diluted in DMSO or H2Obidest according to 
manufacturer`s protocol. For treatment of the cerebella slices, compounds were added 
to the slice culture medium at different concentrations. As control DMSO or H2Obidest 
without any compound were added to the cells. Cerebellar slices were treated for up to 
five weeks. 
 
2.3.6 Propidium iodide (PI) staining 
Propidium iodide solution   10 mg/mL 
      Sigmal-Aldrich, Steinheim, Germany 
Hydrogen peroxide solution (H2O2)   8.8 µM 
      Sigmal-Aldrich, Steinheim, Germany 
Staurosporine      5 µM 
      Enzo, Lausen, Switzerland 
GBSS      Sigma-Aldrich, Steinheim, Germany 
 
The tissue viability was tested by PI incorporation into dead cells of cerebellar slices. 
10 µg/mL PI was added to slices culture medium and slices were incubated for 2 h at 37 
°C. Slices were washed three times with GBSS for 10 min. As a positive control slices 
were treated for two days with slice culture medium containing 8.8 mM H2O2. PI 
incorporation was detected by an inverse epifluorescence microscope (Axio observer 
Z1, Zeiss, Jena, Germany). The exposure time was adjusted in the positive control slices 
and kept constantly during the whole experiment. 
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2.4 Injection of mice with brain homogenate  
2.4.1 Mouse husbandry 
Female and male C57BL/6JRj mice from Janvier (St. Berthevin Cedex, France) were 
housed in cages at a 12:12 light:dark cycle. Food and water were available ad libidum. 
All animal experiments were approved by the Landesamt für Natur, Umwelt und 
Verbraucherschutz NRW and conducted according to the institutional animal care 
committee guidelines and German animal protection laws.  
 
2.4.2 Intracranial injection and tissue dissection 
Isoflurane FORENE     100% 
AbbVie, North Chicago, USA 
Rimadyl Cattle    50 mg/mL Solution 
Pfizer, New York, USA 
 
Mouse work was performed in collaboration with Walker Jackson and Melvin Schleif 
(DZNE, Bonn). Six weeks old mice were anesthetized with 3 – 5 % isoflurane and 20 µL 
of 0.1 % 22L- or RML prion brain homogenate (2.2.6) were injected intracranially into the 
right brain hemisphere at the bregmatic suture. Injection depth was 3 mm starting at the 
outer mouse head skin. As negative control mice were injected with Mock brain 
homogenate. The wound was cleaned with 70 % ethanol (EtOH) and mice were carefully 
observed until full recovery from anesthesia. All injections were done on the same day. 
An analgesic (Rimadyl) was administered within the next 72 h according to the 
manufacturer’s instructions. 
Mice were sacrificed 10, 14 and 18 weeks post injection by CO2 inhalation. Brains were 
dissected, the two hemispheres were separated and each one snap frozen for mRNA 
isolation and stored at -80 °C. 
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2.5 Indirect immunofluorescence staining of proteins 
2.5.1 Indirect immunofluorescence staining of cells 
Table 5. Primary antibodies 
Antibody Origin Specificity Application Reference 
4H11 mouse, 
monoclonal 
anti- PrP 
(C-terminal end) 
WB 1:10000 
IF 1:10 (cells), 
1:5 (cerebellar 
slice) 
Dr. Elisabeth 
Kremmer (155), 
Helmholtz Center 
Munich, Germany 
PrPA mouse, 
monoclonal 
anti- PrP 
(N-terminal end,  
amino acid 23 - 30) 
WB 1:10000 
Dr. Elisabeth 
Kremmer, 
Helmholtz Center 
Munich, Germany 
PrPB mouse, 
monoclonal 
anti- PrP 
(amino acid 89 - 109) 
WB 1:10000 
Dr. Elisabeth 
Kremmer, 
Helmholtz Center 
Munich, Germany 
Saf32 mouse, 
monoclonal 
anti- PrP 
(oktapeptide repeat 
region) 
WB 1:10000 
Cayman 
Chemicals, 
Michigan, USA 
p-Met rabbit, 
monoclonal 
Anti-phosphorylated 
Met 
IF 1:200 
(cerebellar 
slice) 
Cell Signaling 
Technology, 
Leiden, 
Netherlands 
Lamp-1 rat, 
monoclonal 
Lamp-1 of NIH/3T3 
mouse embryo 
fibroblast tissue culture 
cell membranes 
IF 1:200 
(cerebellar 
slice) 
Diagnostics, 
Freiburg, 
Germany 
β-3-
tubulin 
rabbit, 
polyclonal 
epitope in microtubules  
IF 1:250 
(cerebellar 
slice) 
Diagnostics, 
Freiburg, 
Germany 
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Table 6. Secondary antibodies 
Antibody Origin Specificity Application Reference 
Alexa Fluor 
488-
conjugated 
anti-Mouse 
IgG 
goat mouse IgG 
IF 1:300 (cells and 
cerebellar slices) 
Life 
Technologies, 
Darmstadt, 
Germany 
Alexa Fluor 
647-
conjugated 
anti-Mouse 
IgG 
goat rat IgG IF 1:300 (cells) 
Life 
Technologies, 
Darmstadt, 
Germany 
Horseradish 
peroxidase-
conjugated 
anti-Mouse 
IgG 
goat mouse IgG WB 1:10000 
Dianova, 
Hamburg, 
Germany 
 
PBS       Invitrogen, Darmstadt, Germany 
4 % PFA      Paraformaldehyde 
      Sigma-Aldrich, Steinheim, Germany 
      in PBS, pH 7.2 – 7.4 
0.1 % Triton X-100    Roth, Karlsruhe, Germany 
      in PBS 
6 M GdnHCl     Guanidine hydrochloride 
      Sigma-Aldrich, Steinheim, Germany 
      in PBS 
0.2 % Gelatine    from cold water fish skin 
Sigma-Aldrich, Steinheim, Germany 
      in PBS 
Hoechst 33342 Molecular Probes, Eugene, Oregon, USA  
 
For detection of specific proteins, 2 x 104 cells were seeded in 24-wells (BD Biosciences, 
Heidelberg, Germany) on coverslips. Cells were cultured for 3 d and washed with PBS. 
After fixation with 4 % PFA for 20 min at room temperature (RT), cells were rinsed at 
least 3 times with PBS. Cells were permeabilized with 0.1 % Triton X-100 for 10 min and 
washed 3 times with PBS. For specific detection of PrPSc proteins were denatured with 6 
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M guanidine hydrochloride for 10 min at RT and rinsed 5 times with PBS. After blocking 
the cells with 0.2 % gelatine for 1 h at RT, primary antibody (Table 5) in blocking solution 
was added for 1 h at RT and cells were rinsed 3 times with PBS. The fluorophore-
conjugated secondary antibodies (Table 6) were added to the cells, incubated for 1 h at 
RT and removed by three washing steps with PBS. Nuclei were visualized with 1 µg/mL 
Hoechst 3342 DNA (Deoxyribonucleic acid) staining in PBS for 10 min at RT, followed 
by 3 washing steps with PBS and one final washing step with H2O. Cover slips were 
transferred to glass object slides (25 x 75 x 1.0 mm, Menzel-Gläser, SuperFrost Plus, 
Thermo Scientific, Braunschweig, Germany) and mounted with Aqua-Poly/Mount 
(Polysciences, Eppelheim, Germany), dried for at least 1 h at RT and stored at 4 °C until 
microscopic analysis was carried out. Confocal microscopy was performed using the 
LSM 700 (Zeiss, Jena, Germany) or the upright LSM 700 (Zeiss, Jena, Germany). 
 
2.5.2 Indirect immunofluorescence staining of cells for high-throughput 
screen  
PBS       Invitrogen, Darmstadt, Germany 
4 % PFA      Paraformaldehyde 
      Sigma-Aldrich, Steinheim, Germany 
      in PBS, pH 7.2 – 7.4 
0.1 % Triton X-100    Roth, Karlsruhe, Germany 
      in PBS 
6 M GdnHCl     Guanidine hydrochloride 
      Sigma-Aldrich, Steinheim, Germany 
      in PBS 
0.2 % Gelantine    from cold water fish skin 
Sigma-Aldrich, Steinheim, Germany 
      in PBS 
Hoechst 33342 Molecular Probes, Eugene, Oregon, USA  
HCS CellMask Blue stain Molecular Probes, Eugene, Oregon, USA  
 
For the high-throughput screen, 5 x 103 cells were seeded per well on a 96-well plate 
(µclear-plate, Black, Greiner bio one, Frickenhausen, Germany). Cells were stained 
following the protocol described in 2.5.1. In contrast to staining in 24-well plates, the 
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whole 96-well plate was immersed in 6M guanidine hydrochloride for 10 min to 
inactivated prions. Additionally, cytoplasm was visualized with HCS CellMask Blue stain 
(1:5000) for 10 min followed by 3 washing steps with PBS, after Hoechst treatment. 
Thereby, cell borders were defined and intracellular PrPSc detection was possible. 96 
well plates could be stored at 4°C, if all wells were covered with sufficient amount of PBS 
or plates were directly analyzed. Cells were analyzed with an automatic confocal 
microscope (Cell Voyager 6000, Yokogawa, Tokyo, Japan). Image analysis was 
performed using the Columbus Image Data Storage and Analysis System. 
 
2.5.3 Indirect immunofluorescence staining of cerebellar slices  
PBS       Invitrogen, Darmstadt, Germany 
4 % PFA      Paraformaldehyde 
      Sigma-Aldrich, Steinheim, Germany 
      in PBS, pH 7.2 – 7.4 
0.5 % Triton X-100    Roth, Karlsruhe, Germany 
      in PBS 
6 M GdnHCl     Guanidine hydrochloride 
      Sigma-Aldrich, Steinheim, Germany 
      in PBS 
5 % BSA     Albumin from bovine serum 
Fluka, Sigma-Aldrich, Steinheim, Germany 
      in PBS 
Hoechst 33342 Molecular Probes, Eugene, Oregon, USA  
 
For indirect immunofluorescence staining of cerebellar slices, slices were washed with 
PBS and fixed with 4 % PFA at RT for 2 h, followed by three washing steps with PBS for 
10 min. Slices were permeabilized with 0.5 % Triton X-100 at 4 °C for 18 h. After three 
times washing with PBS slices were incubated with 6 M guanidine hydrochloride for 3 h 
at RT for PrPSc detection (147). Slices were thoroughly rinsed three times with PBS. To 
avoid unspecific binding of the antibodies, slices were blocked with 5 % BSA for three 
days at 4 °C. Afterwards, cerebellar slices were cut out of the membrane inserts with 
biopsy punch (8,0 mm, Stiefel, Offenbach am Main, Germany) and transferred to a 24-
well plate (BD Biosciences, Heidelberg, Germany). Primary antibodies (Table 5) diluted 
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in 5 % BSA were incubated at 4 °C for three days, slices were rinsed four times with 
PBS and the fluorophore-conjugated secondary antibody (Table 6) diluted in 5 % BSA 
was added for 3 days at 4 °C. Afterwards, slices were washed four times with PBS and 
nuclei were stained with Hoechst diluted 1:10,000 in PBS for 10 min at RT, followed by 
four washing steps with PBS. Slices were transferred on top of a drop PBS on a glass 
object slide (25x75x1.0 mm, Menzel-Gläser, SuperFrost Plus, Thermo Scientific, 
Braunschweig, Germany) to help smoothening of the membrane. PBS was removed, a 
drop of Aqua-Poly/Mount (Polysciences, Eppelheim, Germany) was added and slices 
were mounted with a cover slip (high precision, No 1.5 H, 12 mm Ø, Marienfeld, Lauda-
Könighofen, Germany). The samples were dried for 1 h at RT and stored at 4 °C until 
microscopic investigation was conducted. Cerebellar brain slices were analyzed with an 
inverse epifluorescence microscope (Axio observer Z1, Zeiss, Jena, Germany). 
 
2.6 Protein biochemical methods 
2.6.1 Preparation of post nuclear cell lysates 
PBS      Invitrogen, Darmstadt, Germany 
Lysis buffer     100 mM NaCl 
      Roth, Karlsruhe, Germany 
      100 mM Tris/HCl, pH 7.5 
      Roth, Karlsruhe, Germany 
      100 mM EDTA 
Fluka, Sigma-Aldrich, Steinheim, Germany 
0.5 % Desoxycholate acid sodium salt  
Roth, Karlsruhe, Germany 
in H2Obidest 
TNE buffer     50 mM Tris/HCl, pH 7.5 
Roth, Karlsruhe, Germany 
150 mM NaCl  
Roth, Karlsruhe, Germany 
5 mM EDTA 
Fluka, Sigma-Aldrich, Steinheim, Germany 
in H2Obidest 
1 % Pefabloc SC (AEBSF)   Roche, Mannheim, Germany 
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in H2Obidest      
100 % Methanol    Roth, Karlsruhe, Germany 
3x SDS sample buffer (SEB)   90 mM Tris/HCl 
      Roth, Karlsruhe, Germany 
      7 % SDS 
      Roth, Karlsruhe, Germany 
      0.01 % Bromphenol blue 
      Merck, Darmstadt, Germany 
      30 % Glycerol 
      Roth, Karlsruhe, Germany 
      20 % β-Mercaptoethanol 
      Sigma-Aldrich, Steinheim, Germany 
      in H2Obidest 
 
Cells were lysed for western blot analysis. Therefore, grown cells were rinsed with PBS 
and incubated for 10 min with lysis buffer at RT. Cell lysates were centrifuged at 
10,817 g (Eppendorf Centrifuge 5417R, Hamburg, Germany) for 1 min at 4 °C to remove 
the cell debris. The total amount of protein in the lysates was detected as described in 
2.6.3. For detection of total PrP and other proteins, lysate containing 10 µg of total 
protein was treated with 0.02 % Pefabloc and mixed with 3x SEB. By boiling the samples 
for 10 min at 95 °C, proteins were denatured. Boiled samples were either stored at -
20 °C or directly loaded onto a NuPAGE Novex 4 – 12 % Bis-Tris Midi gel for western 
blot analysis. 
For the detection of PrPSc lysates were digested with proteinase K prior to Pefabloc 
treatment (2.6.4). Boiled samples were either stored at -20 °C or directly loaded onto a 
NuPAGE Novex 4 – 12 % Bis-Tris Midi gel for western blot analysis. 
 
2.6.2 Preparation of cerebellar brain slice lysates 
PBS      Invitrogen, Darmstadt, Germany 
Brain slice lysis buffer    0.5 % Desoxycholate acid sodium salt 
      Roth, Karlsruhe, Germany 
      0.5 % Nonidet P40 substitute 
      Sigma-Aldrich, Steinheim, Germany 
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      In PBS   
1 % Pefabloc SC (AEBSF)   Roche, Mannheim, Germany 
in H2Obidest 
NuPAGE LDS sample buffer   4X 
      Invitrogen, Darmstadt, Germany 
 
For protein extraction from cerebellar brain slices, inserts were washed once with PBS 
and brain slice lysis buffer was added. Brain slices were scraped off the inserts and two 
brain slices were pooled. Lysis of tissue was performed by three freeze and thaw cycles. 
One cycle consisted of freezing the lysates for 20 min at -80 °C, followed by thawing and 
sonication (Sonoplus HD3200, Bandelin Sonorex Technik, Berlin, Germany) for 30 s. 
After lysis, samples were cleared by low speed centrifugation at 1,152 g (Eppendorf 
Centrifuge 5417R, Hamburg, Germany) for 3 min at 4 °C. Pellets were discarded and the 
protein concentration was determined (2.6.3). For specific detection of PrPSc, 20 µg 
protein was digested with proteinase K as described in 2.6.5, whereas 10 µg protein was 
used to detect total PrP or other proteins. Those samples were directly mixed with 
0.02 % Pefabloc SC and NuPAGE LDS sample buffer and boiled for 5 min at 95 °C. 
Samples were loaded onto a NuPAGE Novex 4 – 12 % Bis-Tris Midi gel (Invitrogen, 
Darmstadt, Germany) or stored at -80 °C. 
 
2.6.3 Determination of protein concentration  
Quick Start Bradford Assay   BioRAD, Hercules, USA  
Quick Start Bovine Serum Albumin  BioRAD, Hercules, USA  
 
The protein concentration of cell lysates was determined by the Bradford protein assay. 
5 µL of the sample, in duplicate, a BSA standard dilution series (62.5 – 2000 µg/mL) and 
a lysis buffer blank control were transferred to a clear 96-well plate and 250 µL Bradford 
reagent was added. Samples were incubated for 5 min and absorbance was measured 
at 595 nm with the plate reader (FLUOstar Omega, BMG Labtech, Offenburg, Germany). 
A standard curve was generated using MARS data analysis software and protein 
concentration could be determined. If necessary samples were diluted 1:5 or 1:10 in 
H2Obidest , in that case H2Obidest served as blank control.  
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2.6.4 Proteinase K digestion of post nuclear cell lysates 
1 % proteinase K (PK)   Carl Roth, Karlsruhe, Germany 
in H2Obidest 
1 % Pefabloc SC (AEBSF)   Roche, Mannheim, Germany 
in H2Obidest 
Blue DEXTRAN 2000    GE Healthcare, Uppsala, Sweden 
      In lysis buffer 
 
For detection of PrPSc post nuclear cell lysates (2.6.1) were incubated with 20 µg/mL PK 
for 30 min at 37 °C. Proteinase inhibitor Pefabloc SC (0.02 %) was added to stop the 
reaction. Blue DEXTRAN was added to the sample for detection of the cell pellet. 
Lysates were centrifuged at 20,817 g (Eppendorf Centrifuge 5417R, Hamburg, German) 
for 1 h at 4 °C and the supernatant was discarded. The pellet was resuspended in TNE 
buffer and 3x SDS sample buffer. Samples were boiled at 95°C for 10 min and loaded 
onto a NuPAGE Novex 4 – 12 % Bis-Tris Midi gel (Invitrogen, Darmstadt, Germany) or 
stored at -80 °C. 
 
2.6.5 Proteinase K digestion of cerebellar brain slice lysates 
1 % proteinase K (PK)   Carl Roth, Karlsruhe, Germany 
in H2Obidest 
NuPAGE LDS sample buffer   4x 
      Invitrogen, Darmstadt, Germany 
 
Cerebellar brain slice lysates were supplemented with 62.5 µg/mL PK and incubated for 
30 min at 37°C. The PK treatment was stopped by adding NuPAGE LDS sample buffer. 
After boiling the samples for 5 min at 95 °C, they were either stored at – 80 °C until use 
or loaded onto a NuPAGE Novex 4 – 12 % Bis-Tris Midi gel (Invitrogen, Darmstadt, 
Germany).  
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2.7 Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
NuPAGE MOPS SDS running buffer  20x 
      Invitrogen, Darmstadt, Germany 
Protein ladder PageRuler Plus Prestained Protein Ladder 
 Thermo Scientific, Rockford, USA 
 
Proteins were separated by their molecular weight in an electrical field using denaturing 
SDS-PAGE. A NuPAGE Novex 4 – 12 % Bis-Tris Midi gel (Invitrogen, Darmstadt, 
Germany) was placed into an electrophoresis chamber (XCell4 Surelock Midi-Cell, 
Invitrogen, Darmstadt Germany). The chamber was filled with 1x NuPAGE MOPS SDS 
running buffer. Protein lysates and protein ladder were loaded onto the gel and 
electrophoresis was performed under a current of 30 mA per gel for 2.5 h.  
 
2.8 Western blot analysis 
100 % Methanol    Roth, Karlsruhe, Germany  
Wet blotting buffer     192 mM Glycin 
      Roth, Karlsruhe, Germany 
      25 mM Tris 
      Roth, Karlsruhe, Germany 
      0.01 % SDS 
      Roth, Karlsruhe, Germany 
      20 % Methanol 
Roth, Karlsruhe, Germany 
in H2Obidest 
10 x TBST     0.5 % Tween-20 
      Roth, Karlsruhe, Germany 
      1.5 M NaCl, pH 8.0 
      Roth, Karlsruhe, Germany 
   in H2Obidest 
Blocking solution    5 % milk powder 
      Roth, Karlsruhe, Germany 
      In 1x TBST buffer 
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Amersham ECL Prime   Solution A : Solution B (1:1) 
      GE Healthcare, Buckinghamshire, UK 
Pierce ECL solution     Solution A : Solution B (1:1) 
      Thermo Scientific, Rockford, USA 
SuperSignalTM West Femto Maximum Solution A : Solution B (1:1) 
Sensitive Substrate    GE Healthcare, Buckinghamshire, UK 
 
Western blot analysis was performed to electrically transfer proteins, separated by SDS-
PAGE (2.7), onto a polyvinylidene difluoride (PVDF) membrane (Amersham Hybon-P, 
GE Healthcare, Buckinghamshire, UK) for the subsequent detection of proteins by 
specific antibodies. Proteins were transferred onto a methanol activated PVDF 
membrane using a wet blot chamber with a constant power of 30 V for approximately 
17 h at 4 °C. The membrane was blocked with 5 % milk powder (MP) in TBST for 1 h to 
saturate unspecific binding sites. Primary antibody was incubated either for 1 h at RT or 
over night at 4 °C in 1 % MP in TBST (Table 5). After removing excess antibody by five 
washing steps for 6 min with TBST, the membrane was incubated with secondary 
antibodies coupled to horseradish peroxidase for 1 h at RT in 1 % MP in TBST (Table 6). 
The membrane was washed five times in TBST and incubated for 1-5 min in ECL 
solution according to manufacturers protocol. The horseradish peroxidase coupled to the 
secondary antibody catalyzed the conversion of the chemiluminescence substrate. The 
chemiluminescence was detected by the Stella Imaging System (Raytest 
Isotopenmessgeräte, Straubenhardt, Germany).  
For detection of other proteins with a similar size on the same membrane, the 
membrane was stripped to remove the antibodies. The membrane was washed with 
H2Obidest for 10 min and incubated twice for 20 min with 1 x Re-Blot Plus Strong Solution 
(1:10 in H2Obidest). The membrane was carefully rinsed five times and blocked again for 
30 min with 5 % MP. Afterwards the membrane was stained as described above. 
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2.9 Molecular biological methods 
2.9.1 RNA isolation of cerebellar brain slices 
PBS      Invitrogen, Darmstadt, Germany 
Guanidine-isothiocyanate 4M in RLT buffer diluted 1:2 with 35 % 
EtOH 
      Roth, Karlsruhe, Germany 
 
RNA of cerebellar brain slices was isolated with the RNeasy Plus Mini Kit (Qiagen, 
Hilden, Germany). The manufacturer’s protocol was adapted to the specific need of the 
experiments. Briefly, cerebellar brain slices were washed once with PBS. Afterwards, 
cerebellar slices were cut out of the membrane inserts with a biopsy punch (8.0 mm, 
Stiefel, Offenbach am Main, Germany) and slices were homogenized in highly 
denaturing guanidine-isothiocyanate-containing Buffer RLT Plus, that protected the RNA 
against degradation, using a dounce homogenizer (Homogenisator potter S, Sartorius, 
Göttingen, Germany). One lysate was split and transferred to two gDNA Eliminator spin 
columns to remove DNA in the samples. After centrifugation, the supernatant was mixed 
with 70 % ethanol (1:2) to provide appropriate binding conditions and passed through a 
RNeasy spin column. Additionally, 4 M guanidine-isothiocyanate in RLT buffer diluted 
1:2 with 35 % EtOH was applied to the RNeasy spin column and incubated for 30 min to 
guaranty inactivation of PrPSc. After incubation, samples were centrifuged and the 
supernatant was loaded a second time to minimize the loss of RNA. After several 
washing steps with different washing buffers according to the manufacturer’s protocol, 
RNA was eluted by adding H2O to the column. The RNA concentration was determined 
as described in 2.9.3 and isolated RNA was stored at -80 °C. 
 
2.9.2 RNA isolation of cerebella 
Guanidine-isothiocyanate 4M in RLT buffer diluted 1:2 with 35 % 
EtOH 
      Roth, Karlsruhe, Germany 
 
RNA of cerebella isolated with the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). The 
cerebella were cut into two halves and manufacturer’s protocol was adapted to the 
specific need of the experiments. Cerebella were homogenized with a glass 
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homogenizer in 1.5 mL highly denaturing guanidine-isothiocyanate-containing Buffer 
RLT Plus. The following steps were accomplished as described in 2.9.1. The RNA 
concentration was determined as described in 2.9.3 and isolated RNA was stored 
at -80 °C. 
 
2.9.3 Determination of RNA concentration  
Qubit® RNA Reagent    Thermo Scientific, Rockford, USA 
Qubit® RNA Buffer         Thermo Scientific, Rockford, USA 
 
The total amount of isolated RNA was determined by using Qubit® RNA Assay Kit 
(Thermo Scientific, Rockford, USA) according to the manufacturer’s protocol. The kit is 
based on measurements of fluorescence signals. Samples were added to a prepared 
working solution and incubated for 15 min at RT after vortexing. The working solution 
was produced by diluting RNA reagent in RNA buffer (1:200). The RNA reagent has 
extremely low fluorescence until it binds to RNA. The fluorescent signal was measured 
by the Qubit® fluorometer (Thermo Scientific, Rockford, USA) and the RNA 
concentration in the samples was calculated using a reference curve of E. Coli rRNA 
concentration.  
 
2.9.4 Next generation sequencing  
RNA- TruSeq RNA sample    Illumina, San Diego, USA 
preparation 2 Kit  
Transcriptor high fidelity   Roche Applied Science, Mannheim, 
cDNA synthesis Kit    Germany 
TruSeq SBS Kit 3-HS    Illumina, San Diego, USA 
TruSeq SR Cluster Kit 3-cBot-HS  Illumina, San Diego, USA 
Qubit®  dsDNA HS Assay Kit   Thermo Scientific, Rockford, USA 
 
RNA-sequencing was done at the DZNE in Göttingen (AG Bonn). Each individual RNA 
sample was checked for quality and RNA integrity number using Nanodrop 2000 
(Thermo Scientific, Rockford, USA) and Agilent 2100 Bioanalyzer (Agilent, Santa Clara, 
USA), respectively. For each condition two individual samples were pooled. RNA was 
converted to cDNA using the Transcriptor High Fidelity cDNA synthesis Kit. RNA-
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sequencing libraries were prepared using the TruSeq RNA Sample Preparation 2 Kit. 
The library quality was checked using an Agilent 2100 Bioanalyzer and concentration 
was measured by a Qubit® dsDNA HS Assay Kit and adjusted to 2 nM before 
sequencing (single end, 50 bp) on a HiSeq 2000 Sequencer using TruSeq SR Cluster 
Kit 3-cBot-HS and TruSeq SBS Kit 3-HS according to the manufacturer’s instructions. 
 
2.9.5 Polymerase chain reaction (PCR) 
iScript reaction mix    5x 
      Biorad, Hercules, USA 
iScript reverse transcriptase   Biorad, Hercules, USA 
 
For generation of cDNA iScript PCR kit was used according to the manufacturer’s 
instructions. RNA samples were kept on ice all the time and were adjusted to 50 ng in 15 
µL water and mixed with 4 µL iScript reaction mix and 1 µL iScript reverse transcriptase. 
The reaction was run as followed: 5 min at 25 °C; 30 min at 42 °C, 5 min at 85 °C and 
held on 4 °C (Biorad T100 Thermal Cycler, Hercules, USA). Concentration of generated 
cDNA was measured (2.9.7) and stored at -20 °C. 
2.9.6 Real time PCR (qPCR) 
Table 7. TagMan probes 
Gene  Species Amplicon length  Label 
Met Mouse 74 FAM 
Apc Mouse 85 FAM 
Hgf Mouse 85 FAM 
SYT1 Mouse 81 FAM 
Slc17a7 Mouse 55 FAM 
Stx1b Mouse 92 FAM 
Cxcl10  Mouse 59 FAM 
Gfap Mouse 75 FAM 
Snap25 Mouse 66 FAM 
Actb Mouse 143 VIC 
 
TaqMan gene expression master mix Thermo Scientific, Rockford, USA  
TaqMan gene expression assay  Thermo Scientific, Rockford, USA  
 
Generated cDNA was diluted in water (200 ng/8 µL). A master mix was prepared 
containing 10 µL of TaqMan gene expression master mix, 1 µL TagMan gene 
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expression assay (target genes) and 1 µL housekeeping gene (actin) (Table 7). TaqMan 
gene expression assays consist of a pair of unlabeled PCR primers and a TaqMan 
probe with an FAM (target genes) or VIC (actin) dye label on the 5’ end and minor 
groove binder and nonfluorescent quencher on the 3’ end. Master mix solution was 
pipetted into a PCR 96-well plate (TW-MT-Plate, Biozym, Hessisch Oldendorf, Germany) 
and 8 µL of the sample was added. The plate was covered with a plastic sheet and 
centrifuged at 300 g for 1 min. The samples were placed into the qPCR machine 
(Applied Biosystems StepOnePlus Realtime PCR System, California, USA) and 
incubated for 2 min at 50 °C, followed by 10 min at 95 °C. 40 cycles of 15 s denaturing at 
95 °C and 1 min annealing and extending at 60 °C were performed. 
2.9.7 Quantification of DNA concentration 
Single stranded DNA concentration was determined by measuring the absorbance in the 
samples at a wavelength of 260 nm (A260) with the NanoDrop spectrophotometer 
(NanoDrop2000). H2Obidest severed as blank control. An absorbance of 1 at 260 nm 
equals a concentration of 50 µg/ml DNA. Possible protein concentration was measured 
at an absorbance of 280 nm (A280). A ratio of A260/A280 lower 1.8 indicates protein 
contamination, whereas a higher value confirms a good quality of the samples. 
 
2.10 Data analysis and statistics  
2.10.1 Image editing  
Confocal images captured with the LSM 700, upright LSM 700 (Zeiss, Jena, Germany) 
or inverse epifluorescece microscope (Axio observer Z1, Zeiss, Jena, Germany) were 
processed using Zen 2010 (black edition) or Zen 2012 (blue edition) software (Zeiss, 
Jena, Germany). 
 
2.10.2 Image data analysis with Columbus software 
Image analysis of the high-throughput screen was performed in collaboration with 
Christoph Möhl (DZNE, Bonn) using Columbus 2.4.1. Briefly, the input data consisted of 
two different channels: Nucleus/Cytoplasm marker (C0) and aggregate marker (C1). 
Nuclei were detected in the C0 channel with “Find Nuclei” (method A, common threshold 
0.4, area > 70 µm2, split factor 7, individual threshold 0.4, contrast 0.1). The cytoplasm 
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region was detected in C0 with “Find Cytoplasm” (method A, individual threshold 0.15). 
With a feature analysis two sensitive features were selected for successfully PrPSc 
detection within cells: Haralick Contrast 1px and Haralick Sum Variance 1px. Haralick 
features contain information about the textural characteristics of an image (156). The 
contrast feature measures the local variation of intensity between two pixels. Cells with 
HaralickContrast > 0.04 and HaralickSumVariance > 0.17 should be classified as PrPSc 
infected cell. 
 
2.10.3 Image data analysis with Cell Voyager Analysis support software 
L92915.9 and L92922L images analyzed by an automatic confocal microscope (Cell 
Voyager) were further assessed by the Cell Voyager support software. An image 
analysis routine was developed for single-cell segmentation and aggregate identification 
(Yokogawa Inc.). The total number of cells was determined by nuclei detection based on 
the Hoechst signal, and morphology properties. The corresponding cytoplasm was 
identified based on intensity levels of HCS CellMask Blue stain. Cells touching the 
borders of an image were excluded. The spot detection module was used for detection 
of PrPSc puncta. The algorithm was carefully trained using specific morphology 
parameters and intensity characteristics. Uninfected control cells served as PrPC 
background signals. If PrPSc puncta were linked to single cells, this cell was considered 
to be infected. The total number of infected and uninfected cells was counted and 
percentage of infected cells per well was calculated. 
 
2.10.4 RNA-sequencing data analysis 
RNA sequencing data analysis was performed in collaboration with Melvin Schleif (AG 
Jackson, DZNE Bonn). Raw RNA-Sequencing data was imported into the CLC 
Genomics Workbench (8.5.1), quality checked, trimmed and mapped to the mouse 
genome (NCBI GRCm38.82). The trimming parameters were ambiguous trim limit = 2; 
quality trim limit = 0.05; minimum number of nucleotides in reads = 30. The mapping 
parameters were maximum number of hits for a read = 1; strand specific = both; 
similarity fraction = 0.8; length fraction = 0.9; mismatch cost = 2; insertion cost = 3; 
deletion cost = 3. Mapped sequence data were compared to each other with CLC (Mock 
vs. RML od Mock vs. 22L). Differential expression analysis was carried out using UER 
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counts from CLC with DESeq1 package (1.9.12) in R-Project Bioconductor (3.1.2). The 
following workflow was run: 
> datafile = system.file("Data/XXX.txt", package="DESeq") 
> CountTable = read.table(datafile, header=TRUE, row.names=1) 
> #not run 
> condition = factor(c("Group1", "Group2”)) 
> library("DESeq") 
> cds =newCountDataSet(CountTable, condition) 
> cds = estimateSizeFactors(cds) 
> sizeFactors(cds) 
> cds = estimateDispersions(cds, method="blind", sharingMode="fit-only") 
> res = nbinomTest(cds, "Group1", "Group2") 
> write.csv(res, file="XXX.csv") 
 
2.10.5 Evaluation of qPCR 
For evaluation of qPCR results the obtained CT values of the housekeeping genes was 
subtracted from CT values of the genes of interest (ΔCT). ΔCT of Mock samples was 
subtracted from ΔCT 22L or RML samples and multiplied by -1 (-ΔΔCT). The power of 
this value was calculated (2^-ΔΔCT) (157). 
 
2.10.6 Statistical analysis 
Statistical analysis was performed using Graph Pad Prism 6 (Graph Pad software, La 
Jolla, CA, USA). Statistical analysis of data was performed using the unpaired two-tailed 
Student´s t-test for single comparisons or one-way ANOVA with Dunnett’s multiple 
comparisons test. Error bars represent the standard deviation (SD) and the sample size 
was at least three. A p-value less than 0.05 was considered as statistically significant (*p 
≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001). 
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3 Results 
The central event in prion disease is the conversion of an α-helix-rich PrPC into a 
misfolded β-sheet-rich, pathogenic and infectious isoform PrPSc (158). Stabilization of 
native PrPC without blocking of the normal function, interruption of the conversion of 
PrPC into PrPSc or reduction of already existing PrPSc aggregates could be possible ways 
to intervene with prion disease. Although there are several compounds known to inhibit 
prion accumulation in cell culture systems (146, 155, 159, 160), a therapeutic compound 
is still missing. We wanted to test a promising anti-prion compound candidate and a 
novel synthesized compound in an ex vivo system as this method provides a more 
complex cellular system, which increases the probability that a compound shows similar 
effects in vivo. For this purpose the iron-containing cationic alkylpyridyl porphyrin 
FeTMPyP was chosen. FeTMPyP is a compound, which previously was shown to bind 
to PrPC, and is capable of inhibitiing PrPC-mediated toxicity and is known to inhibit the 
replication of multiple prion strains in vitro (161). Beside this PIM-B31 was tested. This 
drug was provided in collaboration with Emiliano Biasini (University of Trento) who 
synthesized it as a potential anti-prion compound. 
 
3.1 Ex vivo analysis of compounds 
For ex vivo analysis, the prion organotypic slice culture assay (POSCA) was used, as it 
is an advanced model for prion studies (138). Slice cultures from neonatal mouse 
cerebella can be infected with different prion strains, including prion strains 22L and 
RML (137, 138). Cerebellar organotypic cultures (COCS) present a complex cell 
environment with interactions among highly diverse cell types including neurons, 
astrocytes and microglia. In contrast to in vivo models, the blood-brain barrier, which can 
display an obstruction for drug application is lacking in COCS, but at the same time the 
in vivo microenvironment is largely retained (162). Therefore COCS represents a 
powerful tool to study the effectively of anti-prion compounds.  
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3.1.1 Experimental setup to study anti-prion compounds ex vivo 
For studying the effect of FeTMPyP and PIM-B31 ex vivo the following experimental 
setup was designed. COCS were prepared from 9 - 13 days old pups of C57BL/6JRj 
mice (2.3.2), infected with 22L prions (2.3.3) and grown for 2 weeks (2.3.4) to allow 
establishment of the infection (Figure 5). Two weeks post infection (p.i.), COCS were 
treated with diverse compounds at different concentrations replacing the normal culture 
medium with compound-containing culture medium for five weeks. COCS were analyzed 
seven weeks p.i. by either immunofluorescence staining, western blot analysis, 
propidium iodide staining or a combination of those methods. For specific detection of 
PrPSc by immunofluorescent staining, fixed samples were treated with guanidine 
hydrochloride. GdnHCl reduces PrPC background staining, while drastically increasing 
the immunoreactivity of PrPSc (147). Due to the proteinase K resistance of PrPSc, PK 
treatment of lysates can be used to discriminate between PrPSc and PrPC by western 
blot analysis (16).  
 
 
Figure 5. Experimental setup for compound treatment of 22L or RML prion infected 
cerebellar organotypic cultures. Cerebella were dissected from 9 - 13 days old C57BL/6JRj 
pups and organotypic slices were produced. After incubation for one hour with 20 mg/mL 
22L/RML prion-infected brain homogenate, slices were grown for 2 weeks until treatment with 
compound via culture medium started. Slices were treated for 5 weeks followed by 
immunofluorescence staining, western blot analysis and/or propidium iodide staining. As negative 
control COCS were exposed to uninfected brain homogenate (Mock). 
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3.1.2 FeTMPyP shows a strong toxicity on COCS 
First the toxicity of FeTMPyP on COCS was evaluated. The viability of slices was 
investigated using propidium iodide (PI) that incorporates into dead cells. Therefore, 
COCS were grown for one day and FeTMPyP (solved in water) at six different 
concentrations (100 µM, 50 µM, 25 µM, 12.5 µM, 6.25 µM and 3.75 µM) was added. 
After two weeks of treatment, PI staining was performed. As a positive control for PI 
staining, untreated COCS were incubated with 5 µM staurosporine for 2 days. 
 
 
Figure 6. FeTMPyP-treated COCS showed massive PI incorporation. Uninfected cerebellar 
slices were cultured for 1 day followed by treatment with FeTMPyP for 2 weeks. Slices were 
incubated with 10 µg/mL PI for 2 h to stain dead cells. (A) COCS treated with 5 µM Staurosporine 
for 2 days served as positive controls for the staining method. (B) PI incorporation by COCS 
treated with 3.75 – 100 µM. Samples were analyzed by epifluorescence microscopy with a 
magnification of 10x using tile scanning function with identical imaging settings. Scale bar: 500 
µm. 
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FeTMPyP decreased the viability of cerebellar slices (Figure 6 B). At concentrations 
from 25 µM to 3.75 µM, massive PI incorporation was observed and COCS started to 
shrink, indicative of compound toxicity. Treatment with FeTMPyP was even more toxic 
than the positive control with 5 µM Staurosporine (Figure 6 A). Strikingly, at higher 
concentrations (100 µM and 50 µM), PI incorporation decreased, potentially due to 
precipitation of the drug. For further experiments, a concentration below the tested ones 
was chosen (1 µM).  
To test if FeTMPyP is effective against persistent 22L and RML infection in COCS, slices 
were prepared and exposed to 22L or RML prions for 1 h. Starting 2 weeks post 
infection cerebellar slices were continuously exposed to culture medium containing 1 µM 
FeTMPyP. As visual inspection of slices showed strong toxicity, samples were analyzed 
by immunofluorescence staining 5 weeks p.i.. 
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Figure 7. Treatment with 1 µM FeTMPyP was toxic for cerebellar slices. Mock brain 
homogenate, 22L or RML prion exposed COCS were cultured for 2 weeks. At that time point, the 
treatment with 1 µM FeTMPyP or water was started. Three weeks p.i., PrPSc was specifically 
stained with mAb 4H11 following GdnHCl treatment of fixed cells (green). Neurons were detected 
with pAb β -3-tubulin (red) and lysosomes were labeled with mAb Lamp-1 (magenta). Nuclei were 
counterstained with Hoechst (blue). Cerebellar slices exposed to (uninfected) mock brain 
homogenate served as controls. Samples were analyzed by epifluorescence microscopy with a 
magnification of 10 using tile scanning function with identical imaging settings. Scale bar: 500 µm. 
 
Unfortunately, the treatment of infected COCS with 1 µM FeTMPyP for 3 weeks was 
extremely toxic and led to a nearly complete dissolution of the COCS (Figure 7). 
Therefore, drug treatment with FeTMPyP was discontinued.  
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3.1.3 Treatment of COCS with PIM-B31 is non-toxic, but has variable 
effects on PrPSc accumulation  
Parallel to experiments with FeTMPyP, the compound PIM-B31 was tested on COCS 
with the same experimental setup. To identify a concentration of PIM-B31 on COCS that 
is not toxic, slices grown for one day before treatment for two weeks with different 
concentrations of PIM-B31 (3.75 - 100 µM) and PI staining was performed. Slices 
treated with 5 µM Staurosporine for 2 days served as positive control of PI incorporation. 
 
 
Figure 8. Treatment with PIM-B31 did not result in increased PI incorporation into COCS. 
Uninfected cerebellar slices were cultured for 1 day and subsequently treated with PIM-B31 for 2 
weeks. Slices were incubated with 10 µg/mL PI for 2 h to visualize dead cells. (A) As positive 
control COCS were treated with 5 µM Staurosporine for 2 days. (B) Treatment of COCS with 
different concentrations (100, 50, 25, 12.5, 6.25, or 3.75 µM) of PIM-B31 on COCS. Samples 
were analyzed by epifluorescence microscopy with a magnification of 10x using the tile scanning 
function and identical imaging settings. Scale bar: 500 µm. 
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Treatment of cerebellar slices with PIM-B31 for 2 weeks showed almost no toxic effect, 
independent of the concentration (Figure 8). Therefore, a low concentration (10 µM) and 
a high concentration (50 µM) of PIM-B31 were chosen to test the influence of PIM-B31 
on 22L or RML infected COCS. Two weeks p.i. COCS were treated with culture medium 
containing 50 µM and 10 µM PIM-B31. At week 5 p.i., samples were analyzed and 
western blot analysis, immunofluorescence staining and propidium iodide staining were 
performed. Treatment of 22L infected slices with 10 µM or 50 µM PIM-B31 for 3 weeks 
showed almost no effect on viability (Fig. 6). This time treatment with 8.8 µM H2O2 
served as a positive control, as 5 µM Staurosporine led to little PI incorporation (Figure 
9).  
 
 
Figure 9. Treatment with PIM-B31 showed no toxicity, as no PI incorporation into infected 
COCS could be observed. Infected COCS were cultured for 2 weeks followed by treatment with 
PIM-B31 (50 and 10 µM) for 3 weeks. Slices were incubated with 10 µg/mL PI for 2 h to stain 
dead cells. COCS treated with 8.8 µM H2O2 for 1 days served as positive controls. Samples were 
analyzed by epifluorescence microscopy with a magnification of 10x using the tile scanning 
function and identical imaging settings. Scale bar: 500 µm. 
 
Western blot analysis was conducted (Figure 10) to reveal successful infection of slices. 
In Mock treated COCS, no signal for PrPSc was detected. Infection with 22L and RML 
prions led to a strong signal of PrPSc in DMSO-treated controls. Signal intensity of PrPSc 
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changed in response to PIM-B31 treatment. Treatment of RML prion infected slices 
showed variable results; there appeared to be a reduction in PrPSc signal at 10 µM and 
50 µM, but the variation was very high (Figure 10 A, C). The variation might originate 
from technical problems during sample preparation or western blot procedure. It was 
therefore decided to repeat the experiment. Treatment of 22L prion-infected cerebellar 
slices with 50 µM PIM-B31 led to a reduction of the PrPSc signal in western blot analysis, 
whereas treatment with 10 µM PIM-B31 led to a slight increase in signal (Figure 10 A, 
B). 
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Figure 10. Influence of PIM-B31 on PrPSc levels in cerebellar slices during persistent 
infection with 22L or RML. COCS exposed to Mock brain homogenate, 22L or RML prions were 
cultured for 2 weeks. Subsequently, COCS were continuously exposed to 10 µM or 50 µM SM31. 
COCS were lysed at week 5 p.i. for western blot analysis (A) For one lysate two slices were 
pooled. PK-resistant PrP (PrPSc) was detected using mAb 4H11. Actin was detected in –PK 
samples as loading control. (B – C) Quantification of PrPSc signals normalized to actin. 
Experiments were performed in duplicate. One bar represents one experiment. 
 
Comparable results were observed when 22L infected COCS were stained for 
immunofluorescence analysis (Figure 11). RML infected COCS were not analyzed by 
immunofluorescence staining, because we were not capable to develop a staining 
protocol detecting RML prions in COCS with a quality suitable for analysis.  
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Figure 11. Reduction of PrPSc levels upon treatment with 50 µM PIM-B31 in 22L infected 
COCS during persistent 22L infection. Mock brain homogenate (A) or 22L prion exposed (B) 
cerebellar slices were cultured for 2 weeks. At that time point, the treatment with DMSO or PIM-
B31 was started. At 5 weeks p.i., COCS were fixed and PrPSc was specifically stained with mAb 
4H11 following GdnHCl treatment. Nuclei were counterstained with Hoechst. Cerebellar slices 
exposed to (uninfected) Mock brain homogenate served as controls. Samples were analyzed by 
confocal microscopy with identical imaging settings. Scale bar: 50 µm.  
 
Untreated cerebellar slices demonstrated successful infection with 22L prions. The 
signal intensity of PrPSc showed no noticeable changes after treatment with 10 µM PIM-
B31 (Figure 11 B middle panel), but treatment with 50 µM PIM-B31 led to a decrease in 
the PrPSc signal (Figure 11 B lower panel). 
 
To validate the results, PIM-B31 was tested again on COCS persistently infected with 
22L or RML. Therefore, freshly prepared cerebellar slices were exposed to 22L or RML 
prions or Mock brain homogenate and were treated as described above. As the 
compound batch used in the previous experiment was almost depleted COCS were 
treated with a freshly synthesized batch of PIM-B31 this time. Additionally, COCS were 
analyzed seven instead of five weeks p.i. by western blot analysis and 
immunofluorescence staining as we expected that a longer treatment might lead to more 
significant results. 
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Figure 12. Influence of PIM-B31 on levels of PrPSc in cerebellar slices during persistent 22L 
and RML infection. COCS, exposed to Mock brain homogenate, 22L or RML prions were 
cultured for 2 weeks. Subsequently, treatment with 10 or 50 µM PIM-B31 was started and slices 
were lysed 7 week p.i.. (A) Western blot analysis. PrPSc was detected in PK treated samples 
using mAb 4H11. Actin and total PrP were detected in –PK samples as loading controls. 
Experiments were performed in quintuplicates. (B – C) Quantification of western blot analysis. 
PrPSc accumulation was normalized against actin and PrPSc accumulation in compound-treated 
samples was compared to PrPSc accumulation in DMSO-treated samples, which were set to 100 
%. A single dot represents one experiment, the line the mean and the whiskers the standard 
deviation. One-way ANOVA with Dunnett´s multiple comparisons test was used to statistically 
analyze the data. Asterisks display significant changes (*p ≤ 0.05, ns= not significant). 
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Quantification of western blot analysis revealed successful infection of COCS with 22L 
and RML prions, although the signal intensity of PrPSc was stronger in 22L infected 
COCS. Treatment with 10 µM PIM-B31 of 22L infected led to slightly significant increase 
of PrPSc accumulation, as found in the previous experiment. Surprisingly and in contrast 
to the experiment with the old batch of the compound, treatment with 50 µM showed no 
significant changes in PrPSc accumulation in 22L infected COCS. Results for RML-
infected PIM-B31 treated COCS were also contradictory to the experiment with the old 
batch. This time no significant changes in signal intensity could be observed at both 
concentrations.  
It was possible that the lack of compound activity was due to the new batch of 
compound that was used in the repeat experiment. To exclude this possibility, a 
comparative experiment of the anti-prion activity of the old and new batch of PIM-B31 
was performed. Emiliano Biasini had shown that PIM-B31 successfully reduces PrPSc 
accumulation in N2a cells infected with prion strain 22L (unpublished data). Therefore, 
the old and new batch of PIM-B31 were tested on persistently infected N2a22L cells, 
comparable to his protocol. For testing this, N2a22L cells were treated with 50 µM PIM-
B31 of the old and the new batches of the drug and PrPSc accumulation was analyzed by 
western blot (Figure 13 A). 
 
 
 
 
 
 
 Results  
 58 
 
Figure 13. Influence of two different batches PIM-B31 on levels of PrPSc in persistently 22L 
prion infected cells. (A) Persistently infected N2a22L cells were seeded on 6-well plates and 
treated for 44 h with 50 µM PIM-B31. (B) PrPSc was detected in PK treated samples using mAb 
4H11. Actin and total PrP was detected in –PK samples as loading control. Experiments were 
performed in triplicates. For presentation purposes empty lanes were cut out, indicated by the 
dotted line. (C) Quantification of western blot analysis. A single dot represents one experiment, 
the line the mean and the whiskers the standard deviation. One-way ANOVA with Dunnett´s 
multiple comparisons test was used to statistically analyze the data. Asterisks display significant 
changes (*p ≤ 0.05, ns= not significant). 
Treatment of N2a22L cells with 50 µM PIM-B31 of the old and new compound batch led to 
a significant reduction of PrPSc accumulation. The signal intensity of PrPSc of cells 
treated with the old batch of PIM-B31 decreased to 55 % compared to DMSO-treated 
cells. The reduction of PrPSc accumulation was less if cells were treated with the new 
batch of PIM-B31 (68 %). However, the difference between both batches was not 
significant (Figure 13 C).  
 
In summary, treatment with PIM-B31 of RML infected COCS showed diverse effects on 
PrPSc accumulation with the first compound batch. Treatment with the second batch of 
PIM-B31 resulted in no changes in PrPSc accumulation in RML infected COCS. Signal 
intensity of PrPSc in 22L infected COCS treated with 10 µM PIM-B31 increased slightly 
with both batches, whereas treatment with 50 µM PIM-B31 with the first batch of drug led 
to a strong decrease of PrPSc accumulation, but no effect could be detected with the 
second batch of PIM-B31, maybe due to technical errors. No toxicity of PIM-B31 could 
be observed in COCS or cells. 
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3.2 Identification of compounds effective against 22L mouse 
adapted prions in a cell culture high-throughput screen  
Testing of FeTMPyP, a known in vitro anti-prion compound and PIM-B31, a novel 
synthesized potential anti-prion compound on prion-infected COCS unfortunately did not 
reveal suitable candidates for further in vivo analysis. Therefore, we aimed to discover 
new candidates that are capable of reducing already existing PrPSc aggregates. For this 
purpose a cell culture based high-throughput screen on persistently prion strain 22L 
infected cells was established. 
 
3.2.1 Assay development for PrPSc detection in prion-infected cells in a 96-
well format 
The assay was established in a 96-well format for uninfected L929 cells (L92915.9 ) and 
persistently 22L prion infected cells (L92922L), a subclone highly susceptible to mouse-
adapted scrapie strains 22L and RML  (Table 4). Cells were seeded to be approximately 
90 % confluent at the time of fixation, so that proper separation of cells by the image 
analysis routine was possible and to avoid different cell numbers in each of the imaged 
positions per well. To identify whether different cultivation times affect the percentage of 
infected cells, L92915.9 and L92922L cells were seeded on three different 96-well plates 
(5000 cells/well, 30 wells per cell line) and fixed after 24 h, 48 h and 72 h. Plates were 
stained as described in 2.5.2. Due to biosafety regulations of the screening facility a 
method to inactivate the prion containing plate was established. The whole 96-well plate 
was immersed in 6M guanidine hydrochloride and cells were washed with PBS. The 
external surface was carefully rinsed with water and EtOH. Cells were analyzed with an 
automatic confocal microscope (Cell Voyager 6000) with a 10x objective. Image analysis 
was performed with the Cell Voyager Analysis support software and an image analysis 
routine was developed for single-cell segmentation and aggregate identification (2.10.3). 
If at least one aggregate was detected per cell, this cell was counted as positive. Per 
condition and cell type, at least 27,000 cells were analyzed. The percentage of PrPSc 
containing cells changed only slightly over the time course of 24 – 72 h (Figure 14). 
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Figure 14. Cells cultured for 48 h showed the highest percentage of infected cells in 
contrast to cells cultured for 24 h or 72 h. 5000 cells per well of L92915.9 , which served as 
background control for PrPC , and L92922L were seeded on three 96-well plates and grown for 24, 
48 or 72 h. Plates were fixed and immunofluorescence staining followed by GdnHCl treatment 
was performed. PrPSc was detected by mAb 4H11, nuclei were detected by Hoechst and 
cytoplasm by CellMask. Plates were analyzed by an automatic confocal microscope (Cell 
Voyager 6000) with a 10x objective and PrPSc infected and uninfected cells were detected by Cell 
Voyager Analysis support software. At least 27,000 cells were analyzed per condition per cell 
type. One-way ANOVA with Dunnett’s multiple comparisons test was performed. Bars represent 
mean values ± SD (**p ≤ 0.01, ****p ≤ 0.0001, ns: not significant). 
 
After 48 hours of cultivation the percentage of PrPSc positive cells was the highest 
(22 %). The differences between 24 hours (20 % PrPSc positive cells) and 72 hours 
(19 % PrPSc positive cells) of cultivation were only marginal. Thus, each cultivation time 
would be suitable for further experiments. Due to practical reasons and for optimal 
workflow 46 h hours of cultivation were chosen for future experiments. 
 
3.2.2 Establishment of a cell-based high-throughput screen for PrPSc 
detection in chronically prion-infected N2a cells using automated 
microscopy  
After successful development of an assay for PrPSc detection in L929 cells in a 96-well 
format, a high-throughput screen was established to find potential drug targets for prion 
disease. For the high-throughput screen N2a cells were used instead of L929 cells. N2a 
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cells are a murine neuroblastoma cell line. N2a cells have been extensively used to 
study neuronal differentiation, axonal growth and signaling pathways (163). They are 
fast growing and are capable of differentiating into cells displaying certain properties of 
neurons (163). Several studies of neurodegenerative diseases, like Alzheimer´s disease 
(164) and Creutzfeldt-Jakob disease (123), are based on N2a cell culture work. 
Furthermore, N2a cells are capable of being persistently infected with prions and the 
reproducibility of productive infection in N2a cells was demonstrated (165). For those 
reasons, the developed assay protocol was optimized for uninfected N2a cell 
(N2auninfected) and 22L infected N2a cells (N2a22L). 
Several parameters needed to be adapted: the cell number was changed to 4,000 cells 
per well and a different image analysis was applied. Due to specific characteristics of the 
N2a cells analysis with Cell Voyager Analysis support software was not as accurate as it 
was for L929 cells. Either increased numbers of false positive (detection of putative 
PrPSc in cells that are not infected) or false negative cells (cells were considered as not 
infected although they were PrPSc positive) were identified. A refined analysis was 
performed by the Columbus software in collaboration with Christoph Möhl (DZNE, 
Bonn). The Columbus system is an internet-based, universal high-volume image data 
storage and analysis system that is compatible with Cell Voyager 6000 imaging data. 
Nuclei were detected by Hoechst signal and cytoplasm by CellMask. With a complex 
analysis of in total 62 features, two sensitive features were selected that successfully 
detected cells with PrPSc as described in 2.10.2 (Haralick Contrast 1px and Haralick Sum 
Variance 1px). Haralick features characterize the textural characteristics of an image. 
The contrast feature measures the local variation of intensity between two pixels. 
For a high-throughput screen N2a22L cells were seeded on 96-well plates in 60 wells. 
N2auninfected cells were seeded every plate for detection of the PrPC background signal. 
(Figure 15).  
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Figure 15. Experimental setup for the high-throughput screen. N2a and N2a22L cells were 
seeded on 96-well plates. After 2 h drugs were added to the plates and cells were grown for 44 h. 
For detection of PrPSc with mAB 4H11 immunofluorescence staining following GdnHCl treatment 
was performed. Nuclei were detected by Hoechst and cytoplasm by CellMask. Plates were 
analyzed by an automatic confocal microscope (Cell Voyager 6000) with a 10x objective. 
 
A yeast-based screen identified molecules reducing protein aggregation that were found 
to be also efficient in promoting mammalian prion clearance in an in vitro system (166). 
Therefore, 152 compounds from a preselected library that originated from our 
unpublished screen based on cell-to-cell propagation of the yeast prion Sup35NM (167) 
performed by Shu Liu (DZNE Bonn) were tested. In this assay, donor mouse 
neuroblastoma N2a cells containing aggregated HA-tagged Sup35NM and recipient N2a 
cells expressing soluble GFP-tagged Sup35NM were cocultured for 12 hours. After 
staining with anti-HA antibody and image acquisition, NM-HA aggregates in donor cells 
and NM-GFP aggregates in recipient cells were quantified. 4,050 compounds (from 
Tocris, Selleckchem and Lopac commercially available bioactive compound libraries) 
were tested for their effect on both donor cells for preexisting aggregates and recipient 
cells for intercellular aggregate transmission or aggregate de novo generation. 152 hits 
were identified that affected NM aggregates in donor cells. These hits were tested in the 
present screen in three different concentrations (10, 1 and 0.25 µM) in duplicate to 
analyze their effects on PrPSc aggregates. N2auninfected cells and three wells with N2a22L 
cells remained untreated and only DMSO without any compound was added in 
duplicates at the respective concentration to six wells of N2a22L cells (DMSO control). As 
positive controls three known compounds, that are capable of reducing the percentage 
of PrPSc infected cells, were chosen. Gallotannin is a known inhibitor of PrPSc levels in 
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cells and was used as a control at 2 µM. At a concentration of 100 nM it reduces PrPSc 
levels to 50 % in 22L and RML infected N2a cells analyzed by dot-blot if treated for 5 
days (146). Chlorpromazine, used at 2 µM, is known to dose-dependently decrease 
proteinase K resistant PrP levels, detected by western blotting of 22L prion-infected N2a 
cell lysates (160). In this experiment cells were infected with 22L containing brain 
homogenate and passaged for 5 times and then treated for 4 days with Chlorpromazine. 
A concentration of 3 µM lead to reduction of PrPSc levels to 50 % (160). The third control 
was Imatinib (5 µM). The tyrosine kinase inhibitor showed to be highly effective against 
PrPSc accumulation at concentration of 1 µM. Western blot analysis showed that 
incubation for 3 days reduced PrPSc levels to 50 % (155). The three control compounds 
were added in duplicates. 44 hours after drug treatment cells were fixed and stained for 
PrPSc following GdnHCl treatment (2.5.2). Cells were imaged as above and image 
analysis was performed using the Columbus software (2.10.2). The analysis 
demonstrated that in the DMSO control approximately ~ 18 % of cells were PrPSc 
positive. Imatinib (16 % infected cells) and Chlorpromazine (19 % infected cells) led to a 
weak or no reduction in numbers of infected cells, whereas Gallotannin reduced the 
percentage of infected cells to 5 % if analyzed by immunofluorescence staining. The 
effects of the 152 tested compounds were classified based on their toxicity and were 
categorized as inhibitor or activator (Table 8).  
 
Table 8. Categorization of compound effects compared to DMSO treated control 
 Toxicity Inhibitor Activator 
Strong Survival of cells treated with 
0.25 µM of a compound < 75 % 
Reduction of PrPSc 
positive cells ≥ 50 % 
Increase of PrPSc 
positive cells ≥ 50 % 
Poor Survival of cells treated with 1 µM 
of a compound < 75 % 
Reduction of PrPSc 
positive cells <50 % 
and >25 % 
Increase of PrPSc 
positive cells <50 % 
and >25 % 
Weak Survival of cells treated with 
10 µM of a compound < 75 % 
Reduction of PrPSc 
positive cells ≤ 25 % 
Increase of PrPSc 
positive cells ≤ 25 % 
No Survival of cells treated with 
10 µM of a compound ≥ 75 % 
 
 
 
 
This categorization led to the identification of 83 inhibitors and 104 activators (Figure 
16). 63 compounds had dual effects, which means that the percentage of PrPSc positive 
cells increased or decreased depending on the concentrations. The toxic effect of 
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treatment with 28 compounds was classified as strong, thus no reliable conclusion 
concerning the number of PrPSc positive cells could be drawn, as the high rate of dead 
cells could have distorted the ratio of PrPSc positive to negative cells. 
 
 
Figure 16. Evaluation of anti-prion compounds identified by high-throughput screen. 152 
compounds were tested in a N2a cell-based screen. N2a22L and N2auninfected cells, which served 
as background control for PrPC were seeded on 96-well plates and treated for 44 h with different 
concentrations of compounds starting 2 h after seeding. After antigen retrieval with GdnHCl and 
staining of PrPSc with mAb 4H11 antibody, plates were imaged with an automated microscope 
and PrPSc positive cells were quantified by Columbus software. 
 
3.2.3 Identification of seven compounds that strongly reduce the 
percentage of PrPSc infected cells 
The evaluation of the screen data led to the identification of 84 compounds with 
potentially inhibitory properties on PrPSc levels in cells infected with 22L prions. From this 
list, seven compounds were selected for further analysis. Those seven selected Food 
and Drug Administration (FDA) approved compounds or approved drug candidates were 
strong inhibitors with poor or no toxicity. Their effects on prions were so far unknown, 
except for Quinacrine dihydrochloride. The screen successfully identified quinacrine 
dihydrochloride as positive control as it is a known inhibitor of PrPSc  accumulation.  It is a 
non-selective monoamine oxidase A/B (MAO-A/B) inhibitor. Incubation of persistently 
activator 
37% 
dual 
23% 
inhibitor 
30% 
toxic 
10% 
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22- or RML-infected neuroblastoma cells with Quinacrine induced the clearance of PrPSc 
(159, 168, 169). In the present screen Quinacrine dihydrochloride reduced the 
percentage of PrPSc positive cells about 64 % (Figure 17 A). Three of the inhibitors can 
be grouped as dopamine, norepinephrine and serotonin uptake inhibitors: at 10 µM 
Indatraline hydrochloride reduced the percentage of positive cells about 70 %, 
Maprotiline hydrochloride reduced the signal of PrPSc positive cells about 68 % at a 
concentration of 10 µM and treatment with 1 µM Methiothepin mesylate led to a 
reduction to 53 % (Figure 17 B-D). AEE788 is a potent inhibitor of EGFR and HER2 and 
led to a reduction of PrPSc positive cells about 70 % at a concentration of 10 µM (Figure 
17 E). The strongest inhibitory compounds were SB590885 (- 90 %) and PHA665752 (- 
71 %) at a concentration of 1 µM (Figure 17 F, G). SB590885 is a potent B-Raf inhibitor 
and PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor. 
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Figure 17. The cell-based high-throughput screen identified seven strong inhibitors. Image 
analysis of data generated by Cell Voyager 6000 revealed seven compounds, capable of 
reducing the percentage of PrPSc positive N2a cells after incubated for 44 h (A – G). Cells were 
stained for aggregates and microscopy images were analyzed by the Columbus software. The 
red line indicates the survival of cells in percent normalized against DMSO treated cells. Percent 
of PrPSc positive cells normalized against DMSO is illustrated in blue. Values for three different 
concentrations of compounds are shown; if one concentration is missing it indicates that the 
survival is below 75 %. Mean values of two independent wells are shown (~ 2,500 cells/well).  
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3.2.4 Assessment of anti-prion efficacy of identified compounds by 
western blot analysis 
To confirm the results generated by the cell-based high-throughput screen, a second 
detection method for PrPSc detection in infected cells was performed. For the detection 
of PrPSc by western blot analysis, aliquots of cell lysates were either incubated with PK 
(2.6.4) or processed without any PK addition. In the PK treated lysates only PK resistant 
proteins, like PrPSc, can be detected. Other proteins like actin can be detected in the PK 
untreated lysate. The signal intensity for PrPSc by western blot analysis is often low. To 
detect the changes in intensity levels of PrPSc, due to the drug treatment, it is essential to 
detect a strong and stable signal for PrPSc. Therefore, we performed limited dilution 
cloning of the N2a22L cells used in the screen to generate a high number of PrPSc 
positive cells. Infection of cloned cells was tested by detection of PrPSc by 
immunofluorescence staining. To guarantee a stable, highly 22L infected N2a cell line a 
second round of cloning was conducted with the 10 most infected cell clones from first 
round of cloning. This led to the generation of a highly infected N2a22L cell line with 
~ 80 % positive cells that was used for further experiments (Figure 18). 
For western blot analysis, cells were seeded and treated with seven compounds for 44 h 
(Figure 19 A). Cells were treated with all concentrations that showed no toxic effect in 
the screen, including 10 µM, 1 µM and 0.25 µM or just 1 µM and 0.25 µM. At the same 
time cells were also seeded and immunofluorescence staining was conducted without 
any compound treatment to confirm that N2a22L cells were infected (Figure 18 A). 
Immunofluorescence staining revealed a strong infection of N2a22L (Figure 18 B) and 
western blot analysis was conducted.  
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Figure 18. Immunofluorescence staining indicated a strong N2a22L infection. (A) 
Experimental setup of immunofluorescence staining of N2auninfected and N2a22L. (B) Confocal 
microscopy analysis of the subclone of N2a cells. PrPSc was detected with mAb 4H11 (green). 
Nuclei were stained with Hoechst (blue). Scale bar: 20 µm. 
 
Accumulation of PrPSc in compound or DMSO-treated cells was detected in PK digested 
lysates (+PK). 240 µg of total protein were PK-treated and loaded per well, whereas for 
detection of total PrP and actin untreated (-PK) lysates were used (10 µg were loaded). 
Analysis of western blots accumulation of PrPSc in compound-treated N2a22L cells was 
calculated in relation to the PrPSc signal in DMSO control, which was set to 100 %. 
Signal intensities of PrPSc  in DMSO and compound treated cells were normalized to the 
corresponding actin signal. The experiment was repeated three times, one 
representative blot is shown (Figure 19 B – H). Treatment with Quinacrine 
dihydrochloride (Figure 19 B), Indatraline hydrochloride (Figure 19 C) Maprotiline 
hydrochloride (Figure 19 D) and AEE788 (Figure 19 F) showed no significant reduction 
of PrPSc accumulation. In contrast to the screen, treatment with Quinacrine 
dihydrochloride and AEE788 displayed even a slightly but not significant increase in 
PrPSc accumulation compared to the DMSO control. The accumulation of PrPSc 
decreased if cells were treated with Indatraline hydrochloride at all concentrations, as 
well as if they were treated with 10 µM of Maprotiline hydrochloride (Figure 19 D). 
Considering the western blot image this effect appeared to be drastic, but after statistical 
analysis the reduction of PrPSc accumulation was not significant, likely due to the high 
standard deviation between the different experiments. The accumulation of PrPSc after 
treatment with Methiothepin mesylate, SB590885 and PHA665752 confirmed the results 
found in the screen. Methiothepin mesylate treatment decreased the PrPSc accumulation 
significantly at 10 µM to 60 % compared to DMSO (100 %). Treatment with 1 µM of 
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Methiothepin mesylate led to a PrPSc   accumulation of 73 % (not significant), whereas 
0.25 µM showed no effect on PrPSc accumulation. 
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Figure 19. Validation of the compounds’ inhibitory effect on PrPSc accumulation identified 
by the high-throughput screen in persistently 22L infected N2a cells. (A) Experimental 
setup. N2a22L were seeded and treated with seven identified strong inhibitors at different 
concentrations for 44 hours. Cells were lysed and western blot analysis was conducted. (B – H) 
Accumulation of PrPSc was detected in proteinase K treated lysates using mAb 4H11. Total PrP 
was revealed by mAb 4H11 in PK untreated lysates. This blot was reprobed with anti-Actin Ab as 
a loading control. PrPSc accumulation was normalized against actin and PrPSc accumulation in 
compound-treated cells was compared to PrPSc accumulation in DMSO-treated cells, which was 
set to 100 %. The experiment was done in triplicates. A single dot represents one experiment, the 
line the mean and the whiskers the standard deviation. One-way ANOVA with Dunnett´s multiple 
comparisons test was used to statistically analyze the data. Asterisks display significant changes 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ns= not significant). 
 
The strongest and most significant effects on PrPSc accumulation could be observed 
after treatment with SB590885 and PHA665752 (Figure 19 G – H). As those compounds 
had a toxic effect at 10 µM in the screen, only 1 µM and 0.25 µM were tested. Treatment 
with 1 µM of SB590885 led to a decrease of PrPSc accumulation of 89 % (p ≤ 0.001) and 
treatment with 1 µM PHA665752 decreased PrPSc accumulation to only 15 %, even 
more significantly (****p ≤ 0.0001). PHA665752 was also the only compound that 
showed a significant reduction of PrPSc accumulation at 0.25 µM. Here the signal was 
reduced by 23 % with a p value of p ≤ 0.05 (Figure 19 H). 
As two independent methods demonstrated that Methiothepin mesylate, SB590885 and 
PHA665752 were able to reduce the number of persistently prion infected N2a cells, 
those promising compounds were further characterized and analyzed. A dose response 
analysis was performed to determine the half maximal inhibitory concentration (IC50). For 
this purpose, N2a22L cells were seeded and either treated with drugs (Figure 19 A) or 
immunofluorescence staining was performed (Figure 18 A). As immunofluorescence 
staining revealed that N2a22L cell were still infected, western blot analysis was continued. 
Data analysis was performed as mentioned before, but experiments were performed four 
times (n = 4) (Figure 20).  
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Figure 20. Treatment of N2a22L with Methiothepin mesylate, SB590885 and PHA665752 at 
six concentrations demonstrated the inhibitory effect on PrPSc accumulation. (A, C and E) 
Western blot analysis. Accumulation of PrPSc was detected in +PK samples using mAb 4H11, 
whereas total PrP (mAb 4H11) and actin (mAb anti-actin) were analyzed in –PK samples. Actin 
served as a loading control. (B, D and F) Quantification of western blot analysis. PrPSc 
accumulation was normalized against actin and PrPSc accumulation in compound-treated cells 
was compared to PrPSc accumulation in DMSO-treated cells, which was set to 100 %. 
Experiments were performed four times. A single dot represents one experiment, the line the 
mean and the whiskers the standard deviation. One-way ANOVA with Dunnett´s multiple 
comparisons test was used to statistically analyze the data. Asterisks display significant changes 
(*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, ns= not significant). 
 
Methiothepin mesylate was tested at six different concentrations (10, 5, 2.5, 1, 0.5 and 
0.25 µM). Treatment with 5 µM and 2.5 µM led to a significant reduction of PrPSc 
accumulation to 30 % (Figure 20). Surprisingly, treatment with 10 µM of Methiothepin 
mesylate had a milder effect on PrPSc reduction (79 %). The difference between DMSO 
control and 10 µM Methiothepin mesylate was statistically not significant. Treatment with 
concentration < 2.5 µM had no significant effect on PrPSc accumulation. Analysis of the 
dose response curve displays an IC50 of 1.02 µM (Figure 21 A). 
SB590885 and PHA665752 were also tested at six concentrations; the highest 
examined concentration was lower than for Methiothepin mesylate due to toxicity 
detected in previous experiments (5, 2.5, 1, 0.5, 0.25 µM and 0.1 µM). SB590885 has an 
IC50 of 1.38 µM (Figure 21 B) and showed a significant decrease of PrPSc accumulation 
at 5 µM (8 %) and 2.5 µM (13 %) (Figure 20 B). Incubation of SB590885 at lower 
concentration did not significantly reduce PrPSc accumulation. Treatment of N2a22L cells 
with PHA665752 had the best inhibitory effect. It led to significant reduction of PrPSc 
accumulation at four different concentrations (5, 2.5, 1 and 0.5) as well as the most 
significant reduction tested with a p value ≤ 0.0001 at 1 µM and an IC50 of 0.42 µM 
(Figure 21 B). The strongest reduction of PrPSc accumulation was also at 1 µM with a 
total accumulation of 23 % compared to DMSO control. Treatment of N2a22L cells with 
0.25 µM and 0.1 µM PHA665752 did not significantly reduce PrPSc accumulation. Due to 
consistent inhibitory effects of PHA665752 in the screen, western blot validation and 
dose response analysis, PHA665752 was chosen for further ex vivo analysis.  
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Figure 21. Dose response curve of Methiothepin mesylate, SB590885 and PHA665752. 
Dose response curves were generated by plotting the percentage of PrPSc accumulation in 
compound-treated cells relative to PrPSc accumulation in DMSO-treated cells and normalized to 
actin against the logarithm of drug concentrations in µM. Cells were either treated with 
Methiothepin mesylate (A), SB590885 or PHA665752 (B). Each dot represents the mean value of 
four experiments. 
 
3.2.5 Treatment of 22L prion infected cerebellar slices with PHA665752 
leads to a weak but insignificant decline in PrPSc accumulation 
The performed high-throughput compound screen and our western blot analysis of PrPSc 
accumulation identified PHA665752 as a compound with anti-prion efficacy in a cellular 
prion model. Therefore, the effect of PHA665752 on prion accumulation was tested in 
COCS. The potential target for PHA665752 is the receptor c-Met (170). To test if c-Met 
is expressed in COCS infected with 22L prions, immunofluorescence staining with mAB 
c-Met was performed (2.5.3).  
 
 Results  
 74 
 
Figure 22. Immunofluorescence staining reveals c-Met expression in COCS. 22L prion 
exposed COCS were cultured for 7 weeks. At that time point, immunofluorescence staining was 
performed. PrPSc was specifically stained with mAb 4H11 following GdnHCl treatment (green) 
and c-Met with mAb anti-c-Met (red). Nuclei were counterstained with Hoechst. Samples were 
analyzed by epifluorescence microscopy using the tile scanning function and identical imaging 
settings. Scale bar: 500 µm. 
 
Immunofluorescence staining revealed the expression of c-Met in COCS (Figure 22). 
Next, PHA665752 was tested for its anti-prion efficacy in COCS at a concentration of 
1 µM. This concentration was chosen because it was non-toxic in cell culture and 
showed in vitro a strong reduction of PrPSc accumulation in 22L infected N2a (Figure 20 
F). COCS were infected with 22L prion- and Mock brain homogenate. Two weeks p.i. 
treatment with 1 µM PHA665752 started and seven weeks p.i, COCS were analyzed by 
western blot analysis and immunofluorescence staining for PrPSc accumulation (Figure 
23). 
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Figure 23. Treatment of infected COCS with PHA665752 led to a weak reduction in PrPSc 
accumulation. COCS were treated with 1 µM of PHA665752 or DMSO for five weeks starting 
two weeks post 22L infection. (A) Immunofluorescence staining of COCS. PrPSc was detected 
with mAb 4H11 following GdnHCl treatment and nuclei were visualized with Hoechst. Slices were 
imaged with identical image settings with an epifluorescence microscope with a magnification of 
20x using the tile scanning function. Scale bar: 500 µm. (B) Detection of accumulation of PrPSc by 
western blot analysis. For one lysate two slices were pooled. PrPSc was detected in +PK samples 
with mAb 4H11. Total PrP (mAb 4H11) and actin (mAb anti-actin) were analyzed in –PK samples. 
Actin served as a loading control. (C) For quantification of the western blot analysis PrPSc 
accumulation was normalized against actin. PHA665752 treated COCS were compared to DMSO 
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treated COCS, which were set to 100 %. The experiment was done in triplicates. A single dot 
represents one experiment, the line the mean and the whiskers the standard deviation. Unpaired t 
test was used to statistically analyze the data (ns= not significant). 
 
Immunofluorescence staining revealed the successful infection of COCS with 22L 
prions. Infected slices showed a strong signal of PrPSc (green) (Figure 23 A right panel) 
and only a weak PrPC background staining was detected in Mock infected COCS (Figure 
23 A left panel). Treatment with PHA665752 was not overtly toxic to COCS as visual 
inspection showed no signs of toxicity like holes within the slices, changes in shape or 
frayed borders of the slices. However, PHA665752 treated COCS showed a weak not 
distinct difference in signal intensity between DMSO and PHA665752 treatment (Figure 
23 A). Western blot analysis confirmed the infection of COCS with 22L prions (Figure 23 
B). The PrPSc signal intensity in 22L infected PHA665752 treated COCS was reduced 
compared to the signal in DMSO treated COCS. This reduction was, however, not 
significant (Figure 23 C). To sum up, treatment of 22L prion infected COCS for five 
weeks with 1 µM PHA665752 led to a weak, but not significant reduction of PrPSc 
accumulation.  
 
Beside these findings, western blot analysis of uninfected COCS revealed a molecular 
weight for PrPC lower than expected. Uninfected prion protein presents itself in western 
blot analysis normally with the first diglycosylated band at the height of approximately 27 
kDa, the monoglycosylated band at approximately 23 kDa and the unglycosylated band 
at approximately 19 (171). However, the first band was recognized at approximately 23 
kDa (Figure 23, B) in uninfected COCS. Therefore a comparative western blot analysis 
between COCS and brain lysates with two different antibodies was performed. First 
uninfected COCS and brain lysate were stained with monoclonal antibody 4H11 and 
compared. The binding site for 4H11 is at the C-terminal region, where complex 
carbohydrates can be linked to two asparagine residues (in mice PrP aa residues 180 
and 196), resulting in un-, mono- and diglycosylated PrPC. In brain lysate three bands 
were detected (Figure 24 A). The highest band at approximately 30 kDa likely presented 
diglycosylated PrP, the following band at 23 kDa monoglycosylated PrP and the lowest 
band unglycosylated PrP at approximately 19 kDa. Interestingly, in COCS the 
diglycosylated band is visible, but the signal was fainter. Beside the three typical bands 
the 4H11 antibody also detects a smear. In the cell the prion protein is proteolytically 
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processed. The three main cleavage events are α-cleavage, β-cleavage, and 
ectodomain shedding at the N-terminal part of the PrP, which result in different sizes for 
truncated PrP (172) which might also be detected by the 4H11 antibody. The staining 
with monoclonal antibody 4H11 was compared to a staining with the commonly used 
monoclonal antibody Saf32, which recognizes the octa-repeat region, located in the N-
terminal part of PrP (Figure 24, B). Staining of uninfected brain with Saf32 showed a 
signal between 30 and 27 kDa, which likely comprised the di- and monoglycosylated PrP 
and an additional band for unglycosylated PrP. It is difficult to distinguish between di- 
and monoglycosylated PrP with Saf32 staining, however the overall signal intensity is 
lower in COCS (exposed for 5 min) compared to brain lysate.  
  
 
Figure 24. Saf32 bind to the N-terminal part of PrP and detects also truncated PrP. Lysates 
of uninfected COCS (10 µg per lane) and brain samples (2 µg per lane) were prepared for 
western blot analysis and total PrP was detected by 4H11 (A) and Saf32 (B).  
 
3.3 Identification of pathways deregulated in prion infection in ex 
vivo cerebellar slices and in vivo in mice 
Organotypic cerebellar slice cultures are currently analyzed by a broad range of different 
techniques, for example western blot analysis, immunofluorescent staining and different 
biochemical methods (137, 147). Beside this, molecular biological methods like RNA  
analysis by qPCR or genome linkage analysis are used to study prion disease in COCS 
(138, 173). However, the comparability of the host response between the in vivo prion 
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infected mice and ex vivo prion infected of cerebellar slices is unknown. Therefore, the 
next part of the presented thesis focuses on the analysis of the host response of 22L 
and RML prion-infected COCS by RNA sequencing analysis and differences and 
similarities between ex vivo and in vivo experiments are analyzed. In vivo sequencing 
data were provided by Dr. Melvin Schleif (DZNE, Bonn). 
 
For the in vivo experiments, 6 weeks old C57BL/6 mice were intracranially injected with 
brain homogenate that originated from brains of mice infected with prion strain 22L, RML 
or uninfected mice (Mock control). Mice were sacrificed 10, 14 and 18 weeks post 
injection (Figure 25). Ten weeks of incubation represent, in our experiments, a very early 
stage of prion disease with first signs of prion pathology in the brain. After 14 weeks, as 
an intermediate time point, prion pathology has established in the brain, whereas 18 
weeks post injection represents a late stage of the disease with all signs of prion disease 
in the brain, but mice just start to develop physically impairments (174).  
 
 
Figure 25. Experimental setup for the comparative in vivo / ex vivo transcriptome analysis. 
Six weeks old C57BL/6 mice were intracranially injected with 0.1 % brain homogenate and 
incubated for 10, 14 and 18 weeks. COCS were prepared, exposed for 1 h to 1 % brain 
homogenate and grown for five, seven and nine weeks. Isolated RNA of cerebella and COCS 
were analyzed by next generation sequencing and qPCR. 
 
To compare the gene expression profile of prion infected COCS to mice cerebella, slices 
were prepared and exposed to the same brain homogenates (22L, RML and Mock). 
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COCS were grown for five, seven and nine weeks (Figure 25). Five weeks p.i. is 
comparable to an early stage of disease as western blot of those samples reveals an 
infection of the slice, whereas western blot analysis with shorter incubations do not 
necessarily reveal an infection with prions (135, 147). Incubation of slices for nine weeks 
was taken as a correspondence to 18 weeks incubation in vivo, as slices show a strong 
infection without any impairment of viability like shrinking or holes. Seven weeks was 
chosen as intermediate time point, to analyze the disease progression and the 
accompanied transcriptomic changes. Pooled isolated RNA of mice cerebella and COCS 
was sent to Stefan Bonn (DZNE, Göttingen) for next generation sequencing. Successful 
prion infection of COCS was detected by western blot analysis (Figure 26). The longer 
COCS were grown the more PrPSc accumulation could be detected, which reveals the 
progression of the disease in the slices.  
Figure 26. 22L and RML infected COCS revealed an increase in PrPSc accumulation over 
time. COCS were prepared, exposed for 1 h to 1 % brain homogenate and grown for five, seven 
and nine weeks. COCS lysates were PK-digested (20 µg/mL). PrPSc was detected using mAb 
4H11. Actin was detected in –PK samples (5 µg of total protein of the lysate) and served as 
loading control. 
3.3.1 RNA sequencing analysis reveals differences in transcriptomic 
changes between in vivo and ex vivo, but also some similar 
differential expressed genes 
Generated sequencing data were analyzed (2.10.4) and gene expression of 22L or RML 
samples was compared to expression in Mock samples. The list of genes was ordered 
by p value. Differentially expressed genes with a p value ≤ 0.05 were sorted by log2 fold 
change. The 250 most differential expressed genes at each time point and condition 
(Appendix Table 13, Table 14) were further analyzed. Amongst these 250 genes some 
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similar DEGs between in vivo and ex vivo were found. Infection with 22L prions led to 
the identification of six similar DEGs at early time point, two at intermediate and four 
similar DEGs at late time point (Figure 27, Table 9). Surprisingly, these DEGs were not 
necessarily regulated in the same direction. Some of them, e.g. Dnd were 
downregulated in COCS 5 wpi and upregulated in in vivo infected cerebellum 10 wpi. 
Only three genes were comparably regulated in vivo and ex vivo. Myo5B and Met were 
upregulated at early respectively at late time points, whereas Dlk1 was down regulated 
at the intermediate time point (Table 9).  
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Figure 27. Comparison of gene expression between prion infected brain slices and mouse 
cerebella. COCS were prepared from C57BL/6JRj pups and infected with 22L or RML prions. Six 
weeks old C57BL/6JRj mice were injected with the same prion strains. RNA was isolated at three 
time points and sequencing analysis was performed. Unpaired t test was used to statistically 
analyze the data. Differentially expressed genes with a p value ≤ 0.05 were sorted by log2 fold 
change. The 250 DEGs with the highest log2 fold change were compared to each other. wpi = 
weeks post infection. 
 
Comparison of RML infected COCS to RML infected mice cerebellar showed more 
similarities than 22L infected COCS and cerebella. At early time there were just three 
and at intermediate time point two DEGs found, but at late time point 19 DEGs in vivo 
and ex vivo were deregulated (Figure 27). However, just two genes were regulated in 
the same way, Dlk1 and Serpina3n were down regulated at the late time point (Table 9).  
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Table 9. Genes differentially expressed in cerebellum and COCS infected with 22L or RML 
prions at a different time point  
    COCS Mouse cerebellum 
Strain Time point Gene Description 
Log2 fold  
change 
P 
value 
Log2 fold 
change 
P 
value 
22L 
early 
Ddn Dendrin -3.99 0.0002 2.04 0.0000 
Fam19
a2 
Family with sequence 
similarity 19, member A2  -1.64 0.0188 1.14 0.0004 
Lars2 Leucyl-tRNA synthetase, mitochondrial  1.88 0.0000 0.94 0.0184 
Lcn2 Lipocalin 2 -0.96 0.0005 1.44 0.0024 
Miat Myocardial infarction associated transcript  -1.60 0.0474 1.45 0.0000 
Myo5b Myosin  1.36 0.0416 1.37 0.0000 
inter-
mediate 
Dlk1 Delta-like 1 homolog  -0.97 0.0000 -1.96 0.0000 
Th Tyrosine hydroxylase  -1.58 0.0001 1.21 0.0003 
late 
Ccl6 Chemokine (C-C motif) ligand 6 -0.89 0.01 3.15 0.0000 
Met Met proto-oncogene  1.68 0.02 2.05 0.0000 
Postn Periostin, osteoblast specific factor  -0.99 0.00 1.81 0.0000 
Th Tyrosine hydroxylase  -5.38 0.00 2.88 0.0000 
RML 
early 
Camkv CaM kinase-like vesicle-associated [ -2.41 0.0104 2.19 0.0000 
Ddn Dendrin -4.38 0.0000 2.82 0.0000 
Ecel Endothelin converting enzyme-like 1 -2.95 0.0006 1.56 0.0039 
inter-
mediate 
Dlk1 Delta-like 1 homolog -3.51 0.0000 -1.74 0.0000 
Serpin
a3n 
serine (or cysteine) peptidase 
inhibitor, clade A, member 3N 0.50 0.0212 1.04 0.0002 
late 
Abca4 ATP-binding cassette, sub-
family A (ABC1), member 4  -1.86 0.0004 1.44 0.0000 
Aqp1 Aquaporin 1  -1.99 0.0000 2.03 0.0001 
Car12 Carbonic anyhydrase 12  -1.91 0.0000 2.33 0.0000 
Cldn1 Claudin 1 -1.91 0.0000 1.42 0.005 
Cldn2 Claudin 2 -1.68 0.0000 1.71 0.0000 
Col8a1 Collagen, type VIII, alpha 1  -1.59 0.0000 1.55 0.0000 
Col8a2 Collagen, type VIII, alpha 2 -1.59 0.0000 1.25 0.0049 
En1 Engrailed 1  -1.57 0.0025 1.11 0.0004 
Folr1 Folate receptor 1 (adult)  -1.94 0.0000 1.16 0.0288 
Gm853 Predicted gene 853  -2.75 0.0510 1.45 0.0065 
Krt18 Keratin 18  -2.56 0.0000 1.25 0.0182 
Mfrp Membrane-type frizzled-
related protein  -1.65 0.0009 1.71 0.0000 
Npr3 Natriuretic peptide receptor 3 -1.88 0.0000 2.00 0.0000 
Slc4a5 Solute carrier family 4, 
sodium bicarbonate 
cotransporter, member 5  
-1.88 0.0000 1.75 0.0000 
Sostdc
1 
Sclerostin domain containing 
1  -1.54 0.0001 1.38 0.0083 
Steap1 Six transmembrane epithelial 
antigen of the prostate 1  -1.63 0.0234 1.67 0.0000 
Th Tyrosine hydroxylase  -2.49 0.0000 1.59 0.0000 
Tmem
72 
Six transmembrane epithelial 
antigen of the prostate 1  -2.32 0.0000 1.68 0.0007 
Wdr86 WD repeat domain 86  -2.03 0.0047 1.37 0.0005 
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+ Only genes that were deregulated in cerebella as well as COCS are shown 
++ Time point:  early: COCS 5 wpi vs. cerebellum 10 wpi; intermediate: COCS 7 wpi vs. 
cerebellum 14 wpi; late: COCS 9 wpi vs. cerebellum 18 wpi 
 
3.3.2 Comparison of in vivo ad ex vivo transcriptomes suggest that the 
calcium signaling pathways and the neuroactive ligand receptor 
interactions are strongly deregulated  
To identify pathways and genes of interest that were deregulated, the 250 most DEGs 
were additionally analyzed by DAVID 6.8, an online bioinformatics resource, based on 
the KEGG pathway library. Over 100 pathways were deregulated, but only a few showed 
similarities between in vivo and ex vivo at a distinct time point. Prion infection of COCS 
and mice cerebella with 22L prions resulted in changes in the Ras signaling pathway, 
insulin secretion, cAMP signaling pathway, calcium signaling pathway and neuroactive 
ligand-receptor interaction at early time point. After 7/14 wpi changes in cocaine 
addiction, retrograde endocannabinoid, nicotine addiction, and also calcium signaling 
pathway and neuroactive ligand-receptor interaction were observed. At the late time 
point only three pathways were deregulated, namely regulation of actin cytoskeleton, 
proteoglycans in cancer and chemokine signaling pathways (Figure 28). However, in 
these pathways the kind of the gene, as well as the number of genes that were 
deregulated varied  (Table 10). RML infection resulted in fewer shared pathways 
compared to 22L infected mice and COCS. 10/5 weeks post infection serotonergic 
synapse calcium signaling pathway and neuroactive ligand-receptor interaction were 
changed. At the intermediate time point RML infection led to changes in morphine 
addiction, Chagas disease, nicotine addiction and calcium signaling pathways. At the 
late time point the only changes were observed in the cell adhesion molecules pathway 
in vivo and ex vivo (Figure 28).  
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Figure 28. In vivo and ex vivo deregulated pathways in prion infection. (A – F) Pathway 
analysis was performed with DAVID 6.8 of the 250 most differentially expressed genes. Only 
pathways that are deregulated in vivo and ex vivo at a distinct time point are shown. wks = 
weeks. 
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Table 10. List of genes deregulated in an individual pathway either in the cerebellum or in 
COCS 
Pathway  DEGs Cerebellum 22L 10 wks  DEGs COCS 22L 5 wks 
Neuroactive ligand-receptor 
interaction 
 
OPRM1, GPR83, CGA, TACR3, 
GLRA1, DRD2, NPY2R, TACR1, 
GLRA3, HCRTR1, HTR1A, PRL, 
RXFP3, GABRA5, HTR4, NPY1R, 
NTSR1, NPY5R, GRM5, CRHR2, 
CHRM3, HTR7, MC4R, HTR2C, GH 
GABRD, GRM4, GRIA2, 
GABRA3, GABRB2, GRIN2C, 
GABRA6, GRIN1, GRIN2A, 
GRM1, NTSR2 
Calcium signaling pathway 
 
GRM5, TACR3, CHRM3, TACR1, 
HTR7, HTR4, CACNA1H, NTSR1, 
HTR2C 
ADCY1, SLC8A2, GRIN1, 
CACNA1I, GRIN2A, PRKCG, 
GRM1, ITPR1, CAMK4, 
GRIN2C, ATP2A3, CACNA1G, 
RYR2, CACNA1E, CAMK2B, 
NOS2, CACNA1C, CAMK2A, 
CACNA1B 
cAMP signaling pathway 
 
FXYD2, HTR1A, DRD2, HTR4, 
CREB3L3, NPY1R 
 
ADCY1, GRIA2, CAMK4, 
TIAM1, GRIN2C, GRIN1, 
GRIN2A, RYR2, CAMK2B, 
CACNA1C, CAMK2A 
Insulin secretion 
 FXYD2, STX1A, CHRM3, CREB3L3 
KCNMA1, ADCY1, RYR2, 
PRKCG, CAMK2B, 
CACNA1C, SNAP25, 
CAMK2A, ABCC8 
Ras signaling pathway PAK6, FGF18, RASGRF2, HTR7, HGF, FGF3 
KSR2, FGF9, TIAM1, FGF14, 
VEGFA, GRIN1, GRIN2A, 
PRKCG 
Pathway  DEGs Cerebellum 22L 14 wks  DEGs COCS 22L 7 wks 
Neuroactive ligand-receptor 
interaction 
 
CALCR, GPR83, GLRA1, CCKBR, 
TACR3, DRD2, RXFP3, GLRA3, 
TACR1, TRHR, GABRA5, NPY1R, 
NPY5R, GRM5, HCRTR1, HTR1A, 
CHRM3, CHRNB3, GABRQ, HTR2A 
CRHR1, GABRD, GRM4, 
HTR1B, SSTR3, GRM2, 
GABRB2, OPRL1, GRIN2C, 
GABRA6, GRIN1, GLRA2, 
GRIN2A 
Calcium signaling pathway 
 
GRM5, TACR3, CHRM3, CCKBR, 
TACR1, TRHR, HTR2A 
ADCY1, SLC8A2, NOS1, 
GRIN1, CACNA1I, GRIN2A, 
PRKCG, ITPKA, ITPR1, 
CAMK4, ATP2A3, GRIN2C, 
RYR1, CACNA1E, CAMK2B, 
CAMK2A 
Nicotine addiction 
 SLC17A6, GABRA5, GABRQ 
SLC17A7, GABRD, GABRB2, 
GRIN2C, GABRA6, GRIN1, 
GRIN2A 
Retrograde 
endocannabinoid  
GRM5, SLC17A6, GABRA5, 
GABRQ 
SLC17A7, GABRD, ADCY1, 
KCNJ9, GABRB2, MAPK13, 
GABRA6, GNG13, PRKCG, 
RIMS1, ITPR1 
Cocaine addiction DRD2, TH, PDYN GRM2, GRIN2C, GRIN1, TH, GRIN2A 
Pathway  DEGs Cerebellum 22L 18 wks  DEGs COCS 22L 9 wks 
Chemokine signaling 
pathway 
CCL3, CCL2, FGR, NCF1, CCL9, 
CXCL9, CCL5, CCL4, VAV1, CCL6, 
CXCL10, CCL12, DOCK2, RAC2, 
CXCL13, CXCL16 
ADCY1, TIAM1, ROCK2, 
GNG13, PIK3R1, CCL6 
Proteoglycans in cancer PTPN6, TNF, HPSE, ITGA5, MET, TLR2, HGF, PLAU, PLAUR 
ANK1, TIAM1, ANK3, ROCK2, 
CBL, MET, PRKCG, CAMK2B, 
FLNC, ARHGEF12, PIK3R1, 
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ITPR1 
Regulation of actin 
cytoskeleton 
ITGAX, RAC2, ITGA5, IQGAP3, 
NCKAP1L, ITGB2, VAV1, CD14 
TIAM1, ROCK2, ITGB4, 
IQGAP2, ARHGEF12, 
PIK3R1, APC 
Pathway  DEGs Cerebellum RML 10 wks  DEGs COCS RML 5 wks 
Neuroactive ligand-receptor 
interaction 
CCKAR, CGA, ADORA3, GLRA1, 
TACR3, DRD2, GLRA3, TACR1, 
RXFP3, GABRA5, NPY1R, NPY5R, 
HCRTR1, CRHR2, HTR1A, PRL, 
HTR2C, CHRNE, GH 
CRHR1, GABRD, GRM4, 
GRM2, GRM8, GRIN2C, 
GABRA6, GRIN1, GLRA2, 
GRIN2A, VIPR1, HTR5A 
Calcium signaling pathway CCKAR, TACR3, TNNC1, TACR1, HTR2C 
ADCY1, SLC8A2, NOS1, 
GRIN1, CACNA1I, GRIN2A, 
ITPR1, CAMK4, ATP2A3, 
GRIN2C, CACNA1G, RYR1, 
CACNA1E, CAMK2B, NOS2, 
CAMK2A, HTR5A 
Serotonergic synapse HTR1A, SLC6A4, HTR2C, TPH2 
KCND2, KCNJ6, KCNJ9, 
GNG13, GNG4, KCNJ3, 
HTR5A, ITPR1 
Pathway  DEGs Cerebellum RML 14 wks  DEGs COCS RML 7 wks 
Calcium signaling pathway GRM5, TACR3, CCKBR, CHRM2, TACR1, HTR7, DRD5, TRHR 
ATP2B2, ATP2B3, ADCY1, 
PLCB4, CAMK4, GRIN1, 
CAMK2B, ITPR1 
Nicotine addiction SLC17A6, GABRA5, CHRNA6, GABRQ 
SLC17A7, GABRD, GRIA1 
 
Chagas disease CCL12, CCL3, CCL2, SERPINE1, CCL5 
FOS, ACE, ADCY1, PLCB4, 
NFKBIA 
Morphine addiction OPRM1, GABRA5, PDE11A, GABRQ 
GABRD, ADCY1, GABRA1, 
GABRA6, GNG13 
Pathway  DEGs Cerebellum RML 18 wks 	 DEGs COCS RML 9 wks	
Cell adhesion molecules 
PTPRC, CD86, H2-OB, CLDN1, 
CLDN2, CD22, H2-DMB1, ITGB2, 
PDCD1 
CLDN1, NTNG1, CLDN2, 
CNTNAP2, L1CAM, CDH1, 
CDH3 
 
Interestingly, the calcium signaling pathway and neuroactive ligand-receptor interaction 
were deregulated most frequently. At almost all conditions the calcium signaling pathway 
was changed compared to Mock (Figure 29). Only cerebella at the late time point 
showed no changes in this pathway. Also neuroactive ligand-receptor interactions were 
strongly deregulated in 22L and RML infected COCS and mice cerebella especially at 
early and intermediate time points. Only at late time point in RML infected COCS 
neuroactive ligand-receptor interactions were deregulated. Again the genes involved in 
the deregulated pathways were not necessarily the same (Table 11).  
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Figure 29. Calcium signaling pathway (A) and neuroactive ligand-interaction (B) were most 
frequently deregulated in 22L and RML infected in vivo and ex vivo experiments. 
 
Table 11. Deregulated genes in calcium signaling pathway and neuroactive ligand-receptor 
interaction 
 Genes involved in calcium signaling pathway 
Genes involved in neuroactive 
ligand-receptor interaction 
Cerebellum 22L 10 wks 
GRM5, TACR3, CHRM3, 
TACR1, HTR7, HTR4, 
CACNA1H, NTSR1, HTR2C 
OPRM1, GPR83, CGA, TACR3, GLRA1, 
DRD2, NPY2R, TACR1, GLRA3, 
HCRTR1, HTR1A, PRL, RXFP3, 
GABRA5, HTR4, NPY1R, NTSR1, 
NPY5R, GRM5, CRHR2, CHRM3, 
HTR7, MC4R, HTR2C, GH 
Cerebellum 22L 14 wks 
GRM5, TACR3, CHRM3, 
CCKBR, TACR1, TRHR, 
HTR2A 
CALCR, GPR83, GLRA1, CCKBR, 
TACR3, DRD2, RXFP3, GLRA3, TACR1, 
TRHR, GABRA5, NPY1R, NPY5R, 
GRM5, HCRTR1, HTR1A, CHRM3, 
CHRNB3, GABRQ, HTR2A 
COCS 22L 5 wks 
ADCY1, SLC8A2, GRIN1, 
CACNA1I, GRIN2A, PRKCG, 
GRM1, ITPR1, CAMK4, 
GRIN2C, ATP2A3, CACNA1G, 
RYR2, CACNA1E, CAMK2B, 
NOS2, CACNA1C, CAMK2A, 
CACNA1B 
GABRD, GRM4, GRIA2, GABRA3, 
GABRB2, GRIN2C, GABRA6, GRIN1, 
GRIN2A, GRM1, NTSR2 
COCS 22L 7 wks 
ADCY1, SLC8A2, NOS1, 
GRIN1, CACNA1I, GRIN2A, 
PRKCG, ITPKA, ITPR1, 
CAMK4, ATP2A3, GRIN2C, 
RYR1, CACNA1E, CAMK2B, 
CAMK2A 
CRHR1, GABRD, GRM4, HTR1B, 
SSTR3, GRM2, GABRB2, OPRL1, 
GRIN2C, GABRA6, GRIN1, GLRA2, 
GRIN2A 
COCS 22L 9 wks 
ATP2B3, ADCY1, SLC8A2, 
CAMK4, ATP2A3, CACNA1I, 
GRIN1, CACNA1G, PRKCG, 
CAMK2B, ITPR1 
 
Cerebellum RML 10 wks CCKAR, TACR3, TNNC1, TACR1, HTR2C 
CCKAR, CGA, ADORA3, GLRA1, 
TACR3, DRD2, GLRA3, TACR1, RXFP3, 
GABRA5, NPY1R, NPY5R, HCRTR1, 
CRHR2, HTR1A, PRL, HTR2C, CHRNE, 
GH 
Cerebellum RML 14 wks 
GRM5, TACR3, CCKBR, 
CHRM2, TACR1, HTR7, 
DRD5, TRHR 
CALCR, OPRM1, GPR156, C3AR1, 
MCHR1, CCKBR, GLRA1, TACR3, 
DRD2, RXFP3, GLRA3, TACR1, DRD5, 
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GLRA2, TRHR, GABRA5, NPY1R, 
NPY5R, GRM5, HTR1A, CHRM2, HTR7, 
CHRNB3, CHRNA6, PRL, GABRQ, GH 
COCS RML 5 wks 
ADCY1, SLC8A2, NOS1, 
GRIN1, CACNA1I, GRIN2A, 
ITPR1, CAMK4, ATP2A3, 
GRIN2C, CACNA1G, RYR1, 
CACNA1E, CAMK2B, NOS2, 
CAMK2A, HTR5A 
CRHR1, GABRD, GRM4, GRM2, GRM8, 
GRIN2C, GABRA6, GRIN1, GLRA2, 
GRIN2A, VIPR1, HTR5A 
COCS RML 7 wks 
ATP2B2, ATP2B3, ADCY1, 
PLCB4, CAMK4, GRIN1, 
CAMK2B, ITPR1 
 
COCS RML 9 wks 
ADCY1, SLC8A2, GRIN1, 
CACNA1I, GRIN2A, PRKCG, 
ITPKA, GRM1, ITPR1, 
ATP2B3, CAMK4, PDE1C, 
ATP2A3, GRIN2C, CACNA1G, 
CACNA1E, CAMK2B, HTR2C 
CRHR1, GABRD, GRM4, GRM2, 
GRIN2C, GABRA6, CNR1, LEPR, 
GRIN1, GRIN2A, GRM1, HTR2C 
 
 
Nine genes were chosen for further analysis and validation of differentially expressed 
genes in COCS. The same COCS samples used for next generation sequencing 
analysis were transcribed to cDNA and real time PCR was performed. Three genes 
served as internal controls: Gfap, Cxcl10 and Snap25. GFAP and CXCL10 are known to 
be upregulated in prion disease (175) and Snap25 is typically downregulated (176). The 
other chosen genes were either differentially expressed and/or were potential binding 
partners of DEGs (Figure 30). 
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Figure 30 Sequencing results of DEGs chosen for qPCR validation. (A-I) Log2 fold change of 
different DEGs normalized to actin and relative to Mock samples. Genes above a log2 fold 
change of 1 are upregulated and beneath downregulated (dashed line). Unpaired t test was used 
to statistically analyze the data. Dots indicate a significant deregulation compared to Mock (p ≤ 
0.05). 
 
Quantification of qPCR for COCS showed that Cxcl10 was upregulated at all conditions 
but not necessarily significant, Gfap was significantly upregulated after nine weeks in 
22L and RML infected COCS (Figure 31 B, C) and Snap25 was downregulated from 
week five on, except for COCS infected for 7 weeks with RML prions were it showed no 
significant deregulation  (Figure 31 H). Snap25 data were comparable to sequencing 
data (Figure 30 G), in contrast to Cxcl10, which showed no significant changes in 
sequencing analysis for COCS (Figure 30 B). Gfap showed a not significant down-
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regulation in both, sequencing analysis and qPCR analysis at week five and seven, but 
sequencing analysis showed no upregulation nine weeks post infection with 22L or RML. 
Sequencing analysis of Hgf, Met and Slc17a7 could be validated by qPCR. In both, 
sequencing analysis and qPCR Hgf showed a not significant downregulation at all time 
points, Met a significant upregulation 9 weeks post 22L infection and Slc17a7 was 
significantly downregulated at all time points except for qPCR analysis of COCS 5 weeks 
post 22L infection by (Figure 31 D-F, Figure 30 D-F). However, Stx1b displayed contrary 
results as it showed a significant upregulation by qPCR analysis and for most time points 
a significant downregulation in sequencing analysis (Figure 30 H, Figure 31 H). Also Apc 
showed different results in qPCR analysis and sequencing analysis. Apc was 
significantly downregulated five weeks post 22L infection significantly in qPCR analysis 
(Figure 31 A), but sequencing analysis revealed a significant upregulation 9 weeks post 
22L infection (Figure 30 A). Syt1 could not be detected by qPCR analysis, maybe 
because the amount of DNA was too low in the samples as it was strongly 
downregulated in sequencing analysis. 
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Figure 31. Quantitative qPCR to validate sequencing results for COCS. RNA of COCS 
samples that was sent in for next generation sequencing analysis were transcribed to cDNA. 200 
ng of produced cDNA was mixed with probes of genes of interest (A – H) and actin was used to 
normalize. Gene expression is shown relative to Mock control, which was defined as 1. 
Experiments were done in triplicates. One-way ANOVA with Dunnett’s multiple comparisons test 
was performed. Bars represent mean values ± SD. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 
0.0001, ns: not significant). 
 
To summarize, changes in gene expression of mice and COCS were comparable for 
distinct pathways. Several pathways, but not necessarily the same genes, were 
deregulated in brain as well as in COCS. However, gene expression in general also 
revealed differences between in vivo and ex vivo experiments. Regarding the pathways 
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that might be influenced by prion disease, several pathways like calcium signaling 
pathways or neuroactive ligand-receptor interaction were deregulated in in vivo and ex 
vivo infected cerebella. 
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4 Discussion 
 
Currently, there are no therapies for prion disease and these diseases are always 
invariably fatal. Therefore, it is of great importance to identify compounds with 
therapeutic or prophylactic activity against prion disease (146). The present available 
screening methods were not successful and sufficient to detect such a compound. 
Several compounds could be detected with in vitro efficacy, but in vivo these compounds 
showed no effect (148, 177). Therefore, there is an urgent need to screen more 
compounds to finally identify a compound with in vivo anti-prion activity.  
In this study a screening method for the high-throughput analysis of compound libraries 
was developed based on N2a cells persistently infected with 22L prions. Several 
inhibitory compounds were detected and further analyzed, resulting in the identification 
of at least one compound, PHA665752 with an IC50 of 0.42 µM, that should be tested in 
vivo. 
 
4.1 Successful establishment of a high-throughput screening 
method and its potential and problems  
The established screening method is the first one based on immunofluorescence 
detection of PrPSc on a single cell level. The performed screen was conducted with 152 
compounds from a preselected library on N2a cells persistently infected with prion strain 
22L. 30 % of the compounds had an inhibitory effect on PrPSc accumulation, 37 % were 
considered to act as activators, 23 % had dual effects and 10 % of the compounds were 
toxic and were thus excluded from further analysis.  
This screening method has the potential to be extended to different cells lines, as we 
showed e.g. for persistently prion infected L929 cells, and more prion strains. Beside 
this, another opportunity would be to test compounds on cells infected with different 
prion strains. Different prion strains exhibit specific biological and biochemical properties 
and target different strain-specific brain regions and cause a characteristic lesion profile. 
Prion strains differ in their cell tropism to different kinds of cells like astrocytes and 
neurons (178, 179). Identification of a compound with anti-prion activity on different 
strains in different cell types would present a perfect candidate for in vivo experiments. 
To screen for compounds that influence the establishment of an infection, uninfected 
cells could be infected on 96-well plates and during this infection compounds could be 
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added as well. Also a pre-treatment of cells with different compounds before prion 
infection would be realizable. Pre-treatment can be used to study e.g. the internalization 
process of PrPSc into the cell by blocking specific receptors or routes (178). In this way it 
is also possible to study cell biological processes in prion infected cells. Additionally, the 
transmission of PrPSc between cells could be studied with co-culture experiments, in the 
presence and absence of compounds. For evaluation of a compound effect, the 
percentage of infected cells was determined in this assay. However, beside this, it is 
possible to further characterize the effect on treated cells if the algorithm would be 
adapted. Size, form and amount of aggregates per cell, as well as the effect on size and 
form on the whole cell could be evaluated. Further characterization of cells and 
aggregates would provide more information about the effects of compounds on cells and 
possible mechanism of actions and efficacy, e.g. the reduction of aggregates per cell 
could be monitored.  
These different applications make this screening method powerful to study compounds 
with beneficial effects on stabilization of native PrPC, interruption of the conversion of 
PrPC into PrPSc or the reduction of already existing PrPSc. 
 
However, next to the broad range of advantages and novel applications, the developed 
high-throughput screen exhibits also some limitations. One problem is the lack of an 
antibody that can discriminate between PrPC and PrPSc. In this assay, PrPSc was 
detected by immunofluorescence staining in fixed and permeabilized cells after antigen-
retrieval by guanidine hydrochloride (GdnHCl) treatment. This treatment enables 
discrimination of the two PrP isoforms as it reduces PrPC background staining, while it 
drastically increases the immunoreactivity of PrPSc (147, 180, 181). In this screen, PrPSc 
was detected by an algorithm. This algorithm for detection of PrPSc aggregates is based 
on measured local fluorescent signal peaks. If a compound drastically increases the 
level of PrPC, possibly densely packed within vesicles, this antigen-retrieval might not be 
sufficient so that the algorithm could detect false positive cells due to its inability to 
discriminate between different origins of local signal peaks. An alternative detection of 
PrPSc in immunofluorescence staining could be implemented by a pre-treatment of cells 
with proteinase K (181, 182). However, this could not be established at least for the used 
cell type, as proteinase K treatment reduces the attachment of cells to the substrate, and 
even with different coating methods, prolonged fixation and gentle handling too many 
cells detached and subsequent analysis could not be continued. However, further 
 Discussion  
 95 
training and development of the algorithm might be useful for an even more reliable 
distinction between PrPC and PrPSc. 
At this moment the screening method also has a limitation concerning the amount of 
compounds that can be tested at once, as the 96-well plates had to be stained manually 
until the guanidine hydrochloride treatment due to biosafety regulations of the screening 
facility. However, this limitation could easily be avoided in a screening facility with S2 
permission. Thereby, thousands of compounds could be tested at once with an 
automated staining procedure.  
 
4.2 Several strong inhibitors on PrPSc accumulation are found in the 
screen but cannot necessarily be validated by western blot 
analysis 
Of the 152 tested compounds 84 had an inhibitory effect on PrPSc accumulation in 
persistently infected N2a22L cells. Seven of the strongest inhibitors with no (survival of 
cells treated with 10 µM of a compound ≥ 75 %) or weak toxicity (survival of cells treated 
with 10 µM of a compound < 75 %) were chosen for further validation by western blot 
analysis (Figure 17 and Table 12). Before western blot analysis, two rounds of limited 
dilution cloning were performed to increase the percentage of 22L infected cells. Only 
concentrations of compounds that were not toxic in the screen were tested by western 
blot analysis with the same experimental setup as used for the screen. Three out of 
seven compounds showed significant reduction of PrPSc accumulation after compound 
treatment in western blot analysis (Table 12). Quinacrine dihydrochloride was identified 
by the screen as inhibitor and has previously been reported to have an anti-prion activity 
(183). In contrast to existing studies, we were not able to show a significant reduction of 
PrPSc accumulation in persistently prion-strain 22L infected N2a cells by western blot 
analysis. This might be due to experimental differences, like incubation time and 
concentration of the drug. We incubated the cells only for 44 h with 1 µM or 0.1 µM 
quinacrine dihydrochlorid. In the other studies, cells were incubated at least for 72 h and 
up to six days and medium supplemented with fresh compound was changed daily or 
every second day partly at higher concentration up to 5 µM (159, 168, 183, 184). 
However, beside Quinacrine dihydrochloride and AEE788, all compounds showed a 
reduction of PrPSc signal intensity, but due to variation between the three independent 
western blot results these changes are not significant. 
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Table 12. Summary of further validated compound identified by the screen 
Compound 
Reduction of PrPSc 
infected cells in % 
Conformation by western 
blot analysis 
Quinacrine dihydrochloride 64 No 
Indatraline hydrochloride 70 No 
Maprotiline hydrochloride 68 No 
Methiothepin mesylate 53 Yes 
AEE788 70 No 
SB590885 90 Yes 
PHA665752 71 Yes 
 
The two different experimental setups were tried to be kept as similar as possible. 
However, the slightly different results may arise from some adaptation for western blot 
analysis. Firstly, western blot analysis was performed with a subclone of N2a22L cells. 
Subclones of cells can differ slightly from the bulk population, also a cell population 
develops heterogeneity even after biological cloning (185). It is e.g. known that prion 
susceptibility can differ between clones and also their ability to transmit PrPSc over 
several passages (124, 186). It was reported, that treatment with drugs in different cell 
clones could result in a slightly different response to the treatment (185, 187). Secondly, 
within the two experiments (screen vs. western blot analysis) cells were treated with 
compounds from different batches or even different producers. For the screen 
compounds available in screening libraries from Tocris, Selleckchem and Lopac were 
used. For western blot analysis compounds were ordered, if individually available, from 
Selleckchem and Sigma. Slight differences in cellular response to compound treatment 
might result from the different batch or producer (188, 189). Finally, the biggest 
difference between the two experiments, which cannot be avoided, is the detection 
methods for PrPSc. As described earlier PrPSc in the screen was detected by 
immunofluorescence staining after antigen-retrieval by guanidine hydrochloride 
treatment to reduce PrPC background staining and increase the immunoreactivity of 
PrPSc. For western blot analysis, cell lysates were treated with proteinase K and only PK 
resistant PrPSc was detected. This may also have led to different results for the 
independent experiments.  
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4.3 Identified inhibitors of PrPS accumulation may interfere with the 
autophagy pathway  
The three compounds Methiothepin mesylate, SB590885 and PHA665752, had 
comparably strong inhibitory effects on PrPSc accumulation in the screen as well as in 
western blot analysis. Treatment of N2a22L cells with Methiothepin mesylate decreases 
PrPSc accumulation levels at 10 µM to 60 %, whereas 1 µM of SB590885 led to a 
decrease of PrPSc accumulation of 89 % and 1 µM PHA665752 of 85 %. PHA665752 
was also the only compound that showed a significant reduction of PrPSc accumulation 
at 0.25 µM of 23 % (Figure 19). To determine the half maximal inhibitory concentration a 
dose response curve of these three compounds was produced. Surprisingly, this time 
the reduction of PrPSc accumulation levels was slightly lower than in the experiment 
before. This is likely due to the fact that for both experiments the same stock compound 
was used. Thus, compounds used for the dose response experiment were stored for 
around 5 weeks, compared to one day in the first experiment, and were additionally 
frozen and thawed one more time. Storage of compounds in DMSO, as well as thaw and 
freeze cycles can lead to significant compound degradation and reduces the activity of a 
compound (190). To understand the underlying mechanism that leads to the reduction of 
PrPSc levels in cells, the sites of action of compounds need to be elucidated. 
Methiothepin mesylate is a 5-HT2β receptor antagonist (191) and is used in several in 
vitro and in vivo experiments to study the role of serotonin in different pathways (192-
194). The 5-HT2β receptor is a G-protein coupled receptor for 5-hydroxytryptamine 
(serotonin) (195), but also binds various alkaloid derivatives and psychoactive 
substances (196). Binding of a ligand results in conformational changes that trigger 
signaling via guanine nucleotide-binding proteins (G proteins) and modulate the activity 
of down-stream pathways (195). These affect, amongst others, neural activity, 
perception of pain, and regulation of behavior, including impulsive behavior (197). 
Several studies of the 5-HT2β receptor showed that it might be a potential target in 
cardiovascular diseases (198, 199), as it has functions in heart development, the 
adaptation of pulmonary arteries to chronic hypoxia and protects cardiomyocytes against 
apoptosis (195, 200). 
SB590885 is a small molecule kinase inhibitor of the triarylimidazole class. This novel, 
low molecular weight compound inhibits potently and selectively B-Raf kinase activity, as 
SB-590885 occupies the ATP-binding pocket B-Raf and binds to an active conformation 
of B-Raf (201). It also binds with a lower selectivity to Erk (201). B-Raf is a member of 
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the Raf kinase family of growth signal transduction protein kinases and amongst others it 
plays a role in regulating the MAP kinase and ERKs signaling pathway by which it 
affects cell division, differentiation, and secretion (202). B-raf is composed of three 
conserved domains, a conserved region 1 (CR1), a Ras-GTP-binding self-regulatory 
domain (CR2) and a serine-rich hinge region, and conserved region 3 (CR3) (203). B-
Raf is associated with several types of cancers, such as colorectal cancer, papillary 
thyroid cancer, melanoma, and ovarian cancer (204-207). In vivo administration of 
SB590885 potently decreases tumorigenesis in murine xenografts established from 
mutant B-Raf-expressing A375P melanoma cells, and modestly inhibits tumor growth 
(201).  
PHA665752 is a small molecule inhibitor of c-met kinase. PHA665752 has a high 
specificity for c-Met, as it is 50 times more selective for c-Met than for other 
tyrosine/serine-threonine kinases (208). The receptor tyrosine kinase c-Met is encoded 
by the MET proto-oncogene. Hepatocyte growth factor (HGF) is the only known ligand 
for the c-MET receptor. Binding of HGF to c-Met leads to dimerization and 
autophosphorylation. This creates an active docking site for proteins that mediate 
downstream signaling pathways (209). Via the c-Met signal transduction pathway 
PHA665752 was shown to inhibit cell growth, induce cell-cycle arrest or apoptosis and 
affect cell motility (208). In vivo, administration of PHA-665752 induces a dose-
dependent tumor growth inhibition (210, 211). PHA665752 also significantly inhibits 
angiogenesis, due to decreasing the production of vascular endothelial growth factor and 
increasing the production of the angiogenesis inhibitor thrombospondin-1 (212). 
 
The mechanisms of action of these compounds on PrPSc accumulation were not further 
analyzed within this work. However, several mechanisms are conceivable like inhibition 
of PrPSc formation, degradation or stabilization of PrPC. All three compounds target 
receptors or molecules, which are involved in many different pathways that regulate 
various intracellular processes. However, we focus on one common process that is likely 
to play a role in PrPSc degradation and is affected by the three compounds, namely 
autophagy. 
Autophagy is a highly conserved catabolic process that degrades cytosolic 
macromolecules, damaged organelles, aggregated proteins and pathogens (213). 
Autophagy is required for the removal of proteins and plays a role in neurodegenerative 
diseases, cancer and inflammatory disorders (54, 214, 215). Autophagy functions in 
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maintaining neuronal homeostasis and plays a particularly important role in postmitotic 
neurons, as the level of altered proteins and damaged organelles cannot be diluted by 
means of cell division. Dysfunction in autophagy is denoted as a secondary pathologic 
mechanism for various neurodegenerative diseases, such as Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (213). 
There are three processes of autophagy described, including macroautophagy, which is 
most common and hereafter referred to as autophagy, microautophagy and chaperon-
mediated autophagy. Under physiological conditions autophagy is generally active at low 
levels in most tissues to maintain protein and organelle quality by the elimination of 
damaged material. In response to stress and starvation, but also during inhibition of the 
mTOR pathway autophagy can be upregluated. Autophagy is controlled by products of 
the autophagy-related genes, the Atg (214, 216).  
Here, a possible mechanism of PrPSc degradation in response to Methiothepin mesylate, 
SB590885 and PHA665752 treatment is suggested. Treatment with Methiothepin 
mesylate inhibits the 5-HT receptor, which amongst others leads to reduced activation of 
mTOR via the PI3K/AKT pathway (Figure 32 A) (217). If cells are treated with 
PHA665752, it inhibits the c-Met receptor, which in turn can inhibit mTOR via two 
different pathways. Less activation of GABA leads on one hand also to inhibition of the 
PI3K/AKT pathway and on the other to reduced mTOR activity via inhibition of Ras, 
which inhibits Raf resulting in reduced levels of MEK and Erk activation. It was shown 
that SB590885 is a novel triarylimidazole that selectively inhibits Raf kinases (201, 218) 
and thereby inhibits mTOR (Figure 32 A). Inhibition of mTOR leads to activation of 
autophagy, as it negatively regulates autophagy (217).  
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Figure 32. Proposed mechanism of Methiothepin mesylate, SB590885 and PHA665752 on 
PrPSc accumulation. (A) Compound treatment could inhibit mTOR signaling as shown in other 
cell models (170, 191, 201). Methiothepin mesylate inhibits the 5-HT receptor resulting in mTOR 
inhibition via the PI3K/AKT pathway. PHA665752 inhibits binding of HGF to c-Met receptor, 
resulting in less mTOR activation via PI3K/AKT and Ras/Raf, whereas SB590885 has an 
inhibitory effect via Raf. (B) PrPSc degradation by autophagy. Inhibition of mTOR results in 
activation of autophagy. In the initiation phase a phagophore assembles around PrPSc and is 
accomplished by formation of the UKL1/Atg1-Atg13-FIP200/Atg17 complex. The nucleation of the 
membrane starts with the formation of the Beclin-1/PI3KC3 complex elongated by formation of 
the Atg12-Atg5-Atg16L homology tetramer complex and LC3 is lipidated by binding to 
phosphatidylethanolamine. The formed autophagosome fuses with lysosomes resulting in 
autophagolysosome formation, which could degrade PrPSc . 
 
Inhibition of mTOR leads to activation of ULK1 by dephosphorylation, which in turn forms 
the UKL1/Atg1-Atg13-FIP200/Atg17 complex (Figure 32 B). Once this complex is 
formed, autophagy is initiated. It begins with the formation of an isolation membrane or 
phagophore around the material, in this case PrPSc that should be engulfed (54). The 
phagophore is characterized as a small crescent-shaped structure. Formation of the 
autophagosome is classified in two steps: the nucleation and the elongation. The 
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nucleation of the membrane is initiated by the formation of Beclin-1/PI3KC3 complex 
composed of Beclin-1, UVRAG, Bif-1, ambra1, Vps15, and Vps3. To elongate the 
vesicle membrane, other Atg proteins are required. There are two ubiquitin-like protein 
systems involved in extension and expansion, the Atg12-Atg5-Atg16L homology 
tetramer complex, which leads to formation of vesicle curvature and LC3 (Atg8). LC3 is 
lipidated by binding to phosphatidylethanolamine (PE) located on the surface of the 
autophagic membrane (214). The formed autophagosome fuses with lysosomes and 
forms the autophagolysosome, where PrPSc degradation could take place (215).  
In prion disease autophagy could function as a conserved host defense response to 
prion infection and could play a protective role by degrading aggregate-prone proteins 
accumulated within endosomal/lysosomal vesicles (54, 215). Recently, first studies 
showed that induction of autophagy can result in PrPSc degradation. It was shown that 
pharmacological inhibition of autophagy or siRNA gene-silencing of essential members 
of the autophagic machinery leads to impaired PrPSc degradation (54). Lithium for 
example, enhances clearance of PrPSc in vitro by inducing autophagy in an mTOR-
independent manner (219), whereas Rapamycin reduces PrPSc levels in an mTOR-
dependent manner (214). In contrast, treatment of prion-infected cells with a potent 
inhibitor of autophagy, like 3-methyladenine, counteracted the anti-prion effect of lithium 
(219).  
Taken together there is clear evidence that induction of autophagy mediates degradation 
of PrPSc, which supports the proposed mechanism of action of Methiothepin mesylate, 
SB590885 and PHA665752 in persistently prion infected cells. Western blot pattern and 
reduction of PrPSc accumulation depended on concentrations were highly comparable for 
SB590885 and PHA665752. This might be due to the fact, that they inhibit the same 
signal transduction pathway. Additionally, PHA665752 showed the strongest inhibitory 
effect on PrPSc accumulation, which might result from mTOR dependent autophagy 
inhibition by two different signal transduction pathways. However, these two hypothesis 
needs to be validated by experiments concerning the autophagy pathway.  
As PHA665752 showed such a strong inhibitory effect on PrPSc accumulation and is an 
approved drug candidate (220), it was chosen for ex vivo analysis, as it seems to be a 
promising candidate for a potential therapeutic in prion disease. However, it is unknown 
if PHA665752 is capable to cross the blood brain barrier. Due to the small size and its 
lipophilicity it might be possible that it can pass the blood brain barrier (221).  
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Therefore, 22L prion infected cerebellar organotypic slices (COCS) were treated with 1 
µM PHA665752 for five weeks, as this concentration showed no toxicity at all. Western 
blot analysis revealed a decrease in PrPSc accumulation upon PHA665752 treatment. 
However, this decrease was statistically not significant. There might be several 
explanations why this decrease is statistically not significant and some possible options 
to increase the compound effect in future experiments. A higher number of the samples 
might already be sufficient to monitor a significant reduction of PrPSc accumulation. 
Beside significance a stronger reduction of PrPSc accumulation would be desirable. This 
could be accomplished by treatment with a higher concentration of PHA665752. In cell 
culture experiments 10 µM of PHA665752 was toxic, but 5 µM showed no toxicity. It 
would be also possible to increase the incubation time of COCS with PHA665752 to e.g. 
seven or nine weeks. Furthermore already thawed and frozen drugs were used which 
can reduce the activity of a drug as described earlier (190). Additionally the drug in 
DMSO was thawed, diluted in culture medium, containing amongst others horse serum, 
aliquoted and frozen. Before medium exchange one of this aliquot was thawed again. 
PHA665752 may have interacted with media components, which can result in a 
decreased half-life and activity of the compound (222, 223).  
An improved experimental setup could already be sufficient to increase the reduction of 
PrPSc accumulation in COCS, but also higher concentrations and longer incubation can 
be considered.   
 
4.4 Ex vivo experiments on prion infected COCS revealed that 
FeTMPyP and PIM-B31 appear to be no promising targets for 
PrPSc inhibition  
Furthermore, two other compounds with potential anti-prion activities were tested on 
COCS, FeTMPyP and PIM-B31, in cooperation with Emiliano Biasini (University of 
Trento, Italy) who did the in vitro pretesting.  
5,10,15,20-tetrakis(N-methyl-4´-pyridyl)porphyrinato iron(III) (FeTMPyP) is a 
peroxynitrite decomposition catalyst (PDC), which has been shown to protect against 
cytokine-induced cytotoxicity in hippocampal culture (224) and methamphetamine-
induced neurotoxicity in rats (225). PDCs isomerize peroxynitrites to nitrate anions and 
hence decrease their decomposition to highly reactive intermediates such as nitrogen 
dioxide and hydroxyl radicals (224). In addition to the peroxynitrite decomposition effect, 
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these compounds do have moderate superoxide dismutase activity resulting in a 
neuroprotective effect. Oxidative stress has been shown to play a role in several 
neurodegenerative disorders (226). Peroxynitrite (PN) is a marker for oxidative stress. 
The formation of the powerful oxidant peroxynitrite by the reaction of superoxide anion 
with nitric oxide has been shown to be a kinetically favored reaction and contributes to 
cellular injury and death at sites of tissue inflammation (224). PN has been shown to 
cause lipid peroxidation (227), chemical cleavage of DNA (228), inactivation of key 
metabolic enzymes (229), and reduction in cellular antioxidant defenses (230). PN can 
also nitrate protein tyrosine residues (nitrotyrosine), leading to the disruption of key 
cytoskeletal components that may contribute to the pathogenesis of diseases such as 
amyotrophic lateral sclerosis (231) or ALS. Nitrotyrosine has been detected in tissues 
from Alzheimer’s (232), multiple sclerosis (233), ALS (231), and rheumatoid arthritis 
(234) patients. In scrapie-infected mouse brains, high level of nitrotyrosine were found, 
suggesting damage by free radicals (226). Therefore antioxidants like FeTMPyP, are a 
potential therapy for these disorders. Additionally, recent force spectroscopy analysis on 
single molecule level revealed that FeTMPyP binds to PrP and inhibits misfolding by 
stabilizing the native state while suppressing interactions driving aggregation (235). 
However, in the conducted experiment, already a treatment with 1 µM FeTMPyP had 
such toxic effects that COCS completely dissolved and analysis could not be conducted. 
Further experiments with concentrations below the analyzed molarity range would be 
necessary for FeTMPyP to provide sufficient evidence for anti-prion effects. 
Nevertheless, it is disputable if it makes sense to continue experiments with a compound 
with such a high toxicity at 1 µM.  
The second tested compound was PIM-B31, a self-synthetized compound from Emiliano 
Biasini. In contrast to FeTMPyP, PIM-B31 showed no toxicity on COCS. Treatment with 
the first batch of compound led to a slight increase of PrPSc accumulation in 22L infected 
slices at a concentration of 10 µM. However, treatment with a higher concentration 
decreased PrPSc accumulation strongly. Both concentrations reduced PrPSc 
accumulation in RML infected COCS, but the variation between the two experiments 
was high. For those reasons, experiments were repeated with more cerebellar slices (n 
= 5) and a new synthesized batch of PIM-B31. Treatment of 22L infected COCS with 10 
µM of PIM-B31 led again to a slight but significant increase of PrPSc accumulation. 
Strikingly, treatment with 50 µM on 22L infected COCS and both concentrations on RML 
infected COCS had no effect on PrPSc accumulation. To exclude that the newly 
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synthesized has a lower activity than the old batch, cells were treated with 50 µM of the 
old and new batch. Here, both compounds reduced PrPSc accumulation (- 45 % vs. - 32 
%) but the old batch appeared to be more potent though the differences between the two 
batches were not significant. To summarize, PIM-B31 appears to have a dual effect in 
COCS (inhibitor and activator, depending on concentration and strain). It is a known 
phenomenon that different compounds result in concentration dependent dual effects 
(236-239). Inconsistencies in experiments with new and old batches may in part be 
explained by biological activity of PIM-B31, the old batch appears to be more potent. 
PIM-B31 has a dual effect on PrPSc accumulation in COCS. The results of treatment on 
RML infected COCS are hard to interpret due to the inconsistency of the results. 
Differences among experiments may potentially result from the batch-to-batch variation. 
No precipitation of the compound was observed that could explain lack of activity at high 
concentrations. 
 
4.5 Several comparable pathways are deregulated in vivo and ex 
vivo although differential expressed gene are not that similar 
A comparative study of the host response between ex vivo and in vivo was performed to 
evaluate the comparability between the two systems. To demonstrate this, COCS were 
prepared from pubs of C57BL/6JRj mice, infected with 22L and RML prions and RNA 
was isolated at three different time points post infection. In parallel, C57BL/6JRj mice 
were injected with the same 22L and RML prions and RNA was isolated from the 
cerebella at comparable time points concerning disease progression. RNA sequencing 
analysis was performed and analyzed. The 250 most significant differentially expressed 
genes at each condition were compared to each other. DEGs from COCS (ex vivo) 
infected with one prion strain at a distinct time point were compared to DEGs from 
mouse cerebella infected with the same strain and at a comparable time point (in vivo). 
Between two to nineteen comparable genes were identified at a specific condition.  
Comparison of 22L infected COCS and cerebella revealed that only three genes were 
similarly deregulated between in vivo and ex vivo. Myo5B and Met were upregulated at 
early respectively at late time point, whereas Dlk1 was down regulated at the 
intermediate time point. A possible influence of Met on prion disease was proposed 
earlier in this work. Dlk1 codes for delta like non-canonical Notch ligand 1 which contains 
multiple epidermal growth factor repeats. These growth factor repeats function as 
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regulator for cell growth. Mutation of this gene is associated with obesity and is not 
related to neurodegenerative diseases until now (240). In contrast, Myo5b encodes for 
myosin Vb which is suggested to play a role in Alzheimer’s disease where it might 
interfere the balance of beta-amyloid production and clearance (241).  
Comparison of RML infected COCS and cerebella led to the identification of two similar 
regulated genes, again Dlk1 and Serpina3n. Both genes were downregulated at the late 
time point. Serpina3n encodes for serpin family A member 3 and functions as plasma 
protease inhibitor and serine protease inhibitor. Variation of this protein’s sequence have 
been implicated in Alzheimer’s disease (242), Parkinson disease (243) and chronic 
obstructive pulmonary disease (244) and deficiency of this protein has been associated 
with liver disease. However, in a recent publication, Serpina3n was shown to be 
upregulated in human prion disease (245). The frontal cortex from patients suffering 
from vCJD, iCJD, sCJD, FFI and GSS were analyzed by qPCR and showed a strong up-
regulation of Serpina3n (245). There also an upregulation of Serpina3n in mice infected 
with prion strain RML could be detected. However, in contrast to our experiments, the 
isolated RNA of the frontal cortex of the human brain or one hemisphere of CD1 mouse 
whole brain tissue was analyzed, instead of analyzing the isolated RNA of the 
cerebellum, as presented here. 
DAVID 6.8 pathway analysis of the 250 most significant differentially expressed genes 
revealed that several pathways (Table 10) were similarly affected by prion infection of 
COCS and cerebella. The two most influenced pathways were the calcium signaling 
pathways and the neuroactive ligand-receptor pathway. It is known, that prion infection 
leads to changes in the calcium signaling pathways as PrPSc accumulation leads to 
extensive ER stress, resulting in the rapid release of calcium to the cytoplasm and the 
activation of the UPR (246). Also the neuroactive ligand-receptor pathway is known to be 
deregulated during in vivo and ex vivo (247) prion infection. The neuroactive ligand-
receptor pathway is involved in the communication of several neurotransmitters like 
serotonin, dopamine and glutamate (247). Both pathways can be altered by activation or 
inhibition of the N-Methyl-D-aspartate (NMDA) (246-248). The NMDA receptor is one of 
the major classes of ionotropic glutamate receptors in the mammalian brain that 
interacts with PrPC (249). NMDA receptors are heterotetrameric channels. The assembly 
of two GluN1 and two GluN2/GluN3 subunits forms the receptor. Glycine binds to GluN1 
and GluN3 subunit, while the GluN2 subunit contains the binding site for glutamate. The 
NMDA receptor can be localized synaptic, perisynaptic, extrasynaptic, or presynaptic. 
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The localization of the receptor is coupled to specific cellular events (250). In general, 
activation of synaptic localized NMDA receptors leads to activation of pro-survival 
signaling. In contrast, activation of extrasynaptic localized NMDA receptors leads to 
activation of pro-death signaling (251). In general, NMDA receptor activation by 
glutamate results in the opening of non-selective cation channels and calcium and 
sodium ion influx into the cytosol. At the synapse, glutamate is released by the 
presynaptic terminals, diffuses across the synaptic cleft and activates NMDA receptors 
at the post-synaptic membrane. This activation leads to depolarization of the post-
synaptic membrane and induces an excitatory postsynaptic potential (EPSP) (248). 
Beside the physiological role of NMDA receptors in learning and memory, an altered 
expression is likely to play a role in the pathophysiology of a wide variety of CNS 
disorders like neurodegenerative diseases (248). Mice inoculated with variant CJD 
prions showed increased NMDA receptor excitation (252). In vitro cultured neurons were 
incubated with PrPSc-like PrP106-126 peptide and treatment with NMDA receptor 
antagonists blocked the resulting neurotoxicity (253). However, down regulation of 
NMDA receptor activity may lead to a loss of the physiological PrPC function, which may 
also contribute to the pathogenic process (254). Genetic PrPC depletion leads to an 
increased hippocampal NMDA receptor-mediated excitation and glutamate excitotoxicity 
(255) . Furthermore, PrP knockout mice showed to be more susceptible to seizures 
induced by kainic acid than wild-type controls (256), likely due to facilitated NMDA 
receptor-mediated excitation in the hippocampus (257). However, although the exact 
physiological function of PrPC on the NMDA receptor is not fully understood, it is 
becoming clear that loss of PrPC regulation of NMDA receptor can result in toxicity in a 
variety of pathological conditions (258). There is a need to investigate the physiological 
interaction between PrPC and NMDA receptors and how this activity impacts signal 
transduction in both healthy and diseased organisms.  
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4.6 Outlook 
 
The developed high-throughput screen represents a powerful tool to identify potential 
compounds to treat prion disease. In the future the presented screen can be extended to 
several different cell lines, but also different strains. Further improvement of the 
algorithms that detect prion aggregates in the screen could reveal more information of 
the effect of a single compound with regard to e.g. amount and size of PrPSc aggregates 
in a single cell.  
Beside in vitro experiments, it would be necessary to test more compounds e.g. 
Methiothepin mesylate and SB590885 on prion infected cerebellar slices. Here it would 
be also interesting, if the identified compounds are capable of inhibiting PrPSc 
accumulation, if slices were infected with different strains. Genetic manipulation of slices 
e.g. by viral transduction is also a possible method to gain more information on the mode 
of action of different compounds. 
Identified compounds capable of inhibiting PrPSc accumulation in vitro and ex vivo 
without any toxicity should be tested in vivo in mouse experiments. In the case of 
PHA665752, we will test it again on 22L infected COCS with a newly ordered compound, 
solved in DMSO, aliquoted and solved in slices culture medium right before use. If 
treatment results in a significant reduction of PrPSc accumulation, PHA665752 will be 
tested in prion infected mice and might be tested further in a prion therapeutic clinical 
trial.  
RNA sequencing analysis led, amongst others, to the identification of Dlk1, which was 
downregulated at every time point, in cerebella and cerebellar slices infected with 22L 
and RML prions. Further analysis of Dlk1 and associate proteins could reveal 
cytopathological pathways and hands additional insights in prion disease pathology.  
Further investigation of the interaction between NMDA receptors and PrPC and better 
understanding of the underlying molecular mechanism might lead to the possibility of 
targeted modulation of this interaction in neurodegenerative diseases, such as prion 
disease.  
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Abbreviations 
 
µ micro (10-6) 
µl microliter 
AD Alzheimer’s disease 
BH brain homogenate 
bp base pare 
BSA bovine serum albumin 
BSE bovine spongiform encephalopathy 
c concentration 
°C degree Celsius 
cDNA complementary deoxyribonucleic acid 
CJD Creutzfeldt-Jakob disease 
CNS central nervous system 
COCS cerebellar organotypic cultures 
C-terminal carboxy terminal 
Cu copper 
CWD chronic wasting disease 
d day 
DEG differential expressed genes 
dest. destilled 
DMEM Dulbecco´s modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNase desoxyribonuclease 
DOC sodium deoxycholate 
dsDNA double strand DNA 
e.g. for example (“exempla gratia”) 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid disodium salt 
ER endoplasmatic reticulum 
et al. and others (“et alii”) 
fCJD familiar Creutzfeldt-Jakob disease 
FFI fatale familial insomnia 
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g gram; acceleration of gravity 
GdnHCl guanidine hydrochloride 
GFP green fluorescent protein 
GPI glycosyl-phosphatidyl-inositol 
GSS Gerstmann-Sträußler-Scheinker syndrome 
h hour(s) 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HGF Hepatocyte growth factor 
H2Odest. destilled water 
HRP horseradish peroxidase 
IC50 half maximal inhibitory concentration 
iCJD iatrogenic Creutzfeldt-Jakob disease 
IF immunofluorescence 
IgG immunoglobulin G 
kb kilo base pairs 
kDa kilodalton 
l  liter 
m milli 
M molar 
mAb monoclonal antibody 
min minute 
ml milliliter 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA messenger RNA 
n nano 
NaCl sodium chloride 
NaN3 sodium azide 
NaOH sodium hydroxide 
N-terminal amino terminal 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
pAb polyclonal antibody 
PBS phosphate buffered saline 
PFA paraformaldehyde 
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p.i. post infection 
PMCA protein misfolding cyclic amplification 
PK proteinase K 
POSCA prion organotypic slice culture assay 
PrP prion protein 
Prnp-/- PrP knock-out 
PrPC cellular non-pathogenic form of the prion protein 
PrPSc pathogenic isoform of the prion protein 
PVDF polyvinylidene difluoride 
RNA ribonucleic acid 
RNase ribonuclease 
RT room temperature 
sCJD sporadic Creutzfeldt-Jakob disease 
SDS sodium dodecyl sulfate 
sec second 
SD standard deviation 
SOD1 superoxide dismutase1 
t time 
Tris tris-(hydroxymethyl-)aminomethan 
TME transmissible mink encephalopathy 
TSE transmissible spongiform encephalopathy 
U unit 
UTR untranslated region 
UV ultraviolet 
V Volt 
vCJD variant Creutzfeldt-Jakob disease 
W Watt 
WB western blot 
WT wild type 
% (w/v) weight/volume percentage 
% (v/v) volume/volume percentage 
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Table 13. 22L vs. Mock: 250 significant DEGs sorted by log2 fold change in COCS 
5 wks 7 wks 9 wks 
Gene name log2Fold
Change 
P value Gene name log2Fold
Change 
P value Gene name log2Fold
Change 
P value 
Nos2 -4.99 5.17E-03 Xist 4.76 4.30E-04 Th -5.38 4.88E-11 
Ddn -3.99 1.98E-04 Sln -2.97 3.84E-04 Mast1 -4.68 6.53E-03 
Il22 -3.52 1.32E-02 Srrm4 -2.88 2.95E-02 Slc8a2 -4.45 1.55E-02 
Car9 -3.38 8.82E-08 Gm26917 2.83 7.43E-03 Slc17a7 -4.41 1.64E-16 
Ndufa4l2 -2.57 4.34E-05 Mapk13 -2.69 2.81E-02 Tmem178 -4.39 1.92E-02 
Fam163b -2.54 2.67E-02 A330094K24Rik -2.62 1.15E-02 Synpr -4.25 1.10E-03 
Sln -1.95 4.98E-03 Otx2os1 -2.43 4.06E-02 Ecel1 -4.25 2.94E-02 
Gm15169 -1.95 5.07E-02 Ecel1 -2.41 3.29E-03 Cntnap5b -4.18 3.64E-02 
Samd3 -1.94 4.23E-02 Bcl2l15 -2.13 1.58E-04 Calb2 -4.14 2.19E-14 
Pcdh8 -1.92 1.49E-02 Vgf -2.12 3.90E-03 Vsnl1 -4.13 1.37E-04 
Ankrd37 -1.89 5.14E-02 Mybpc3 -2.03 1.50E-04 Mybpc3 -4.02 3.70E-03 
Xist -1.89 5.14E-02 Glra2 -1.92 4.71E-02 Pcp2 -4.00 1.49E-17 
Lars2 1.88 7.51E-37 Slc5a1 -1.85 8.33E-04 Grm4 -3.93 5.53E-03 
Klc3 1.87 4.06E-02 Doc2g -1.85 4.07E-02 Fat2 -3.84 2.54E-06 
Fndc1 -1.79 1.70E-02 4833427G06Rik -1.83 2.97E-02 Slco1c1 -3.74 1.68E-03 
Dlk1 1.77 1.10E-09 Grm2 -1.81 1.80E-02 Aqp1 -3.67 2.46E-03 
Xkr7 -1.73 4.79E-02 Car4 -1.80 2.53E-04 Slc1a6 -3.61 1.46E-12 
Abcc8 -1.73 7.08E-03 Caly -1.78 1.08E-02 Snap25 -3.59 7.11E-25 
Prss35 -1.72 5.74E-05 Nrn1 -1.77 3.81E-06 Sycp1 -3.47 6.29E-03 
Fam19a2 -1.64 1.88E-02 Serinc2 -1.75 4.87E-04 Ppp1r17 -3.45 1.00E-04 
Car4 -1.62 1.30E-04 Slc16a11 -1.73 1.65E-02 Dlk1 -3.45 9.59E-10 
Eomes -1.61 1.11E-03 Nell1 -1.73 1.31E-04 Rasgef1a -3.44 4.26E-04 
Colq -1.60 4.74E-02 Krt8 -1.73 2.14E-03 Stmn2 -3.40 4.03E-07 
Miat -1.60 4.74E-02 Gm10800 1.72 1.02E-03 Dpp10 -3.39 4.50E-06 
Snhg11 -1.59 4.15E-04 Snca -1.71 3.33E-09 St6galnac2 -3.39 2.29E-03 
Trhde -1.57 1.34E-02 Sstr3 -1.71 2.92E-02 Asb10 -3.39 3.92E-02 
Cntnap5b -1.50 5.54E-03 Kcnk10 -1.69 4.33E-02 Nrn1 -3.39 3.92E-02 
Trank1 -1.50 3.81E-05 Grin2c -1.69 1.53E-06 Pld5 -3.39 3.92E-02 
Camk2a -1.50 7.37E-07 AI118078 -1.65 9.36E-05 Gabra6 -3.36 6.22E-06 
Wdr86 1.50 3.10E-02 Sowahb -1.64 1.94E-02 Serinc2 -3.30 1.32E-02 
Nuak2 1.48 2.45E-02 Sv2c -1.61 8.29E-05 Rbfox3 -3.29 4.36E-06 
Moxd1 1.46 5.04E-03 Pcp2 -1.60 1.36E-10 Cbln1 -3.25 4.68E-03 
Elfn2 -1.45 4.85E-02 Hes3 -1.60 6.41E-03 Ttr -3.24 2.26E-44 
Saa3 1.44 3.40E-02 Mast1 -1.59 1.73E-02 Clstn3 -3.24 2.45E-10 
Stra6 1.44 1.01E-03 Kcnk3 -1.58 1.50E-04 Gabrd -3.21 2.19E-04 
Prr32 1.44 5.68E-03 Sidt1 -1.58 4.47E-02 Gng13 -3.20 2.56E-08 
Sycp1 -1.39 6.35E-03 Th -1.58 8.40E-05 Car12 -3.20 4.85E-06 
Th -1.39 3.17E-03 Vsnl1 -1.58 4.14E-11 Nptx1 -3.14 7.94E-03 
Myo5b 1.36 4.16E-02 Mir124a-1hg -1.57 4.16E-04 Clec2l -3.13 1.09E-03 
Sfrp4 1.35 3.99E-02 Barhl2 -1.56 6.41E-03 Rph3a -3.11 1.22E-05 
Pnmal1 -1.33 1.36E-03 Nhlh2 -1.56 3.81E-02 Sv2b -3.10 3.43E-03 
Neb -1.29 4.05E-02 Tmem51 -1.55 6.19E-03 D11Wsu47e -3.10 2.72E-02 
Plcxd2 -1.28 1.39E-02 Tll1 -1.54 2.31E-02 Car8 -3.09 5.00E-20 
Vegfa -1.27 7.23E-09 Kcnip4 -1.54 1.66E-02 Prkcg -3.09 2.95E-07 
Meg3 -1.26 8.81E-05 Abcc8 -1.54 1.49E-02 Camk2b -3.05 1.13E-10 
Dgkg -1.26 2.14E-04 Cbln3 -1.53 2.55E-17 Folr1 -3.00 3.90E-06 
Cntn6 -1.26 1.68E-02 Atp2a3 -1.53 5.23E-07 Pcp4 -2.95 9.78E-07 
A330050F15Rik -1.25 6.98E-03 Crhr1 -1.52 4.55E-03 Dnm1 -2.94 1.09E-13 
Exph5 -1.25 9.99E-04 Neb -1.52 2.22E-02 Sncb -2.93 1.29E-06 
Necab1 -1.23 2.17E-03 Meg3 -1.52 1.29E-07 Tmem63c -2.93 4.64E-02 
Cacna1e -1.23 7.66E-05 Itpka -1.51 1.07E-03 Mfrp -2.90 3.17E-08 
Kcnip4 -1.23 5.19E-02 Rps6kl1 -1.50 1.64E-02 L1cam -2.90 4.10E-03 
Vsnl1 -1.21 4.34E-09 Diras2 -1.48 1.82E-12 Npr3 -2.88 2.24E-02 
Gm13111 1.20 3.45E-02 Npas4 -1.48 8.57E-03 Sphkap -2.84 5.67E-03 
Kif2c 1.20 5.42E-02 Clec2l -1.47 2.67E-06 Sptbn4 -2.84 2.65E-02 
Slc6a5 -1.19 7.16E-03 Kcnj9 -1.47 4.03E-06 Mpp3 -2.83 7.17E-04 
Rims1 -1.18 1.97E-05 Arhgdig -1.47 3.68E-02 Sptbn2 -2.80 9.44E-15 
Cdk1 1.18 1.11E-03 Gabra6 -1.45 5.84E-12 Grin1 -2.79 3.91E-05 
Itpr1 -1.18 4.66E-16 Dpp10 -1.45 1.91E-07 Atp1a3 -2.79 2.14E-20 
Cabp7 -1.17 3.64E-05 Syt13 -1.45 1.08E-06 Dlgap3 -2.78 1.55E-02 
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Rasgef1a -1.17 5.61E-04 Cntn6 -1.45 1.16E-02 Clic6 -2.77 8.88E-06 
Gabra6 -1.16 7.41E-10 Snhg11 -1.43 3.78E-04 Rap1gap2 -2.77 7.82E-03 
Gabra3 -1.16 4.27E-02 Sycp1 -1.43 3.49E-03 Slc12a5 -2.74 1.56E-07 
Ntsr2 -1.15 5.05E-05 Fhad1 -1.43 1.02E-04 Snca -2.74 3.90E-04 
AI118078 -1.14 4.41E-03 Snap25 -1.43 1.21E-17 Cpne9 -2.71 1.53E-03 
Camk4 -1.13 2.83E-10 Ramp3 -1.42 5.16E-03 Cacna1i -2.68 4.38E-02 
Barhl2 -1.12 1.73E-02 Sptbn4 -1.42 7.33E-04 Galnt9 -2.65 2.52E-02 
Ralyl -1.12 1.73E-02 Rltpr -1.41 5.29E-03 Slc4a10 -2.65 5.18E-10 
Mfrp 1.12 1.30E-02 Ppp1r17 -1.41 4.33E-10 Frmpd4 -2.63 5.16E-02 
Kl 1.12 6.83E-07 Fxyd6 -1.39 2.29E-07 Slc29a4 -2.59 3.24E-03 
Gpc5 -1.11 4.35E-02 Ryr1 -1.39 3.93E-02 Ckmt1 -2.58 1.25E-03 
Fhad1 1.11 2.06E-02 Cntnap4 -1.38 1.62E-04 Camk4 -2.55 2.01E-02 
Krt18 1.10 2.39E-03 Atp10b 1.37 4.77E-02 Strip2 -2.55 2.58E-05 
Col8a1 1.10 1.44E-06 Rgs8 -1.36 8.68E-11 Gabra1 -2.54 1.66E-03 
Car12 1.10 2.63E-06 Kif26b -1.36 1.35E-03 Atp2a3 -2.51 8.31E-03 
Folr1 1.09 2.12E-04 Pnck -1.36 4.49E-02 Otx2 -2.51 4.05E-02 
Scn2a1 -1.09 4.25E-07 Rec8 -1.35 2.66E-02 Syt1 -2.49 3.57E-03 
Snhg14 -1.09 2.08E-03 Crtam -1.35 1.22E-04 Oca2 -2.48 1.61E-02 
Ttr 1.08 3.25E-15 Slc35f3 -1.34 3.47E-02 Dgkg -2.48 1.00E-03 
Kcnk3 -1.08 2.76E-03 Olfm3 -1.34 2.37E-06 Nell1 -2.47 2.74E-02 
Col8a2 1.08 1.31E-04 Kcnj12 -1.32 1.21E-03 Eps8l2 -2.46 6.74E-03 
Grin1 -1.08 1.81E-04 Calb2 -1.32 5.82E-09 Spint2 -2.43 1.88E-04 
Loxl1 1.08 2.34E-02 Plch2 -1.32 5.59E-04 Sez6l -2.43 6.08E-04 
Serpinb1b 1.07 4.01E-02 Neurl1a -1.32 7.66E-04 Cacna1g -2.42 6.93E-05 
Cbln3 -1.07 5.28E-12 Oprl1 -1.32 5.46E-02 Celf4 -2.40 9.00E-03 
Nptx1 -1.07 2.77E-09 Stmn2 -1.31 8.57E-11 Shf -2.39 2.76E-03 
Adcy1 -1.07 7.20E-12 Cplx1 -1.31 2.65E-09 Rims1 -2.39 3.71E-02 
Trpv4 1.06 2.22E-02 Nefh -1.30 4.12E-03 Itpr1 -2.36 1.56E-20 
Cldn2 1.05 3.94E-04 Slc17a7 -1.29 3.80E-10 Napb -2.35 1.63E-03 
Ank1 -1.05 5.23E-06 Cadps2 -1.29 9.08E-08 Krt18 -2.34 2.59E-03 
Myt1 -1.05 1.20E-03 Kcnip1 -1.29 1.13E-03 Prmt8 -2.31 2.13E-03 
Nell1 -1.04 1.81E-02 Grm4 -1.28 1.30E-05 Adcy1 -2.29 1.75E-03 
Grin2a -1.04 1.56E-02 Tmem200b -1.28 5.00E-02 Cyb561 -2.28 1.59E-02 
Wscd2 -1.04 4.36E-05 Pifo -1.28 1.37E-02 Trpc3 -2.25 1.82E-02 
Rtn4r -1.04 2.25E-02 Rasgef1a -1.28 1.93E-04 Kcnip1 -2.25 2.65E-02 
Tiam1 -1.03 2.29E-05 Fgf14 -1.28 3.46E-03 Kl -2.25 2.65E-02 
Slc17a7 -1.03 1.41E-08 Cbln1 -1.27 2.96E-10 Kalrn -2.22 2.10E-02 
Galnt13 -1.03 1.56E-03 Pxylp1 -1.27 3.80E-03 Rian -2.19 4.65E-03 
Celsr3 -1.02 5.06E-03 Trank1 -1.27 8.35E-05 Slc6a15 -2.18 3.51E-02 
Grin2c -1.02 1.06E-03 Cgn -1.27 4.11E-02 Pde5a -2.17 5.19E-02 
Olfm3 -1.02 1.94E-05 Tmem130 -1.26 1.17E-03 Plekhd1 -2.17 5.19E-02 
Car8 -1.02 3.12E-11 Rtn4r -1.26 3.19E-02 Tacc2 -2.15 4.29E-03 
Fgf14 -1.02 1.11E-02 Shf -1.26 9.71E-06 Slc4a5 -2.13 8.69E-05 
Calb2 -1.02 7.37E-08 Ank1 -1.26 2.35E-07 Baiap2l1 -2.06 5.31E-02 
Cfap54 -1.02 2.36E-02 Cacna1e -1.25 2.06E-05 Ace -2.06 3.38E-11 
Dpp10 -1.01 8.97E-05 Susd4 -1.25 2.51E-04 Car7 -2.05 4.14E-02 
Caly -1.01 4.63E-02 Kcne2 -1.25 2.81E-05 Gad1 -2.04 4.36E-07 
Ppfia2 -1.01 3.86E-04 Scn4b -1.25 3.49E-03 Pcsk2 -2.02 2.81E-03 
Cacna1g -1.01 1.26E-05 Spint2 -1.24 1.39E-05 Dync1i1 -2.01 6.05E-05 
Slitrk4 -1.01 1.04E-02 Ttr -1.24 3.83E-15 Rgs7 -2.00 8.23E-03 
Gsg1l -1.01 4.34E-02 Wscd2 -1.23 3.18E-05 Calb1 -1.97 2.92E-11 
Car7 -1.00 3.72E-03 Sostdc1 -1.23 1.18E-04 Emb -1.93 1.85E-02 
Pxylp1 -1.00 1.03E-02 Cxcl1 1.23 2.91E-02 Gm2694 -1.93 3.74E-02 
Il16 -1.00 3.49E-03 Emb -1.23 1.54E-04 Pvalb -1.93 1.71E-07 
Gm2694 -1.00 1.45E-02 Slc8a2 -1.23 1.18E-04 Calml4 -1.91 1.66E-02 
Cdh7 -1.00 6.28E-03 Nptx1 -1.22 1.72E-09 Tiam1 -1.89 5.43E-02 
Syt1 -1.00 1.44E-08 Gabrd -1.22 1.26E-05 Atp2b3 -1.85 1.61E-03 
Stxbp5l -0.99 1.05E-02 Hpca -1.22 3.68E-03 Cadps2 -1.84 1.78E-03 
Zfp385b -0.99 2.98E-03 Sema5b -1.22 4.46E-02 Cplx1 -1.82 2.99E-02 
Cpne9 -0.99 1.54E-02 Lgi2 -1.22 1.71E-05 Fxyd6 -1.81 3.78E-02 
L1cam -0.99 2.20E-03 Camk2b -1.22 1.61E-09 Dpp6 -1.80 1.05E-04 
Slco1c1 0.98 2.91E-02 Dgkg -1.22 9.42E-05 Igfbp2 -1.76 1.04E-04 
Sptbn2 -0.98 2.26E-08 Gprin3 -1.20 5.28E-02 Rab3a -1.74 1.69E-04 
Kcne2 0.98 3.07E-03 Sncb -1.20 1.76E-05 Abca4 -1.72 6.64E-03 
Firre -0.97 8.87E-03 Slc6a17 -1.19 2.78E-07 Ank1 -1.70 3.70E-03 
Inadl -0.97 1.83E-05 Pcp4 -1.19 6.35E-08 Met 1.68 2.33E-02 
Atp2a3 -0.97 4.87E-04 1110017D15Rik -1.19 4.12E-02 Chgb -1.66 4.51E-03 
St6galnac2 0.96 2.78E-02 Htr1b -1.19 2.92E-02 Dner -1.65 1.68E-05 
Fgf9 -0.96 2.66E-02 Rian -1.17 6.75E-07 Sptb -1.62 1.10E-02 
Lcn2 -0.96 4.63E-04 Sv2b -1.17 1.37E-07 Mical2 -1.54 3.96E-02 
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Scn1a -0.96 2.30E-04 Cdh7 -1.17 4.24E-03 Stxbp1 -1.54 4.48E-06 
Snap25 -0.95 5.72E-11 Ckmt1 -1.17 6.31E-05 Arhgef33 -1.54 3.14E-02 
Arhgef33 -0.95 3.19E-04 Npr3 -1.17 1.84E-05 Hsd11b1 -1.53 2.50E-02 
Ryr2 -0.95 7.09E-04 Cdr1 1.16 9.94E-04 Slc13a4 -1.51 8.57E-03 
Sptb -0.95 2.14E-06 Pde5a -1.16 2.57E-04 Tmem132a -1.50 1.57E-02 
Ebf1 -0.94 1.11E-03 Cyb561 -1.16 8.31E-06 Pik3c2b 1.47 1.86E-02 
Sv2b -0.94 1.31E-06 Epn3 -1.15 5.96E-03 Eno2 -1.47 1.75E-05 
Caln1 -0.94 3.79E-07 Kcnt1 -1.14 1.36E-04 Gabbr2 -1.47 6.77E-03 
Kcnt1 -0.93 1.98E-03 Syt1 -1.14 1.42E-08 Snap91 -1.46 8.43E-04 
Megf11 -0.93 5.04E-06 Actl6b -1.13 1.84E-02 Flnc 1.46 3.13E-05 
Snca -0.93 4.02E-04 Dnm1 -1.13 3.04E-09 Zmym6 1.44 5.23E-02 
Unc13c -0.92 5.24E-04 Itpr1 -1.13 3.24E-12 Olfm1 -1.43 2.46E-04 
Fat2 -0.92 2.05E-07 L1cam -1.12 1.76E-03 Gpx3 -1.40 2.99E-08 
Cntnap2 -0.91 6.13E-03 Pcsk2 -1.12 9.21E-05 Cds1 -1.40 3.90E-02 
Iqsec3 -0.91 1.03E-02 St6galnac2 -1.12 2.62E-03 Pfkp -1.39 2.92E-05 
Cacnb2 -0.91 3.49E-02 Tc2n -1.12 6.53E-03 Rnf112 -1.38 4.28E-02 
Diras2 -0.91 4.04E-07 Jph4 -1.12 5.43E-05 Sh3gl2 -1.36 5.86E-03 
Cnksr2 -0.91 1.29E-03 Mfrp -1.12 4.27E-03 Enpp2 -1.36 2.69E-10 
Cbln1 -0.90 1.37E-07 Eps8l2 -1.12 1.87E-02 Elmod1 -1.35 1.45E-02 
Tmem178 -0.90 1.86E-04 Tenm1 -1.11 2.81E-04 Nfat5 1.35 1.34E-02 
Susd4 -0.90 2.76E-03 Nos1 -1.11 1.01E-06 Nrep -1.34 3.87E-03 
Slc16a3 -0.90 1.43E-02 Atp1a3 -1.11 6.10E-10 Ndrg4 -1.32 8.81E-06 
Kcnj12 -0.89 1.36E-02 Kcnd2 -1.11 3.72E-06 Cadm3 -1.32 9.60E-04 
Tenm1 -0.89 5.90E-03 Caln1 -1.11 6.32E-08 Podxl2 -1.29 7.25E-03 
Stac2 -0.89 2.04E-02 Cntnap2 -1.11 1.66E-03 Lbp -1.28 1.10E-02 
Tmem72 0.89 1.46E-03 Unc13c -1.10 1.83E-04 Rap1gap -1.28 4.52E-02 
Rbfox1 -0.89 2.41E-04 Capsl -1.10 1.59E-02 Tbc1d9 -1.27 1.18E-03 
Tmem63c -0.89 2.05E-02 Igfbp2 -1.10 1.43E-07 Cbl 1.26 9.47E-03 
Tenm2 -0.89 3.46E-02 Sptbn2 -1.10 4.76E-09 Nbeal1 1.26 1.09E-02 
Pdzd2 0.89 1.31E-02 Folr1 -1.10 8.35E-05 Kmt2a 1.22 1.29E-02 
Rap1gap2 -0.88 1.90E-04 Rims1 -1.10 3.90E-04 Pde9a -1.22 1.72E-02 
Pld5 -0.88 7.28E-03 Synpr -1.09 1.13E-05 Crmp1 -1.21 2.46E-02 
Sacs -0.88 1.12E-03 Col8a2 -1.09 2.40E-05 Glb1l2 -1.19 5.21E-02 
Cacna2d1 -0.88 5.57E-03 Rbfox3 -1.09 7.42E-06 Syp -1.18 6.49E-03 
Dnm1 -0.88 9.27E-08 Tmem63c -1.09 1.01E-02 Stmn3 -1.16 2.21E-03 
Perp 0.88 2.10E-02 Dpp6 -1.09 3.87E-07 Inadl -1.14 1.61E-02 
Tmem132c -0.88 4.80E-02 Gng13 -1.09 2.18E-04 Fbln1 -1.12 2.59E-02 
Msx1 0.87 5.29E-02 Grin1 -1.09 9.03E-04 Apc 1.12 2.89E-03 
Camk2b -0.87 6.45E-07 Cacna1i -1.09 9.62E-04 Igfbp4 -1.10 1.57E-02 
Shank1 -0.86 6.19E-03 Tmem132c -1.09 2.61E-02 Micu3 -1.10 4.94E-02 
Ckap2 0.86 3.12E-03 Penk -1.08 2.92E-03 Klc2 -1.08 2.44E-02 
Clic6 0.86 6.59E-06 Rab3c -1.08 7.27E-06 Lrp8 1.07 3.10E-02 
Sphkap -0.86 6.19E-07 Kcnh1 -1.08 2.63E-02 Abi3bp 1.06 1.88E-02 
Chgb -0.86 4.82E-07 Epha8 -1.07 2.11E-02 Slc24a2 1.06 1.94E-02 
Ablim3 -0.86 1.04E-02 Ptpru -1.07 2.64E-02 Sema3b -1.06 4.48E-03 
Gabrd -0.85 7.54E-04 Oca2 -1.07 5.08E-02 Enpp6 1.04 4.50E-02 
Slc8a2 -0.85 2.71E-03 Grin2a -1.07 1.27E-02 Rbp1 -1.03 3.35E-03 
Pcnxl2 -0.85 5.40E-02 Prkcg -1.07 2.84E-05 Plec 1.03 4.24E-03 
D430041D05Rik -0.84 3.56E-04 Car8 -1.06 4.22E-10 Tnrc6b 1.01 5.35E-02 
Nrn1 -0.84 1.69E-02 Ccdc153 -1.06 6.06E-03 Prkar1b -1.00 4.43E-02 
Gprin1 -0.84 1.71E-03 Rims4 -1.06 1.56E-04 Postn -0.99 4.87E-03 
Rims3 -0.84 1.04E-04 Napb -1.06 4.12E-08 Chn2 -0.97 4.72E-03 
Slc6a15 -0.84 1.78E-03 Krt18 -1.06 6.49E-04 Dst_1 0.96 4.98E-05 
Slc12a5 -0.84 1.31E-06 Tmem145 -1.05 3.50E-02 Mast4 0.96 3.40E-02 
Kif26b -0.84 2.57E-02 Pdzd2 -1.05 7.43E-04 Ptgds -0.96 1.65E-05 
Slc4a5 0.84 1.27E-03 Mpp3 -1.04 1.17E-04 Fam63b 0.95 1.37E-02 
Rgs6 -0.84 2.00E-02 Scn1a -1.04 1.56E-04 Heg1 0.95 2.44E-02 
Neurl1a -0.84 1.44E-02 Nefm -1.04 1.93E-03 Zranb1 -0.94 3.53E-02 
Grm4 -0.83 1.00E-03 Sphkap -1.04 5.00E-08 Nsg1 -0.93 1.07E-02 
Cnnm1 -0.83 3.02E-03 Exph5 -1.03 9.17E-03 Vat1l -0.93 4.86E-02 
Trpc3 -0.83 5.48E-03 Slc6a5 -1.03 4.06E-02 Arhgap32 0.93 3.09E-02 
Dpf1 -0.82 3.41E-02 Gap43 -1.03 5.92E-05 Reln -0.92 3.40E-02 
Kcnma1 -0.82 7.60E-03 Abca4 -1.03 3.34E-03 Taok1 0.92 1.77E-02 
Pgm2l1 -0.82 1.42E-04 Tub -1.03 4.32E-04 Epb4.1l3 -0.91 4.18E-02 
Gabrb2 -0.82 3.88E-04 Srrm3 -1.03 4.06E-02 Sox6 0.91 4.03E-02 
Reln -0.81 1.36E-04 Dusp5 -1.02 3.73E-03 Dennd4c 0.90 3.71E-02 
Kcnj9 -0.81 4.13E-03 Syt7 -1.02 4.13E-06 Eef1a2 -0.90 6.22E-03 
Syt2 -0.81 4.39E-05 Car12 -1.02 3.45E-06 Fam120c 0.90 3.55E-02 
Gria2 -0.81 1.78E-05 Trpv4 -1.02 7.98E-03 Abca1 0.90 5.03E-04 
Panx2 -0.81 3.49E-02 Tiam1 -1.02 2.64E-04 Ccl6 -0.89 1.46E-02 
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Mybpc3 -0.80 4.97E-02 Dnah6 -1.02 7.14E-03 Got1 -0.89 1.81E-02 
Grm1 -0.80 1.55E-04 Aqp1 -1.02 1.87E-05 Arsg -0.88 4.94E-02 
Galnt9 -0.80 2.00E-02 Slc9a5 -1.02 3.55E-02 Ralgps1 0.88 5.42E-02 
Kcnd2 -0.79 1.31E-04 Camk2a -1.02 3.77E-03 Itih3 -0.87 3.91E-03 
Abca4 0.79 5.25E-02 Slc29a4 -1.01 3.19E-03 Ptpn4 0.87 2.42E-02 
Syt7 -0.79 1.58E-04 Sptb -1.01 5.92E-06 Tgfbi 0.87 1.73E-02 
Lgi2 -0.79 1.40E-03 Ifitm10 -1.01 3.56E-02 Gdf10 -0.86 8.10E-03 
Cacna1b -0.79 2.12E-02 Slitrk4 -1.01 1.51E-02 Tnks 0.86 8.72E-03 
Mpp3 -0.79 8.42E-04 Sez6l -1.01 4.61E-05 Snrpn -0.85 1.69E-03 
Cacna1i -0.79 7.25E-03 Iqsec3 -1.01 4.23E-03 Dip2b 0.84 3.42E-03 
St8sia5 -0.79 5.10E-03 Celf3 -1.00 4.09E-02 Nkain4 -0.84 1.95E-02 
Bzrap1 -0.79 7.98E-03 Rbfox1 -1.00 2.63E-04 Tacc1 0.82 1.83E-02 
Cadm3 -0.79 6.96E-07 Mtus2 -1.00 8.85E-04 Acap2 0.82 5.66E-03 
Cacna1c -0.79 1.18E-02 Fbxl12 -1.00 3.26E-02 Pitpnm1 -0.81 2.60E-02 
Crtam -0.78 8.55E-03 Galnt9 -0.99 1.11E-02 Nf1 0.81 5.86E-03 
Cntnap1 -0.78 6.67E-04 Wdr86 -0.99 5.44E-02 Iqgap2 0.81 2.33E-02 
Dab1 -0.78 7.08E-03 Tuft1 -0.99 1.31E-02 Kat6a 0.81 2.12E-02 
Doc2b -0.78 1.54E-02 Slc4a10 -0.98 1.58E-07 Chd6 0.80 4.81E-02 
Golga7b -0.78 2.04E-02 Adcy1 -0.98 1.39E-08 Vps13d 0.79 7.65E-03 
Ksr2 -0.78 1.87E-02 Gabrb2 -0.98 9.52E-05 Adgrg6 0.79 1.51E-02 
Dpp6 -0.77 2.20E-05 Golga7b -0.98 7.45E-03 Sned1 0.78 3.17E-03 
Cdh18 -0.77 2.71E-02 Prr32 -0.98 2.32E-02 Ildr2 0.78 5.40E-02 
Sez6l -0.77 7.90E-04 Cnnm1 -0.98 1.52E-03 Macf1 0.78 1.31E-03 
Kcnab2 -0.77 3.10E-03 Otx2 -0.97 2.07E-04 Sep_05 -0.78 1.18E-02 
Fry -0.77 7.85E-04 Scd3 -0.97 3.75E-02 Bptf 0.78 3.38E-02 
Chn2 -0.77 1.27E-04 Rapgef4 -0.97 7.61E-05 Atp5g1 -0.77 5.25E-02 
Sptbn4 -0.76 4.72E-02 Dlk1 -0.97 4.89E-05 Hipk2 0.76 5.15E-02 
Slc1a6 -0.76 1.68E-04 Scrt1 -0.97 1.22E-02 Utrn 0.76 5.79E-03 
Gxylt2 0.76 4.40E-02 Clstn3 -0.97 2.35E-06 Birc6 0.74 1.64E-02 
Cntn4 -0.76 3.55E-02 Elmod1 -0.97 5.53E-06 S100a6 0.71 1.44E-02 
Syne1 -0.76 3.34E-04 Camk4 -0.97 9.88E-07 Pamr1 0.71 2.95E-02 
Plekhd1 -0.76 1.90E-02 Trpc3 -0.97 1.50E-03 Pik3r1 0.71 8.03E-03 
Napb -0.76 8.67E-06 Stxbp1 -0.96 9.78E-08 Ank3 0.71 4.08E-02 
Syt13 -0.75 1.74E-03 Slitrk1 -0.96 8.43E-03 Tmem59l -0.70 4.54E-02 
Cadps2 -0.75 6.03E-04 Rap1gap -0.96 1.07E-03 Rock2 0.70 2.12E-02 
Syp -0.75 8.09E-05 Fam110b -0.96 1.23E-02 Wdfy3 0.70 1.74E-02 
Arfgef3 -0.74 1.26E-02 Rap1gap2 -0.95 2.76E-04 Hprt -0.69 3.19E-02 
Mctp1 -0.74 1.71E-02 Dpysl4 -0.95 1.62E-02 Gucy1a3 0.69 2.50E-02 
Chga -0.74 1.86E-02 Mmp24 -0.95 1.10E-04 Cab39l -0.68 4.35E-02 
AI593442 -0.74 3.06E-02 Slc1a6 -0.95 1.91E-05 Prex2 0.66 4.93E-03 
Ppp1r17 -0.73 4.00E-04 Map3k9 -0.94 6.22E-03 Notch1 0.66 4.96E-02 
Brinp2 -0.73 1.24E-02 Inadl -0.94 6.14E-05 Serinc5 0.66 2.43E-02 
Pde10a -0.73 4.35E-02 Kcnq2 -0.94 2.18E-03 Usp53 0.65 2.06E-02 
Rgs8 -0.73 5.40E-05 Galnt13 -0.94 6.24E-03 Erbb2ip 0.64 5.46E-03 
Eml5 -0.73 5.07E-03 Frmpd4 -0.94 1.73E-04 Arhgef12 0.63 8.03E-03 
Kcnc1 -0.72 9.86E-05 Cldn2 -0.94 4.41E-04 Mfge8 -0.63 5.20E-02 
Bsn -0.72 2.46E-03 Clic6 -0.94 1.19E-06 Itgb4 0.63 4.34E-02 
Nrk -0.72 4.79E-02 6030419C18Rik -0.94 2.56E-03 Kif5a -0.62 5.08E-02 
Rgs7 -0.72 1.01E-02 Zfp385b -0.93 1.69E-02 Tmod2 0.62 1.63E-02 
Prkcg -0.72 7.47E-04 Phyhip -0.93 2.85E-06 Scn1b -0.62 3.12E-02 
Table 14. RML vs. Mock: 250 significant DEGs sorted by log2 fold change in COCS 
5 weeks 7 weeks 9 weeks 
Gene name log2 fold change p-value Gene name 
log2 fold 
change p-value Gene name 
log2 fold 
change p-value
B230312C02Rik 5.81 3.11E-05 Gm14005 -4.81 1.31E-02 Scand1 4.76 1.06E-14 
Gm10800 4.58 1.25E-02 Lrrc71 -4.37 4.54E-02 1810049J17Rik 4.40 2.27E-02 
Nrgn 4.13 4.60E-04 Sv2b 4.17 2.70E-04 Gm26917 4.12 2.35E-04 
Ddn 3.93 4.45E-07 S100a3 -4.15 9.28E-03 Gm1673 4.06 1.06E-12 
Fam163b 3.83 1.20E-02 Xist -4.04 8.96E-04 Gm14236 3.59 2.62E-02 
Nrtn 3.74 7.39E-07 Fbxl15 -3.78 8.35E-03 Nrtn 3.51 2.70E-07 
mt-Nd3 3.73 4.21E-13 Snhg18 -3.71 3.60E-02 Gm11681 3.45 3.92E-02 
Bpifb6 -3.69 2.47E-02 Tcerg1l 3.68 1.15E-02 Th 3.34 6.10E-06 
Iltifb 3.64 5.16E-03 Calca -3.64 1.35E-02 Ccdc85b 3.19 7.60E-13 
Scand1 3.35 1.15E-04 Marc1 -3.61 4.75E-02 Pcsk1n 3.13 7.66E-25 
A530053G22Rik 3.26 8.10E-03 Nudt6 -3.36 1.39E-04 Sumo2 3.11 4.61E-03 
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Tmem200b 3.03 9.05E-03 Tha1 -3.32 3.62E-02 Itpka 3.06 5.84E-03 
C1qtnf4 2.96 2.40E-02 Fcna -3.30 1.78E-02 Nme3 3.02 1.68E-02 
Htr1b 2.95 3.72E-03 1700007G11Rik -3.23 2.24E-02 Cox8b 3.00 4.50E-02 
1700026J14Rik 2.86 9.79E-03 Etohi1 -3.23 4.65E-02 Prr7 2.94 3.46E-05 
Gpx4 2.86 3.32E-09 Scand1 -3.23 4.65E-02 Fam181b 2.81 2.07E-04 
Ppp1r17 2.85 1.08E-07 Th 3.18 1.71E-02 Yjefn3 2.69 8.12E-03 
BC089491 2.83 6.56E-03 1810032O08Rik -3.18 8.19E-03 Vkorc1 2.64 3.78E-08 
Stra13 2.78 1.26E-08 Gabrd 3.16 3.81E-03 Gadd45gip1 2.59 4.67E-09 
Gadd45gip1 2.78 2.64E-07 Gm14326 -3.15 2.80E-02 Pcp2 2.48 1.26E-05 
Sycp1 2.78 8.24E-03 Lmo1 -3.15 2.80E-02 Rnaseh2c 2.44 3.42E-13 
Wfdc3 2.72 4.35E-03 BC051226 -2.99 7.15E-03 Rps16 2.39 3.61E-10 
Tmem256 2.70 2.08E-08 Chst2 -2.83 1.21E-03 Zfp771 2.36 8.04E-10 
BC051226 2.69 1.61E-06 Klk8 -2.83 1.70E-05 Erdr1 2.36 3.19E-02 
Batf 2.69 1.16E-02 Slc17a7 2.82 3.11E-04 Tpgs1 2.27 7.64E-13 
Cntnap5a 2.69 5.41E-02 Alkbh2 -2.80 2.09E-02 Bola1 2.26 8.50E-08 
Pigyl 2.67 5.29E-08 Ifi27l2a -2.77 2.26E-05 Hist1h4h 2.24 2.64E-03 
Fbll1 2.65 2.99E-03 Klc3 -2.77 3.73E-03 1110008P14Rik 2.21 1.06E-07 
Dctpp1 2.65 8.77E-08 Tro 2.71 3.50E-02 Drd1 -2.17 4.05E-02 
Adcyap1 2.64 3.67E-02 Gpx4 -2.67 2.24E-05 Fadd 2.16 1.03E-02 
Mrpl12 2.62 6.43E-08 Pigyl -2.64 1.68E-03 Gng13 2.14 3.81E-03 
Rpl22l1 2.60 8.57E-08 Ppp1r35 -2.64 1.68E-03 Cpne9 2.14 3.60E-02 
AW047730 2.59 8.48E-04 2810002D19Rik -2.64 4.75E-02 Tecrl -2.12 2.05E-02 
Camk2a 2.57 9.29E-06 Siva1 -2.62 9.59E-04 Shisa8 2.12 2.05E-03 
Cpne6 2.57 2.89E-02 Ccdc115 -2.62 3.84E-03 Crlf2 2.10 5.09E-08 
Vstm2l 2.57 2.89E-02 1500026H17Rik -2.60 9.40E-03 Slc1a6 2.04 5.06E-05 
Nr2f6 2.56 4.76E-06 Grm4 2.58 4.93E-02 Junb 1.98 4.69E-11 
Gm26917 2.55 4.72E-02 Nudt11 -2.54 2.69E-02 H2afj 1.96 7.03E-09 
Efcab10 2.54 6.83E-05 Sft2d1 -2.53 1.63E-04 Acox2 1.95 4.26E-02 
Sft2d1 2.53 3.90E-07 Samd1 -2.52 1.94E-04 Ppp1r17 1.84 1.18E-04 
Ly6h 2.51 3.88E-06 1810044D09Rik -2.49 3.18E-02 1810043H04Rik 1.84 3.88E-06 
Tppp3 2.45 2.86E-07 Lin7b -2.49 5.29E-02 Scrt1 1.82 4.19E-03 
Fbxl15 2.42 4.29E-05 Calb2 2.49 5.42E-04 AI849053 1.82 4.46E-02 
Gm14322 2.42 1.60E-04 Vps37d -2.46 1.16E-02 Grm4 1.80 5.65E-03 
Ifi27l2a 2.42 7.43E-07 Mrpl12 -2.44 1.33E-04 Bbc3 1.79 1.02E-04 
Polr2k 2.41 7.57E-07 Dctpp1 -2.43 3.26E-04 Gm13889 1.79 9.10E-03 
1810044D09Rik 2.40 1.63E-05 Fam92b -2.43 4.84E-02 Nkx6-2 1.77 3.26E-10 
1810022K09Rik 2.37 3.37E-06 Fat2 2.42 6.51E-03 Klf2 1.77 2.72E-02 
Nkx6-2 2.37 9.91E-07 Csrp2 -2.41 2.37E-03 Rsph10b 1.76 3.92E-02 
Gm14005 2.36 1.14E-03 Polr2k -2.39 1.91E-04 Grcc10 1.74 1.10E-04 
Rnaseh2c 2.34 3.44E-06 Crlf2 -2.37 1.48E-03 Rbfox3 1.72 4.17E-04 
2410006H16Rik 2.33 2.06E-06 Gadd45gip1 -2.37 1.16E-03 Kcnk3 1.71 4.12E-02 
Pet100 2.33 1.32E-06 Ahnak -2.36 1.04E-03 Cacna1g 1.67 1.94E-03 
Vcpkmt 2.33 1.68E-05 Stra13 -2.36 2.14E-04 Flywch2 1.67 1.60E-02 
2410015M20Rik 2.29 1.51E-06 
1810026B05Rik_
1 -2.35 6.37E-04 Jund 1.66 2.21E-10 
Nme2 2.27 6.60E-06 Tmem256 -2.33 1.98E-04 Cacna1i 1.64 1.84E-02 
Angptl6 2.27 1.34E-05 Syt1 2.33 1.62E-02 Sptbn2 1.63 2.24E-06 
Snhg3 2.26 2.27E-04 Prkcg 2.32 2.09E-02 Chadl 1.62 3.04E-03 
Plin5 2.26 6.48E-03 Trappc6a -2.31 4.69E-04 Car8 1.61 1.33E-07 
Rps16 2.25 2.85E-05 Gm10687 -2.31 2.34E-02 Ank1 1.61 1.28E-03 
Smc2os 2.24 4.22E-03 Cgref1 -2.30 1.57E-03 Calb2 1.59 1.78E-04 
AA465934 2.22 4.54E-03 Tppp3 -2.30 2.50E-04 Romo1 1.58 2.12E-08 
Gm26534 2.22 4.42E-02 Gm12092 -2.28 3.52E-02 Snhg20 1.58 5.23E-02 
Arf5 2.21 4.82E-06 Nkx6-2 -2.27 6.65E-04 Rims4 1.57 2.23E-03 
Mrps28 2.21 6.87E-06 Fam120aos -2.26 1.69E-02 Gpr4 1.56 1.95E-02 
3930402G23Rik 2.19 2.10E-03 2610316D01Rik -2.25 4.42E-02 Ppp1r35 1.55 3.13E-05 
Snhg11 2.19 4.50E-04 Cdc34 -2.22 4.95E-04 Gabrd 1.55 9.35E-03 
Meg3 2.18 1.75E-04 3930402G23Rik -2.20 5.15E-02 Dlgap3 1.55 1.57E-02 
A330069E16Rik 2.17 1.66E-02 Nme2 -2.20 5.88E-04 Pcp4 1.54 5.57E-04 
Mpc1 2.17 8.22E-06 1810022K09Rik -2.19 4.92E-03 Fbxl15 1.54 4.57E-04 
Ppp1r14a 2.17 5.46E-06 Rpl22l1 -2.19 4.93E-04 Enkd1 1.53 4.30E-03 
Metrn 2.17 4.50E-06 Isoc2b -2.19 2.79E-03 Vps37d 1.52 2.65E-03 
Ppp1r35 2.16 4.53E-05 2810410L24Rik -2.19 1.66E-02 Col9a2 1.51 3.80E-02 
Hist1h4h 2.15 4.37E-03 Zfp945 -2.18 7.41E-03 Ier5l 1.47 5.73E-05 
Ndufb4 2.14 3.51E-05 Gm1673 -2.18 1.14E-02 Golga7b 1.47 4.20E-02 
Cdc34 2.14 7.36E-06 Vwc2 -2.18 2.04E-02 Nr2f6 1.46 3.75E-04 
Mrpl27 2.13 8.81E-06 Procr -2.18 4.73E-02 Galnt9 1.45 4.05E-02 
Vash2 -2.12 2.18E-02 Saa3 -2.17 3.07E-03 Grin2c 1.44 3.53E-02 
Yjefn3 2.12 4.74E-02 Nat14 -2.16 3.24E-03 Uqcrq 1.44 4.74E-09 
Adprhl2 2.11 1.01E-05 Serpinb6b -2.15 2.28E-02 Endog 1.43 3.43E-03 
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Junb 2.11 2.00E-05 Enho -2.15 1.01E-02 Ppp2r3d 1.43 5.09E-04 
Gm14325 2.11 3.88E-05 Gm14322 -2.14 5.93E-03 Rhpn1 1.43 3.05E-03 
Drap1 2.10 7.74E-06 2410006H16Rik -2.13 8.28E-04 Ssbp4 1.43 4.93E-08 
Fam120aos 2.10 1.44E-04 Smim5 -2.13 5.48E-02 Nkx3-2 1.42 2.97E-02 
Ppp1r14b 2.10 1.21E-05 Ppp1r14a -2.12 7.42E-04 Ppp1r1b 1.42 1.11E-07 
Nat14 2.10 1.53E-05 Ptpn18 -2.12 3.45E-03 Ccdc124 1.41 1.03E-07 
A930006K02Rik 2.08 2.98E-03 Rnaseh2c -2.12 1.99E-03 Sdsl 1.40 1.04E-03 
Ormdl2 2.07 1.60E-05 Rph3a 2.10 7.28E-03 Cdkn1c 1.39 1.28E-02 
Mrap 2.07 1.76E-02 Comtd1 -2.10 4.01E-03 Irx1 1.39 3.94E-06 
Ubtd1 2.07 1.76E-05 Adprhl2 -2.10 1.35E-03 Unc5a 1.39 2.59E-02 
Glrx3 2.07 1.26E-05 Efcab10 -2.09 2.87E-02 Cebpd 1.38 5.66E-06 
Car8 2.06 1.90E-05 Nme4 -2.08 8.60E-03 Eps8l1 1.37 1.73E-03 
Zeb2os 2.06 9.64E-05 Rps27a -2.07 4.66E-03 Slc39a4 1.37 3.33E-02 
Gm1673 2.05 1.45E-03 Car8 2.06 6.88E-03 Ier2 1.35 2.55E-03 
Atp6v0e 2.05 1.30E-05 Dmkn -2.06 5.42E-03 Chil1 1.35 2.32E-04 
Rnf139 2.04 9.30E-04 Tmsb15b1 -2.04 4.49E-02 Cbln1 1.34 7.51E-05 
Arl5c 2.04 2.16E-04 Snhg3 -2.04 5.93E-03 Timm23 1.34 3.76E-02 
Gm15860 2.04 2.83E-02 Hmga1 -2.03 1.12E-02 Irs4 -1.34 7.05E-03 
Ttc9b 2.03 1.90E-03 Rbfox3 2.03 1.64E-02 Abhd8 1.34 8.54E-07 
Clec2l 2.03 2.64E-04 Bcl7c -2.03 1.75E-03 Mblac1 1.33 3.17E-02 
Grin2b 2.03 5.80E-03 Miip -2.03 1.03E-02 Mrpl52 1.33 4.78E-06 
Emc8 2.03 3.23E-05 Tagln -2.02 4.49E-03 Zfp865 1.32 1.68E-04 
Iigp1 2.01 1.24E-03 Tspo -2.02 1.79E-03 Gpx3 1.31 1.12E-08 
Hyi 2.00 5.55E-05 Ubtd1 -2.01 5.80E-03 Toporsos 1.31 1.18E-02 
Ssbp4 2.00 2.75E-05 Mrpl27 -2.01 2.14E-03 Map1s 1.30 5.48E-05 
Fam195a 2.00 2.33E-03 Xlr -2.01 3.35E-03 Ly6h 1.29 2.42E-03 
BC051019 2.00 1.54E-02 Rnf180 -1.99 7.40E-03 Mpc1 1.29 2.13E-06 
Lin7b 1.99 8.09E-03 Nos1 1.98 3.75E-02 Sssca1 1.28 3.36E-02 
Cd164l2 1.98 3.64E-03 Tnfrsf12a -1.98 3.13E-03 Rplp2 1.27 4.34E-07 
Snrpd2 1.98 2.76E-05 Mxd3 -1.98 3.79E-02 Slc17a7 1.27 8.04E-04 
Plekhj1 1.97 4.14E-05 Pmp2 -1.96 2.66E-02 Hic1 1.26 4.48E-02 
Flywch2 1.95 1.29E-03 Pop5 -1.96 2.64E-03 Mrpl57 1.26 2.38E-04 
Swi5 1.95 3.27E-05 Susd3 -1.95 4.56E-03 Rpl27 1.26 2.30E-02 
E530001K10Rik 1.94 1.25E-02 Synpo2 1.95 4.16E-02 2810428I15Rik 1.25 9.96E-06 
Stxbp5l 1.94 4.04E-02 Arf5 -1.95 1.82E-03 Dpm3 1.25 8.82E-05 
Serpinb2 1.93 1.60E-02 Cenpw -1.94 4.55E-02 Llgl2 1.25 3.83E-02 
3830403N18Rik 1.93 7.91E-03 Zeb2os -1.94 3.24E-03 Nfkbil1 1.24 8.79E-03 
Tspo 1.93 5.40E-05 Gm14325 -1.94 4.93E-03 Crocc 1.24 6.26E-03 
Gm19412 1.93 1.46E-02 Pet100 -1.94 1.90E-03 Fam179a 1.24 2.90E-02 
Ccdc115 1.92 6.68E-05 Zfp593 -1.93 2.92E-02 Znhit2 1.23 3.68E-04 
Trappc6a 1.92 7.86E-05 4933434E20Rik -1.93 2.06E-03 Slc8a2 1.22 2.00E-02 
Tomm40l 1.92 6.15E-05 Hyi -1.93 3.10E-03 Wfikkn2 1.22 3.22E-04 
Enho 1.91 5.01E-05 Fam181b -1.92 1.10E-02 Tmem160 1.22 4.53E-05 
Vps37d 1.91 1.01E-03 Ccdc153 -1.92 7.07E-03 Lzts2 1.22 1.77E-06 
6030407O03Rik 1.91 4.79E-03 Glrx3 -1.91 2.26E-03 Pdlim7 1.21 1.43E-05 
C1qb 1.90 4.45E-05 Phf11b -1.91 4.12E-02 Ifitm10 1.21 3.52E-02 
Snhg20 1.90 5.35E-03 Wnt4 -1.91 4.12E-02 Il17rc 1.21 6.37E-03 
S100a14 1.88 4.23E-02 Sdc1 -1.91 4.41E-02 Nos1 1.20 2.97E-03 
Hspb2 1.88 1.51E-02 2410015M20Rik -1.90 2.20E-03 Celf4 1.20 1.28E-03 
Zfp444 1.87 1.25E-04 Apex1 -1.90 3.12E-03 Igfbp6 1.19 4.23E-02 
Nudt6 1.87 2.95E-03 C1qb -1.88 2.29E-03 Ltc4s 1.19 3.77E-02 
Chchd1 1.87 7.70E-05 Gm14403 -1.87 4.92E-02 Cox17 1.18 8.84E-03 
Bcl7c 1.86 1.01E-04 Vcpkmt -1.86 1.11E-02 Zfp628 1.17 4.69E-03 
Golga7b 1.86 2.53E-03 Nov -1.86 6.39E-03 Zfp219 1.17 3.60E-06 
Gm15972 1.85 4.61E-02 Emc8 -1.86 3.10E-03 Ppp1r14a 1.17 1.93E-05 
Bbc3 1.85 6.85E-04 Angptl6 -1.85 1.10E-02 Prkcg 1.17 3.16E-02 
Tmem160 1.85 1.24E-04 Bax -1.85 2.92E-03 Gadd45g 1.16 2.39E-05 
Il11ra1 1.85 1.19E-04 Ppp1cc -1.84 9.29E-03 Ankrd9 1.16 2.05E-02 
Grin2a 1.84 1.45E-02 1110038B12Rik -1.83 4.95E-03 Arhgef33 1.15 3.91E-02 
Rabac1 1.84 8.07E-05 Rgs1 -1.82 1.74E-02 1110017D15Rik 1.15 5.02E-02 
Rita1 1.84 4.04E-04 Acbd4 -1.82 5.91E-03 Epn3 1.14 1.41E-02 
Olfm3 1.83 1.33E-03 Pkdcc -1.81 3.50E-02 Csf2ra 1.13 1.81E-03 
Gm14306 1.83 3.08E-02 Wfdc17 -1.81 5.77E-03 Rplp1 1.13 1.20E-06 
Rpl27 1.82 1.56E-03 Drap1 -1.81 3.34E-03 Dlk1 1.12 1.59E-05 
Gm17750 1.82 4.55E-04 Taf1d -1.80 3.09E-02 Chpf 1.12 1.14E-05 
Lyrm4 1.82 2.10E-04 Znrf2 -1.80 8.16E-03 Macrod1 1.12 8.55E-04 
Card11 -1.82 4.94E-02 Lyrm4 -1.79 1.03E-02 Gm5617 1.11 1.20E-02 
Rapsn 1.81 2.40E-02 1110065P20Rik -1.79 4.72E-02 Bsn 1.11 1.07E-02 
Hpca 1.81 2.98E-03 Zfp444 -1.78 1.60E-02 Slc29a4 1.11 9.58E-03 
Rasl2-9 1.81 3.73E-02 Sirt6 -1.77 4.55E-02 Rgs8 1.11 1.55E-02 
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Tenm1 1.80 5.39E-03 Atp6v0e -1.76 4.38E-03 Sv2b 1.11 1.45E-02 
Kcnip2 1.80 5.47E-02 Lage3 -1.76 6.84E-03 H19 -1.10 4.53E-03 
4933434E20Rik 1.80 1.19E-04 Mrps12 -1.76 5.19E-02 Rps26 1.10 2.18E-05 
Gm10687 1.80 2.33E-04 Rita1 -1.76 4.15E-02 Tmem121 1.09 1.87E-02 
Mrps24 1.79 1.73E-04 9130401M01Rik -1.76 1.41E-02 Fat2 1.08 1.92E-03 
2810428I15Rik 1.79 1.95E-04 Mea1 -1.75 5.39E-03 Id3 1.08 3.15E-06 
Susd3 1.79 2.45E-04 Mrps24 -1.75 1.20E-02 Pifo 1.07 4.96E-02 
Samd1 1.79 1.74E-04 Atp1a3 1.74 5.81E-03 Pou3f1 1.07 2.19E-02 
Mea1 1.78 3.00E-04 Tomm40l -1.74 5.26E-03 Plk5 1.07 2.27E-02 
Rbm7 1.77 1.60E-04 Gdf10 1.74 1.28E-02 Akt1s1 1.07 3.80E-05 
Galk1 1.77 2.27E-04 Lyrm9 -1.73 3.63E-02 Lmtk3 1.07 1.39E-02 
Crlf2 1.77 8.50E-04 Cbx8 -1.72 5.12E-02 Nfkbib 1.06 5.43E-04 
Ptpn18 1.77 7.32E-04 Macrod1 -1.72 7.83E-03 Mrps12 1.06 7.22E-04 
Kctd8 1.77 9.51E-03 Tradd -1.72 2.19E-02 Btbd17 1.06 5.75E-04 
Crls1 1.77 1.85E-04 Clstn3 1.72 1.48E-02 Bahcc1 1.05 1.28E-03 
Ankrd39 1.76 1.32E-03 Ms4a6d -1.70 6.73E-03 Fam109a 1.05 3.16E-03 
Hspbp1 1.76 1.83E-04 Rgs4 -1.70 4.49E-02 2810410L24Rik 1.05 4.46E-03 
Rps15 1.76 1.56E-04 Nr2f6 -1.70 1.69E-02 Mrpl34 1.05 7.80E-04 
Macrod1 1.74 4.14E-04 Gm11974 -1.70 3.40E-02 Tmem132a 1.04 6.18E-04 
Avpi1 1.74 4.56E-04 Cenpk -1.69 3.81E-02 Sh2b2 1.04 6.80E-03 
C1qtnf5 1.74 3.44E-03 Plscr2 -1.69 1.01E-02 Fam171a2 1.04 2.99E-03 
Ccne2 1.73 2.39E-03 2810428I15Rik -1.68 8.35E-03 1110001J03Rik 1.04 2.12E-03 
Atad3aos 1.72 1.50E-02 Nudt22 -1.67 1.31E-02 Id1 1.04 6.95E-05 
Bax 1.72 2.31E-04 Snap25 1.66 1.14E-02 Dok3 1.03 4.45E-02 
Plscr2 1.72 3.43E-04 Mrps26 -1.66 1.47E-02 1500015O10Rik 1.03 1.97E-04 
Apex1 1.71 4.07E-04 Plekho1 -1.66 9.81E-03 Ckb 1.02 5.45E-06 
Ryr2 1.71 5.17E-03 Tmem141 -1.66 2.29E-02 Avpi1 1.01 1.75E-03 
mt-Co3 1.71 4.70E-03 Plekhj1 -1.65 9.20E-03 Ace 1.01 2.93E-04 
Csrp2 1.71 2.54E-03 Ppp1r14b -1.65 1.40E-02 Apba3 1.00 8.40E-04 
Runx3 -1.70 5.26E-02 Dusp15 -1.65 7.97E-03 Abca4 1.00 2.50E-02 
Tpt1 1.70 2.47E-04 Snrpd2 -1.65 8.58E-03 1500011K16Rik 1.00 2.36E-04 
Cgref1 1.70 5.89E-04 Ctla2b -1.64 1.57E-02 F13a1 1.00 3.57E-02 
Rpl13 1.70 4.13E-02 Lsm5 -1.64 1.39E-02 Mt1 1.00 7.64E-06 
Gt(ROSA)26Sor 1.70 5.93E-04 Gng13 1.64 4.80E-02 Chchd10 1.00 5.27E-05 
Cacna1e 1.70 4.42E-03 Ly96 -1.63 2.19E-02 1700003E16Rik 1.00 1.39E-02 
Ift20 1.69 3.36E-04 Cd5l -1.63 1.15E-02 Gtpbp6 1.00 1.88E-02 
Tmem243 1.69 4.66E-04 Slirp -1.63 8.53E-03 Wdr86 1.00 5.30E-02 
Tagln3 1.69 3.03E-04 Cstb -1.63 9.17E-03 Pigyl 0.99 8.00E-04 
Fam71e1 1.68 1.93E-02 Ap1s1 -1.63 8.68E-03 Ahdc1 0.99 5.18E-04 
Dgkg 1.68 5.25E-02 Swi5 -1.62 8.15E-03 Galk1 0.99 5.68E-04 
Gnb2l1 1.68 2.88E-04 Clic1 -1.62 8.35E-03 Dao 0.99 1.97E-02 
Pdcd2l 1.68 4.94E-04 Cebpzos -1.62 9.85E-03 Hlx 0.98 5.36E-02 
Cebpzos 1.67 5.17E-04 Ccdc12 -1.62 1.03E-02 Tbcc 0.98 2.36E-03 
Pafah1b3 1.67 8.15E-04 Pcp2 1.61 4.33E-02 Mdfi 0.97 2.38E-03 
Zfp931 1.67 7.13E-04 Gnb2l1 -1.61 8.36E-03 Mpst 0.97 2.35E-04 
Lsm5 1.67 7.22E-04 Ccdc90b -1.61 9.96E-03 Comtd1 0.97 3.35E-02 
Xlr 1.67 9.70E-04 Ssbp4 -1.61 9.35E-03 Nat14 0.97 6.08E-04 
1010001B22Rik 1.67 2.04E-02 Mrps28 -1.61 1.63E-02 Psmg4 0.96 1.39E-02 
Tmem240 1.67 1.65E-02 Metrn -1.60 8.73E-03 Nckap5l 0.96 3.73E-02 
Cyc1 1.66 3.47E-04 S100a4 -1.60 1.15E-02 Pgp 0.95 1.75E-03 
Rpl13a 1.66 3.40E-04 Rgs17 -1.60 4.77E-02 Lrrc4b 0.95 1.30E-04 
Lage3 1.66 4.54E-04 Josd2 -1.59 1.08E-02 Dmrta1 -0.95 1.89E-03 
Atp6v0b 1.65 3.73E-04 Sirt7 -1.59 1.73E-02 Cdkn2a 0.95 2.41E-02 
Pou2f1 1.64 2.59E-02 1110046J04Rik -1.58 2.48E-02 Mdk 0.95 1.94E-03 
Mdfi 1.64 9.52E-04 Gin1 -1.58 4.86E-02 Rara 0.95 3.44E-02 
Actr6 1.64 5.77E-04 Dnajc19 -1.58 1.39E-02 Dgcr6 0.94 1.72E-02 
Sep_15 1.64 3.98E-04 Tstd3 -1.58 4.25E-02 Map3k10 0.94 7.23E-04 
Ramp3 1.64 2.84E-02 Galk1 -1.58 1.45E-02 Egln2 0.94 2.16E-04 
1700016K19Rik 1.63 1.45E-02 Tmem160 -1.57 1.62E-02 Stmn3 0.94 2.73E-04 
Snrpc 1.63 9.04E-04 Snhg6 -1.57 1.52E-02 Arhgef19 0.94 2.10E-04 
RP24-80F7.5 1.62 2.11E-02 Tmf1 -1.57 1.74E-02 Zfp579 0.94 6.42E-03 
Fam174a 1.61 5.77E-04 Sap30 -1.57 2.28E-02 Gm13111 0.94 4.98E-02 
Ms4a6d 1.60 6.23E-04 Atp6v0b -1.57 1.04E-02 2410006H16Rik 0.93 1.77E-03 
Pop5 1.60 7.37E-04 Pdcd2l -1.56 1.78E-02 Adgrb1 0.93 2.38E-03 
C630043F03Rik 1.60 2.41E-03 Snhg12 -1.56 3.29E-02 Itpr1 0.93 1.62E-04 
Cytip 1.60 4.27E-02 Sdf2l1 -1.56 2.13E-02 Cactin 0.93 3.01E-03 
Stard6 1.60 4.27E-02 Agpat2 -1.55 4.08E-02 Zfp444 0.93 2.95E-03 
Slirp 1.60 6.86E-04 Ppil3 -1.55 1.40E-02 Sema6b 0.93 5.52E-03 
Ucma 1.60 1.10E-03 Pdlim2 -1.54 1.25E-02 Irf2bpl 0.92 2.39E-04 
1700047M11Rik 1.59 1.10E-03 Crls1 -1.54 1.51E-02 Zfp428 0.92 1.04E-02 
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Coro1a 1.59 6.54E-04 Rrp9 -1.54 1.78E-02 St6galnac2 0.92 2.52E-02 
Clic1 1.59 6.19E-04 Coro1a -1.54 1.28E-02 Cbln3 0.91 3.99E-03 
Uqcrq 1.58 7.08E-04 1700047M11Rik -1.54 3.66E-02 Sf3b5 0.91 1.26E-03 
Zfp771 1.57 3.74E-03 Fkbp8 -1.54 1.22E-02 Hspbp1 0.91 3.07E-04 
Acbd4 1.57 1.06E-03 Rps15 -1.53 1.23E-02 Klhl36 0.91 1.82E-02 
Isoc2b 1.57 1.79E-03 Coa3 -1.52 3.27E-02 Atp13a2 0.91 3.08E-04 
Ly96 1.57 2.67E-03 Arhgdig -1.52 4.14E-02 Dohh 0.90 1.18E-03 
Tma7 1.57 8.65E-04 Amdhd2 -1.52 1.55E-02 Mex3d 0.90 5.64E-03 
Lmo1 1.57 4.87E-02 Sptbn2 1.52 3.56E-02 Cplx1 0.89 1.22E-02 
L3hypdh 1.56 5.05E-03 Dpf1 -1.52 5.17E-02 Alkbh7 0.89 8.86E-03 
Upp2 1.56 2.50E-03 Rbm7 -1.52 1.68E-02 Ifi27l2a 0.89 1.43E-03 
Crtam 1.56 8.09E-03 Slc12a5 1.52 3.86E-02 Spint2 0.88 8.26E-03 
1810026B05Rik_1 1.56 4.26E-03 Sh3gl2 1.52 2.93E-02 Fbl 0.88 5.36E-02 
Tnfrsf12a 1.56 1.04E-03 Chchd1 -1.51 1.69E-02 Snx21 0.88 8.02E-03 
Pvalb 1.55 1.02E-03 Sep_15 -1.50 1.37E-02 Thap3 0.88 2.14E-02 
1110008P14Rik 1.55 6.47E-03 Tbca -1.50 1.80E-02 Adcy1 0.87 1.85E-03 
Gabra6 1.55 2.09E-03 Mrpl54 -1.50 3.21E-02 Tcf3 0.87 9.20E-04 
Usmg5 1.55 1.01E-03 Lyrm2 -1.50 2.31E-02 Shf 0.87 3.94E-02 
Gm14418 1.55 2.93E-02 Snrpe -1.49 1.83E-02 Hmg20b 0.87 4.70E-03 
Clec2d 1.55 9.99E-03 Igfbp2 -1.49 1.91E-02 Rnf126 0.87 9.00E-03 
Dpm3 1.55 1.63E-03 Pafah1b3 -1.49 2.85E-02 Ppia 0.86 3.82E-04 
Serp2 1.55 4.91E-03 Dnm1 1.48 2.75E-02 6030419C18Rik 0.86 1.60E-02 
A430005L14Rik 1.54 1.49E-03 Dao 1.48 4.92E-02 Tesc 0.86 3.26E-02 
Itpka 1.54 3.20E-02 Snrnp25 -1.48 2.47E-02 Ubxn10 0.86 4.22E-02 
Snrpe 1.54 1.14E-03 Rpl13a -1.48 1.50E-02 Med25 0.86 5.18E-04 
Fam96b 1.54 1.12E-03 Abhd16a -1.48 1.58E-02 Papss2 -0.85 4.20E-02 
1500011K16Rik 1.54 1.17E-03 Gria1 1.48 1.53E-02 Numbl 0.85 1.08E-02 
Cnr1 1.53 1.94E-03 Ak1 -1.46 1.88E-02 Fance 0.85 6.55E-03 
Abhd16a 1.53 9.86E-04 Bad -1.46 2.58E-02 Irf8 0.84 2.91E-02 
Efna3 1.53 4.54E-02 Nt5c -1.46 2.21E-02 Uqcr11 0.84 5.63E-04 
